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Characterization of the GFAP cell specific RFX4 conditional knockout mice 
 
RFX4_v3 is the brain-specific splice variant of the transcription factor RFX4 
(Blackshear et al., 2003; Matsushita et al., 2005). It was shown to play an important role 
during early brain development and in the genesis of congenital hydrocephalus 
(Blackshear et al., 2003). 
To study the astrocytic role of RFX4_v3 in demyelination, GFAP cell specific RFX4 
conditional knockout mice were generated that possess an astrocyte-specific disruption 
of the RFX4_v3 gene by deletion of exon 4. A proportion of these GFAP cell specific 
RFX4 conditional knockout mice showed a severe brain phenotype. Macroscopical and 
histological analysis of the brains at time of birth and during adulthood revealed a 
hydrocephalus with dramatic extension of the lateral ventricle, which is indicative for a 
congenital, non-communicating hydrocephalus. Homozygous RFX4 conditional knockout 
mice were more severely affected than heterozygotes pointing toward a gene dosage 
effect. The subcommissural organ (SCO), an ependymal brain gland that is important for 
the patency of the Sylvian aqueduct, was altered and dysfunctional, which was evidenced 
by reduced or absent SCO glycoprotein (Reissner fiber) secretion. Furthermore, 
astrocytes from RFX4 conditional knockout mice at the time of birth showed differential 
expression of genes critical for brain morphogenesis such as Wnt signaling pathways that 
regulate dorsal midline structuring and development of the SCO. These observations 
were in line with previous findings (Blackshear et al., 2003) and supported the idea that 
the hydrocephalus in RFX4 conditional knockout animals is caused by maldevelopment 
and dysfunction of the SCO. My data further show that RFX4_v3 depletion in GFAP cell 
lineages including astrocytes and ependymal cells is sufficient to induce congenital 
hydrocephalus. I conclude that astrocytic and ependymal RFX4_v3 is highly relevant for 
brain development and the pathogenesis of congenital hydrocephalus. 
 
The role of astrocytic RFX4_v3 in demyelination 
 
In recent years, growing evidence for a contribution of astrocytes in MS pathogenesis 
has emerged in the literature. In particular, the immunomodulatory capacities of 
astrocytes have been suggested to play an important role during de- and remyelination 
processes in MS (Nair et al., 2008). Recent studies in animal models of MS show that 
astrocytes influence the activation and recruitment of microglia and peripheral leukocytes 
by secretion of inflammatory mediators (Skripuletz et al., 2013; Mayo et al., 2014). 
However, how astrocyte activation and secretion of inflammatory factors, such as 
  Abstract IV 
chemokines and cytokines, is regulated during inflammatory demyelination in MS lesions 
is poorly understood. 
Our group previously identified RFX4_v3 as a highly up-regulated factor in MS lesions. 
IHC of MS lesions showed RFX4 expression in various cell types with a prominent 
nuclear localization in astrocytes. The aim of the present study was to investigate the 
potential astrocytic role of RFX4_v3 in MS and a demyelinating mouse model. Therefore, 
to study the impact of astrocytic RFX4_v3, GFAP cell specific RFX4_v3 conditional 
knockout mice were subject to cuprizone induced demyelination. RFX4_v3 deficient mice 
showed increased demyelination, a reduced number of oligodendrocytes and enhanced 
axonal damage. In addition, remyelination in RFX4_v3 deficient mice was delayed. These 
alterations were associated with increased microglia activation in RFX4_v3 deficient 
mice. Further investigations during the early phase of cuprizone treatment indicated that 
increased microglia activation may be caused by enhanced oligodendrocyte apoptosis 
and increased transcript levels of pro-inflammatory chemokines and cytokines in 
RFX4_v3 deficient mice. This study demonstrates that astrocytic RFX4_v3 expression is 
important for regulation of myelination and activation of microglia during the processes of 
de- and remyelination in the cuprizone mouse model. In addition these results point 
towards a control of the inflammatory environment by the transcription factor RFX4_v3 to 
restrict the activation and recruitment of microglia cells as well as oligodendrocyte 
apoptosis, which eventually controls the extent of de- and remyelination in the cuprizone 
mouse model. Altogether these findings indicate that RFX4_v3 plays a protective role in 
the cuprizone mouse model. The fact that RFX4_v3 has been described as a 
transcriptional repressor suggests that astrocytic RFX4_v3 in MS might act as a regulator 
of production and release of inflammatory mediators and exerts a beneficial role in MS by 
restricting neuroinflammation.  
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1 Introduction 
1.1 Multiple sclerosis 
Multiple sclerosis (Encephalomyelitis disseminata) is a chronic inflammatory 
demyelinating disease of the central nervous system (CNS), which was first described in 
detail by the French neurologist Jean Martin Charcot in 1868. The etiology of multiple 
sclerosis (MS) is not fully clarified, but it is widely believed that MS is a T cell mediated 
autoimmune disorder of the CNS. MS affects approximately 2.5 million people worldwide 
and is most often diagnosed between the early and middle adulthood. The disease leads 
to lesions, also known as plaques, in the white and gray matter of the CNS. These 
lesions are characterized by demyelination, inflammation, axonal loss and gliosis (Brück, 
2005; Milo and Kahana, 2010; Lassmann, 2011; Kutzelnigg and Lassmann, 2014). 
Astrocytes are the most abundant cell type in MS lesions and, for a long time, they were 
considered to only play a secondary role in MS. However, more recently it was shown 
that astrocytes play an active role in MS through their immunomodulatory capacities 
(Williams et al., 2007; Nair et al., 2008; Brosnan and Raine, 2013).  
 
1.1.1 Symptoms, clinical course and diagnosis  
In MS, symptoms and clinical course of individual patients cover a broad spectrum. 
Common symptoms are blurred or double vision for several days to weeks, loss of 
balance, fatigue, numbness and tingling, weakness in arms or legs and hemiparesis. 
These symptoms wax and wane over time.  
Patients with MS typically display one of the following clinical courses: Relapsing 
remitting (RR), secondary progressive (SP) or primary progressive (PP) (Thompson, 
2004; Lublin et al., 2014).  
Relapsing remitting multiple sclerosis (RRMS) is a disease form where patients have 
relapses and periods of recovery or remission in between relapses. RRMS is the most 
frequent initial form of MS with about 80- 85% of MS patients being affected. The relapse 
period is characterized by appearance of new or worsening symptoms for a period of at 
least 24 hours or longer. The relapse period is followed by a period of recovery or 
remission in which symptoms partially or completely disappear.   
Most patients with RRMS later develop secondary progressive MS (SPMS). SPMS is 
defined by a switch from relapses and remission to a steady and chronic deterioration. 
 About 10-20% of the patients are initially diagnosed with primary progressive MS 
(PPMS) that shows no relapses and remission. In general, PPMS is diagnosed later than 
other types of MS. Due to a greater degree of spinal cord abnormalities, patients with 
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PPMS often show spinal cord symptoms such as weakness in arms or legs, fatigue and 
bladder and bowel difficulties (Thompson, 2004). 
MS is diagnosed by the Mc Donald criteria, which were introduced 2001 with the latest 
revision in 2011 (McDonald et al., 2001; Polman et al., 2011; Lublin et al., 2014). These 
diagnosis criteria include analysis of clinical symptoms, cerebrospinal fluid parameters 
and MRI data, which allows the diagnosis of MS after a single symptomatic episode 
(Polman et al., 2011). 
 
1.1.2 Pathology of MS  
The pathological hallmark of MS is the presence of multifocal lesions in the gray and 
white matter of the CNS. These lesions are characterized by an inflammatory infiltrate, 
axonal loss, astrogliosis, extensive demyelination and a variable degree of remyelination 
(Brück and Stadelmann, 2005). The MS plaques are present throughout the CNS with 
preferential localization in the subcortical and periventricular white matter, the spinal 
cord, optic nerve and the pons and medulla (Kutzelnigg and Lassmann, 2014). 
Macroscopically, focal demyelinating lesions of the white matter appear as gray to 
brownish discolored areas, with a size between less than a millimeter up to several 
centimeters (Brück and Stadelmann, 2005; Kutzelnigg and Lassmann, 2014). 
Based on the demyelinating activity MS lesions can be divided into active lesions 
characterized by an extensive inflammatory infiltrate and ongoing demyelinating activity 
and inactive lesions that are hypocellular and show no evidence of myelin breakdown 
(Pittock and Lucchinetti, 2007).  
Active lesions are subdivided in early and late active lesions. Early active lesions 
contain macrophages and activated microglia containing myelin debris reactive for myelin 
oligodendrocyte glycoprotein (MOG), myelin associated glycoprotein (MAG), myelin basic 
protein (MBP), proteolipid protein (PLP) and 2',3'-Cyclic-nucleotide 3'-phosphodiesterase 
(CNPase) and express the early activation marker myeloid-related protein 14 (MRP14). In 
contrast, late active lesions contain macrophages and microglia with myelin debris, which 
are only reactive for MBP and PLP - an indication for advanced myelin degradation. Late 
active lesions loose MRP14 expression (Brück et al., 1995; Lucchinetti et al., 2000).  
Inactive lesions are characterized by fibrillary gliosis, reduced axonal density, 
diminished or absent mature oligodendrocytes and a variable degree of inflammation. 
However, phagocytes in inactive lesions do not contain myelin debris that are 
immunoreactive for any of the myelin proteins described for active MS lesions.  
MS lesions with ongoing remyelination, a CNS intrinsic repair mechanism, are divided 
into early and late remyelinating lesions. Early remyelinating lesions contain a phagocytic 
inflammatory infiltrate and axons surrounded by thin myelin sheaths, while late 
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remyelinating lesions (shadow plaques) contain no foamy phagocytes, axons surrounded 
by newly formed thin myelin sheath and mild astrogliosis (Brück et al., 1995).  
 
1.1.3 Pathogenesis 
MS is a chronic inflammatory demyelinating disease of the CNS. It is believed that 
infiltration of autoreactive T cells into the CNS is the primary trigger and cause of 
demyelination in MS. The inflammatory infiltrate in lesions mainly contains CD4+ and 
CD8+ T lymphocytes, activated phagocytes, few B lymphocytes and plasma cells. This 
inflammatory reaction in MS is accompanied by up-regluation of cytokines (e.g. 
interleukin 2 (IL-2), IL-1, IL-12, tumor necrosis factor alpha (TNF-α)) and chemokines 
(e.g. chemokine (C-C motif) ligand 5 (CCL5), CCL3, chemokine (C-X-C motif) ligand 10 
(CXCL10)) including their receptors (e.g. chemokine (CC motif) receptor 5 (CCR5), 
chemokine (CX3C motif) receptor 1 (CX3CR1)), which are associated mainly with Th1 
mediated processes. Further it has been demonstrated by MRI studies of MS patients 
that many lesions are preceded by focal blood brain barrier (BBB) breakdown (Lucchinetti 
et al., 1998; Lucchinetti et al., 2001; Pittock and Lucchinetti, 2007). In addition, activated 
endothelial cells in active lesions express adhesion molecules, fibronectin, major 
histocompatibility complex class II (MHC class II) molecules and stress molecules, which 
were shown to impact on the BBB integrity (Lucchinetti et al., 2000; Minagar and 
Alexander, 2003). These observations are highly similar to experimental autoimmune 
encephalomyelitis (EAE), a T-cell mediated autoimmune disease and animal model for 
human MS. EAE is induced by either administration of myelin proteins or peptides in 
adjuvants or by the adoptive transfer of autoreactive T cells. Based on the MS pathology 
and EAE it is believed that T cells become activated in the periphery, attach to the vessel 
endothelium by interacting with adhesion molecules and pass through the BBB to enter 
the CNS. In the CNS these T cells are reactivated by antigen presenting cells and 
produce pro-inflammatory cytokines and chemokines, thereby recruiting phagocytes and 
increasing the permeability of the BBB. This leads to an increasing inflammatory infiltrate 
and subsequent myelin destruction (Baker et al., 1991; Lucchinetti et al., 1998; 
Lucchinetti et al., 2001; Pittock and Lucchinetti, 2007; Williams et al., 2007).   
Although MS is mainly considered as a T cell mediated disease, innate immune cells 
such as microglia/macrophages and dendritic cells contribute to disease pathogenesis 
(Gandhi et al., 2010). In MS patients, dendritic cells are activated, show increased 
expression of activation markers and secrete pro-inflammatory cytokines to promote T 
cell responses (Karni et al., 2006). Microglia/macrophages contribute to MS through the 
secretion of pro-inflammatory molecules and antigen presentation, thereby promoting 
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inflammation. In addition, these cells are involved in demyelination and phagocytosis of 
the degraded myelin (Bauer et al., 1994; Benveniste, 1997).  
Over the last years, it became clear that astrocytes also contribute to MS 
pathogenesis. Astrocytes were believed to only play a role in providing a support 
mechanism for neuronal functions such as regulating the local ion and pH homeostasis, 
storing CNS glycogen, uptaking of glutamate and clearing neuronal waste (Kang et al., 
1998; Nedergaard et al., 2003; Liberto et al., 2004). However, astrocytes actually play an 
active role in MS through their immunomodulatory capacity (Williams et al., 2007; Nair et 
al., 2008; Brosnan and Raine, 2013).  
1.1.4 The role of astrocytes in the pathogenesis of MS  
In response to tissue damage astrocytes become reactive and undergo astrogliosis. 
Astrogliosis is characterized by hypertrophy of cellular processes, proliferation and the 
up-regulation of type III intermediate filament proteins such as the glial fibrillary acidic 
protein (GFAP) and vimentin, which form an intermediate filament network. In MS 
reactive and proliferative astrocytes can form a glia scar, a dense network of hypertrophic 
cells and processes. These cellular processes are accompanied by changes in gene 
expression of growth factors, cytokines, chemokines, receptors and adhesion molecules. 
Accordingly, astrocytes exhibit multiple immune functions that are involved in MS 
pathogenesis (Williams et al., 2007; Sofroniew and Vinters, 2010; Sofroniew, 2014).  
One major function of astrocytes is maintaining the BBB, which is a selective 
permeable barrier that separates the circulating blood from the CNS parenchyma. The 
BBB is composed of endothelial cells, basal lamina, perivascular pericytes and astrocyte 
endfeets. By production and secretion of chemokines and cytokines astrocytes can 
modulate the BBB permeability. The pro-inflammatory factors IL-6 and IL-1ß were 
reported to increase BBB permeability during inflammation, whereas transforming growth 
factor beta (TGF-ß) tightens the BBB (Schwaninger et al., 1999; Didier et al., 2003).  
In addition, astrocytes activate autoreactive T cells by expression of adhesion 
molecules, in particular intercellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1). ICAM-1 was detected in astrocytes of demyelinating MS 
lesions (Cannella and Raine, 1995), while VCAM-1 was identified in astrocytes during 
EAE (Sobel et al., 1990; Gimenez, Mary Ann T et al., 2004). These adhesion molecules 
bind to LFA-1 and VLA-4 on activated lymphocytes, an important step during migration of 
T cells through the vascular endothelium into the parenchyma (Gimenez, Mary Ann T et 
al., 2004). 
Another way in which astrocytes may promote MS pathogenesis is through acting as 
non-professional antigen presenting cells. Although the literature is controversial there is 
evidence that in human MS tissue astrocytes express MHC class I and class II and 
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costimulatory molecules such as CD80 and CD86, which may promote the activation of 
autoreactive T cells (Zeinstra et al., 2000; Zeinstra et al., 2003).  
Furthermore, astrocytes express Toll-like receptors (TLR), a class of innate immune 
receptors that are critical in modelating cytokine and chemokine secretion in response to 
exogenous pathogens. In MS astrocytic TLR3 expression has been observed in late 
stage MS lesions (Bsibsi et al., 2002). On the one side, TLR3 stimulation on astrocytes 
triggers the release of pro-inflammatory cytokines such as type I interferons (IFN-α,β) 
and IL-6, which in turn cause an increase in MHC class I and class II expression and thus 
promote a pro-inflammatory response (Carpentier et al., 2007). On the other side, TLR3 
activation on astrocytes was shown to trigger the release of neuroprotective factors such 
as brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) and 
anti-inflammatory cytokines (IL-9, IL-10, IL-11) to inhibit, for example, the secretion of IL-
12 and IL-23 (Cua et al., 2003; Jack et al., 2005; Bsibsi et al., 2006). The secretion of 
pro- and anti-inflammatory mediators as well as neurotrophic factors has both detrimental 
and beneficial consequences for de- and remyelination in MS lesions. 
The astrocytic secretion of pro-inflammatory cytokines and chemokines recruits T 
cells, macrophages and microglia to the demyelinating lesion, which supports 
demyelination. Based on EAE and in vitro studies astrocyte-derived cytokines such as IL-
12, IL-17, IL-23 and TNF-α lead to T helper 1 (TH1) and T helper 17 (TH17) cell response 
(Langrish et al., 2005; McFarland and Martin, 2007; Miljkovic et al., 2007). Moreover, 
astrocytes were shown to be major producers of the chemokines CCL5, CXCL12, CCL2, 
CXCL8, and CXCL10, which recruit macrophages, microglia, and lymphocytes towards 
MS lesions or have effects on migration of lymphocytes across the BBB (Dong and 
Benveniste, 2001; Calderon et al., 2006; Mayo et al., 2014).  
By contrast, astrocytes also can create an environment that inhibits demyelination and 
supports remyelination. Astrocytes expressing anti-inflammatory molecules such as IL-
10, TGF-ß, IL-4 and IL-5 lead to an inhibition of the Th1 and Th17 response (Bjartmar 
and Trapp, 2001; Bsibsi et al., 2006). By secretion of chemokines and neurotrophic 
factors astrocytes promote oligodendrocyte precursor cells (OPC) migration (CCL2), 
proliferation (IL-6, IL-11, insulin-like growth factor 1 (IGF-I)), maturation (leukemia 
inhibitory factor (LIF), IL-11) and survival (BDNF, CNTF) (Barres et al., 1993; Gensert 
and Goldman, 1997; Bjartmar and Trapp, 2001). 
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1.1.5 The cuprizone mouse model  
To study MS pathology and pathogenesis several animal models have been 
established in the past. Each animal model only mimics parts of MS pathology. The most 
widely used model is EAE in mice. In EAE, immunization with myelin antigens or adoptive 
transfer of myelin specific T lymphocytes induces inflammation, demyelination, axonal 
loss and gliosis in the CNS, with a preference for the spinal cord (Torkildsen et al., 2008; 
Croxford et al., 2011). This model is mainly used to study the inflammatory aspects of 
MS. 
The cuprizone mouse model was established to study the process of demyelination 
and remyelination. In contrast to EAE, the BBB is intact in this model, which allows to 
study de- and remyelination without significant influence of the peripheral immune system 
(Kondo et al., 1987; Baker et al., 1991; McMahon et al., 2002). Cuprizone (bis-
cyclohexanone-oxaldihydrazone) is a copper chelating reagent, which is typically added 
to normal diet at a concentration of 0.2 - 0.25%. Mice are then fed for 4 to 6 weeks to 
induce significant and reproducible demyelination. In young adult mice cuprizone diet 
directly or indirectly causes oligodendrocyte apoptosis (after 3 to 7 days) with subsequent 
demyelination of several brain areas including corpus callosum, hippocampus, anterior 
commissure, olfactory bulb, optic chiasm, brain stem, cerebellum, caudate, putamen, 
cerebral cortex and cingulum (Matsushima and Morell, 2001; Gudi et al., 2009; 
Koutsoudaki et al., 2009; Hesse et al., 2010; Silvestroff et al., 2010; Gudi et al., 2014). 
The mechanism of cuprizone-induced oligodendrocyte damage is not completely 
understood. However, it is believed that selective toxicity of cuprizone towards 
oligodendrocytes is mediated by mitochondrial dysfunction leading to oligodendrocyte 
death and initiation of demyelination (Matsushima and Morell, 2001; Pasquini et al., 2007; 
Ransohoff, 2012; Bénardais et al., 2013). Early loss of oligodendrocytes results in 
astrogliosis, microglial activation, and demyelination in the following weeks of cuprizone 
diet (Hiremath et al., 1998). Microglia cells become activated in week 1 and significantly 
increase after week 3 to clear myelin debris (Hiremath et al., 1998). Once demyelination 
is complete microglia reach their maximum density and start to decrease (Mason et al., 
2001a). The most abundant phagocyte population in the cuprizone mouse model is the 
CD11b-positive and CD45-low population, which identifies parenchymal microglia 
(Remington et al., 2007; Voss et al., 2012). Only 0.5-7% are infiltrating macrophages 
(Remington et al., 2007; Voss et al., 2012). In addition, the group of Trevor Owens found 
an increase of CD86 and MHC class I receptors on microglia cells in cuprizone-treated 
mice. Hereby, the mean fluorescent intensity of CD80 only increased slightly and 
expression of MHC class II and CD40 was unchanged (Remington et al., 2007). In vitro, 
these cells revealed high phagocytic activity and up-regulated phagocytic receptors, 
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including Trem2b, CD23b (FcgRII/III), CD36 and Tim-3 (Voss et al., 2012). These results 
indicate that phagocytosis is the dominant characteristic of microglia cells in the 
cuprizone mouse model (Remington et al., 2007; Voss et al., 2012). 
During the first 2 weeks of cuprizone treatment astrocytes become hypertrophic with 
thick processes and up-regulate GFAP expression. Astrocytes significantly increase in 
number after week 3, when significant levels of demyelination are present (Hiremath et 
al., 1998). This phase of acute demyelination is followed by spontaneous remyelination 
upon cuprizone withdrawal. Thereby, extensive remyelination is evident after 3–4 weeks 
(Matsushima and Morell, 2001; Mason et al., 2004; Lindner et al., 2008; Torkildsen et al., 
2008).  
In the cuprizone mouse model astrocytes and microglia are thought to express and 
secrete cytokines and chemokines, which are important for microglia activation and 
recruitment to clear myelin debris, and to stimulate migration, proliferation and 
regeneration of myelin forming oligodendrocytes (Arnett et al., 2001; Kotter et al., 2006; 
Raasch et al., 2011; Skripuletz et al., 2013). The chemokine CCL2 is strongly up-
regulated during the first weeks in the cuprizone mouse model (McMahon et al., 2001). 
CCL2 is produced by astrocytes and is relevant for microglia migration and recruitment 
(Ransohoff et al., 1993; Hayashi et al., 1995; Raasch et al., 2011; Kim et al., 2014).  
Deletion of the chemokine CCL3 in the cuprizone mouse model delayed 
demyelination, which was accompanied by reduced recruitment of microglia and 
astrocytes (McMahon et al., 2001). The work from Skripuletz and colleagues implicated 
that also astrocytic CXCL10 is crucial for activation and recruitment of microglia and 
macrophages (Skripuletz et al., 2013). In the cuprizone mouse model the cytokines IL-1ß 
and TNF-α infere with oligodendrocyte recruitment, proliferation and differentiation. (Lee 
et al., 1993; Mason et al., 2001b; Raasch et al., 2011). TNF-α acts through two receptors 
TNFR1 and TNFR2, whereas in the cuprizone mouse model TNF-α only acts through 
TNFR2, which is critical for oligodendrocyte regeneration (Arnett et al., 2001). 
Accordingly, TNF-α and IL-1ß deletion in the cuprizone mouse model significantly 
reduces remyelination (Arnett et al., 2001; Mason et al., 2001b). 
 
1.2 Regulatory factor X4: Member of the protein family 
regulatory factor X 
In 2008, Cahoy and colleagues provided a detailed characterization and comparison of 
genes expressed by isolated astrocytes, neurons, and oligodendrocytes from the 
developing and mature mouse forebrain (Cahoy et al., 2008). In this study RFX4 was 
found to be highly enriched in astrocytes. Based on this work Dr. Andreas Junker 
performed a quantitative PCR study of 96 astrocyte specific genes of MS lesions together 
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with normal brain white matter as a control to determine astrocyte functions during 
inflammatory demyelination. In this study he found RFX4 to be highly up-regulated in MS 
lesions. In the present work the impact of the transcription factor RFX4 for inflammatory 
demyelination was further investigated in the cuprizone mouse model. 
 
In 1992, Dotzlaw and colleagues isolated human RFX4 from breast cancer as a partial 
cDNA, which encoded a short RFX-type DNA-binding domain (DBD) fused to the 
estrogen receptor (Dotzlaw et al., 1992). RFX4 is a member of the protein family 
regulatory factor X (RFX), which belongs to the winged-helix subfamily of helix-turn-helix 
transcription factors (Gajiwala et al., 2000). This protein family shares a highly conserved 
76-amino-acid winged helix DNA binding domain and regulates the expression of their 
target genes by binding to the X-box consensus sequence (Gajiwala et al., 2000). These 
transcription factors are present in many eukaryotic organisms such as nematodes, fungi, 
yeast, fruit flies and mammals (Morotomi-Yano et al., 2002). 
Five RFX proteins (RFX1-RFX5) have been identified in mammals (Morotomi-Yano et 
al., 2002). Besides the conserved DBD, RFX4 contains 3 additional conserved regions 
including region B, C and the dimerization domain, which are highly conserved in RFX1, 
RFX2 and RFX3 (Figure 1). Compared to other members of the RFX family RFX4 lacks 
the Q (glutamine-rich), the PQ (proline and glutamine-rich) and the A region (Figure 1). 
These regions are important for transcriptional activation. Therefore, it has been 
suggested that RFX4 is rather a transcriptional repressor than a transcriptional activator 
(Morotomi-Yano et al., 2002). However, Zhang and colleagues showed that RFX4 can 
also act as transcriptional activator as shown for activation of chemokine (CX3C motif) 
ligand 1 (CX3CL1) (Zhang et al., 2006a).   
RFX transcription factors, such as RFX2, RFX3 and RFX4 have been described to 
play a crucial role in regulation of ciliogenesis by controlling many genes involved in cilia 
assembly or function (Swoboda et al., 2000; El Zein et al., 2009; Thomas et al., 2010; 
Didon et al., 2013; Kwon et al., 2014). RFX3 deficient mice show several features of 
ciliopathies, which includes left–right asymmetry defects and hydrocephalus (Didon et al., 
2013). In addition, RFX3 regulates early midline structuring and is required for corpus 
callosum development (Benadiba et al., 2012). RFX4 itself has been shown to regulate 
sonic hedgehog signaling to control ciliogenesis in certain regions (Ashique et al., 2009). 
Members of the RFX family are implicated in regulation of genes important for the 
immune response. RFX1 is a well characterized member, which modulates the 
expression of interleukin-5 receptor α (Gajiwala et al., 2000). In addition, a recent paper 
suggests that RFX1 directly regulates CD44 expression, which may contribute to 
proliferation, survival and invasion of glioblastoma cells (Feng et al., 2014). The best 
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characterized member of the RFX family is RFX5, which is structurally different from all 
other human RFX members only sharing the DNA binding domain with other members of 
the RFX family (Steimle et al., 1995; Emery et al., 1996). RFX5 binds to the MHC class II 
promoter and is essential for the MHC class II gene expression (Moreno et al., 1997). 
Germline mutations of the RFX5 gene lead to the bare lymphocyte syndrome, a disease 
with severe immunodeficiency (Steimle et al., 1995; Reith and Mach, 2001). In addition, 
CX3CL1, a chemokine gene highly expressed in the brain was identified as direct target 
for RFX4_v3 (Tarozzo et al., 2003; Zhang et al., 2006a).  
 
Up to now six alternative splice variants of RFX4 have been identified. These six isoforms 
are either termed as RFX4_v1, _v2, _v3, _v4, _v5, _v6 or RFX4 A, -B, -C, -D, -E, -F 
(Figure 1). RFX4_v1 and RFX4_v2 were the first isolated isoforms of RFX4 (Morotomi-
Yano et al., 2002). These two isoforms together with variant 4 are testis specific 
(Blackshear et al., 2003; Matsushita et al., 2005). The study from Matsushita and 
colleagues showed that variant 3 is the only variant expressed in normal brain tissue. The 
mRNAs of RFX4 variant 5 and 6 in addition to the mRNA of RFX4_v3 were found in 
gliomas, but no expression was observed in other tumors such as lung, esophageal, 
stomach, colon or liver cancers (Matsushita et al., 2005). RFX4 variant 5 and 6 lack the 




Figure 1: Schematic representation of the six RFX4 isoforms (A) and its RFX family members in 
mammals (B).  
A, B, and C represent evolutionarily conserved regions, DE = acidic region, P = proline-rich region, Q 
= glutamine-rich regions, PQ = proline and glutamine rich region, DBD = RFX-type DNA-binding 
domain, DIM = dimerization domain. 
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1.2.1 RFX4_v3: The brain specific variant of RFX4  
In 2003, Blackshear and colleagues generated transgenic mice for cardiac specific 
expression of the human epoxygenase gene (Blackshear et al., 2003). One line of these 
strains showed a brain phenotype including head swelling and rapid neurological decline 
in young adulthood (Blackshear et al., 2003). Analysis of the genomic sequences 
revealed that the transgene was inserted into an intron of the mouse RFX4 locus. This 
insertion created a null allele for the expression of the RFX4 variant 3 (Blackshear et al., 
2003). An alignment of the human and mouse RFX4_v3 amino acid sequences showed 
96% sequence identity between the mouse and human RFX4_v3 protein (Blackshear et 
al., 2003), which could point towards similar functions of RFX4_v3 in mouse and human.  
The RFX4_v3 expression is restricted to the brain. RFX4_v3 expression is found 
during early development as well as during adulthood (Blackshear et al., 2003; 
Matsushita et al., 2005). The first expression of RFX4_v3 was detected at embryonic 
stage (E) 8.5 in the neural plate. At E9.5 RFX4_v3 is expressed in two large regions, the 
spinal cord and the caudal diencephalon/mesencephalon, while at E10.5 the expression 
extends throughout the neural tube. From E12.5 to birth, levels of RFX4_v3 mRNA were 
detected in the neuroepithelium and the ependym of the neural tube. In addition, from 
E14.5 to birth RFX4_v3 transcripts were found in the ependymocytes of the developing 
subcommissural organ (SCO) (Blackshear et al., 2003). In the adult brain RFX4_v3 is 
expressed in several brain tissues including brainstem, midbrain, cerebellum, 
hippocampus, striatum, frontal lobe and olfactory bulb (Zhang et al., 2007). In addition, 
Araki and colleagues found high levels of RFX4_v3 in the suprachiasmatic nucleus. This 
implicated that RFX4 function may be related to the circadian clock, because the 
suprachiasmatic nucleus is the central clock locus for the circadian rhythm (Araki et al., 
2004).  
1.2.2 RFX4_v3 deficiency leads to non-communicating congenital 
hydrocephalus 
As mentioned before, RFX4_v3 deficient mice develop head swelling and neurological 
decline in young adulthood. Investigations of these transgenic mice line revealed severe 
hydrocephalus in all mice at the time of birth, indicative of a congenital hydrocephalus 
(Blackshear et al., 2003). Disruption of both RFX4_v3 alleles leads to severe brain 
deformation with failure of dorsal midline formation. All pups homozygous for RFX4_v3 
deletion died shortly before or after birth (Blackshear et al., 2003). RFX4_v3 +/- mice 
survived, but suffered from congenital hydrocephalus associated with hypoplasia or 
absence of the SCO.  
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Histological analysis of the brains showed severe hydrocephalus in the anterior brain, 
with dramatic extension of the lateral ventricles. The SCO was absent in the transgenic 
mice, while other midline structures such as the pineal body and posterior commissure 
appeared to be normal (Blackshear et al., 2003). Furthermore immunohistochemistry with 
an antibody specific for SCO-produced Reissner’s fibers showed in contrast to wild type 
mice an absence of SCO glycoproteins in RFX4_v3 +/- mice (Blackshear et al., 2003). 
Therefore, the agenesis and resulting dysfunction of the SCO was considered as the 
main cause for the hydrocephalus in RFX4_v3 deficient mice (Blackshear et al., 2003; 
Zhang et al., 2006a). 
Interruption of both alleles of RFX4_v3 severely alters brain morphogenesis 
(Blackshear et al., 2003). Heads of RFX4_v3 -/- mice at E12.5 are smaller than of wild 
type mice and show an abnormal doming of the skull. Heads of RFX4_v3 -/- lack 
morphological differentiation of dorsal structures, which was most obvious by the loss of 
dorsal midline structures and the formation of a single central ventricle (Blackshear et al., 
2003). Blackshear and colleagues assumed that disruption of both alleles possibly 
interferes with the expression of downstream genes, which leads to failed dorsal midline 
structuring (Blackshear et al., 2003; Zhang et al., 2006a). 
 
1.2.3 Potential target genes and interacting partners of RFX4_v3 
To identify potential target genes of RFX4_v3 the group of Blackshear and colleagues 
performed a microarray analysis of RFX4_v3 +/+ and RFX4_v3 -/- mouse brains at the 
embryonical stage 10.5 to identify differentially expressed genes in RFX4_v3 -/- mice 
(Zhang et al., 2006a). This approach revealed that many of the differentially expressed 
genes are critical for brain morphogenesis. These included genes involved in signaling 
pathways of Wnt, bone morphogenetic protein (Bmp) and retinoic acid (RA) (Zhang et al., 
2006a). Wnt signaling pathways play an important role in early and late stages of brain 
development (Zhang et al., 2007). One of genes regulated by RFX4_v3 was Wnt-3a. 
Wnt-3a deficient mice show defects in growth and patterning of the dorsomedial cerebral 
cortex indicating that Wnt signaling regulates the development of the cerebral cortex (Lee 
et al., 2000; Louvi A and Wassef M, 2000; Huh et al., 2009). The Bmp signaling was 
described to be important for the patterning of the dorsal telencephalic midline and for the 
regulation of dorsal forebrain development (Furuta et al., 1997; Hébert et al., 2002; Liu 
and Niswander, 2005). RFX4_v3 down-regulates msh homeobox 3 (Msx3), a gene that 
belongs to a family of homeodomain transcriptional repressors (Zhang et al., 2006a). 
Together with Msx1 Msx3 has been shown to mediate Bmp signaling during neural tube 
development (Liu et al., 2004). The RA signaling pathway is also implicated in brain 
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morphogenesis as shown by LaMantia and colleagues, who demonstrated that the 
pathway plays a role in forebrain development (LaMantia et al., 1993).  
In addition to these pathways critical for brain morphogenesis, Zhang and colleagues 
identified transcription factors that have been shown before to be important for brain 
development, such as forkhead box A2 (Foxa2) and retina and anterior neural fold 
homeobox (Rax) (Zhang et al., 2006a; Nelander et al., 2009; Miranda-Angulo et al., 
2014). In the same study CX3CL1 was found as direct target for RFX4_v3. The 
chemokine was significantly down-regulated in heads of RFX4_v3 -/- mice. The human 
and mouse promoters of CX3CL1 contain the highly conserved X-boxes, which are 
essential for RFX binding to DNA (Zhang et al., 2006a). Zhang and colleagues showed 
that RFX4_v3 directly binds to X-box 1 of the CX3CL1 promoter and activates the 
expression of this gene (Zhang et al., 2006a).  
A yeast two-hybrid screening was performed to identify potential interaction partners of 
RFX4_v3 (Zhang et al., 2008). With this approach nine potential interaction partners were 
found, including the G-protein pathway suppressor 2 (GPS2), a nuclear factor (Zhang et 
al., 2008). Immunohistochemistry showed that GPS2 and RFX4_v3 co-localize in the 
nucleus and co-immunoprecipitation assays indicated a physical interaction between 
GPS2 and RFX4_v3. In addition, GPS2 was recruited by RFX4_v3 to the promoter of 
CX3CL1 indicating that GPS2 functions as transcriptional co-activator of RFX4_v3 
(Zhang et al., 2008). 
 
1.3 Hydrocephalus 
Hydrocephalus is characterized by excessive accumulation of cerebrospinal fluid 
(CSF) inside the skull. The accumulation of CSF leads to abnormal dilation of the 
ventricles, which creates a harmful pressure level on the brain tissue. CSF is produced 
and secreted by the epithelial cells of the choroid plexus, which is located in the 
ventricles and subarachnoid space. The CSF production follows a cycle of constant 
production and reabsorption. The fluid circulates through the ventricular system, which is 
composed of two lateral ventricles, the third and fourth ventricle and the cerebral 
aqueduct. The CSF flows through the ventricles from the lateral to the third and via the 
cerebral aqueduct into the fourth ventricle. From the fourth ventricle the CSF flows via the 
median aperture of Magendie and the lateral aperture of Luschka into the subarachnoid 
space before being drained into the venous circulation (Ortloff et al., 2013). The balance 
between production and absorption of CSF is important. Conditions that block normal 
CSF flow or absorption can result in overproduction of CSF. All types of hydrocephalus 
are either communicating or non-communicating. In the communicating hydrocephalus 
the block of the CSF flow is mainly in the subarachnoid space distal to the ventricles, 
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whereas in non-communicating hydrocephalus the impairment of the CSF flow is within 
the ventricles (Pérez-Fígares et al., 2001). 
 
1.3.1 Congenital hydrocephalus 
Congenital and acquired forms of hydrocephalus can be distinguished. Acquired 
hydrocephalus usually occurs postnatally. Possible causes are tumors, intraventricular or 
subarachnoid hemorrhage, and diseases such as meningitis and traumatic head injury 
(Pérez-Fígares et al., 2001; Sztriha et al., 2002; Gangemi et al., 2014).  
Congenital hydrocephalus appears during fetal development and is already present at 
birth. The incidence of congenital hydrocephalus in humans is about 1-3 in every 1,000 
live births (Pérez-Fígares et al., 1998; Huh et al., 2009). 
Although the cause of congenital hydrocephalus is not well understood, it is believed 
that genetic abnormalities causing aqueductal stenosis and developmental disorders, 
which include neural tube defects, can lead to congenital hydrocephalus. Only one gene 
the X-linked L1 cell adhesion molecule (L1CAM) gene has been identified in humans to 
cause congenital hydrocephalus. Mutations in this gene are responsible for about 5% of 
the congenital cases with genetic cause (Bruni et al., 1988a; Sztriha et al., 2002; Zhang 
et al., 2006b). Apart from humans, congenital hydrocephalus occurs in several laboratory 
mammals. The analysis of several genetically modified animal models has led to the 
identification of more than 15 genes causing hydrocephalus in rodents (Rolf et al., 2001; 
Blackshear et al., 2003; Baas et al., 2006; Dietrich et al., 2009; Huh et al., 2009; 
Benadiba et al., 2012). Several studies support that stenosis of the aqueduct is a key 
event and the main cause for development of congenital hydrocephalus (Bruni et al., 
1988a; Boillat et al., 1999; Jones and Klinge, 2008; Huh et al., 2009). The reason of 
stenosis is not well understood, but it was shown that dysfunction of the subcommissural 
organ during the fetal period may lead to aqueductal stenosis (Rodriguez et al., 1987; 
Rodríguez et al., 1998; Huh et al., 2009).  
1.3.2 Subcommissural organ and Reissner fiber glycoproteins 
The SCO is the a small brain gland located on the roof of the third ventricle, at the 
entrance of the cerebral aqueduct (Pérez-Fígares et al., 2001; Ortloff et al., 2013). This 
organ consists of secretory ependymal and hypependymal cells, which are arranged into 
2 cell layers. It differentiates early in the ontogenesis and is active during throughout life 
(Naumann, 1986; Schoebitz et al., 1986; Pérez-Fígares et al., 1998). However, in 
humans the SCO differentiates very early during embryonic development. It is completely 
developed during the second half of the embryonic stage and is regressing during early 
childhood (Rodríguez et al., 1992). The SCO releases glycoproteins of high molecular 
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weight into the ventricular CSF. In the CSF these glycoproteins condense to form a 
fibrous structure, which is known as Reissner fiber (RF). The RF grows in a rostracaudal 
direction by continuous addition of newly released glycoproteins. The condensed fibrous 
structure runs along the aqueduct, fourth ventricle, spinal cord and ends in the filum 
terminale. In the filum the RF glycoproteins undergo chemical changes before entering 
the bloodstream (Rodriguez et al., 1987; Nualart et al., 1991; Grondona et al., 1994). 
In 1954, work by Overholser indicated that the secretion of SCO glycoproteins in the 
CSF during early embryonic stage prevents closure and stenosis of the aqueduct 
(Overholser et al., 1954). Therefore, it was suggested that maldevelopment of the SCO 
and resulting dysfunctional glycoprotein secretion lead to aqueductal stenosis and 
congenital hydrocephalus (Overholser et al., 1954; Newberne, 1962). Several 
publications support this hypothesis (Huh et al., 2009; Ortloff et al., 2013). It was shown 
that X-irradiation induced maldevelopment of the SCO during fetal life results in 
aqueductal stenosis and congenital hydrocephalus (Takeuchi and Takeuchi, 1986). In 
addition, immunization of pregnant rats with RF glycoproteins induced SCO defects, 
stenosis and hydrocephalus (Sara Rodriguez et al, 1999). Furthermore, several 
genetically modified animal models showed that maldevelopment of the SCO leads to the 
development of a congenital hydrocephalus (Huh et al., 2009). One example is the 
MT/HokIdr mouse, which lacks an SCO resulting in congenital hydrocephalus (Takeuchi 
et al., 1987). Likewise, the SUMS/np mice developed a hydrocephalus due to aqueductal 
stenosis and a small SCO (Jones et al., 1987; Bruni et al., 1988b). Lastly, severe 
morphological alterations of the SCO were observed in hydrocephalic human fetuses 
(Castañeyra-Perdomo et al., 1994).  
The SCO originates from neuroepithelial cells that line the lumen of the dorsocaudal 
aspect of the diencephalon. These epithelial precursors of the SCO differentiate into 
specialized secretory ependymocytes in response to the induction of genes involved in 
the Wnt and bone morphogenetic protein (Bmp) signaling pathways (Liem et al., 1995; 
Liem et al., 1997). It was shown that SCO hypoplasia and dysfunction are associated 
with a number of genetic mutations including Wnt and Bmp signaling (Louvi A and 
Wassef M, 2000; Bach, 2003; Ramos et al., 2004). One example is the transcription 
factor Msx1, which is induced by Bmp proteins and was shown to play an important role 
for dorsal neural patterning (Bach, 2003; Hayashi et al., 2006). The factor is expressed 
along the dorsal midline and neural tube and was also found in the SCO (Ramos et al., 
2004). Deletion of both alleles leads to absence or malformation of the SCO, stenosis of 
the cerebral aqueduct, and development of a hydrocephalus (Fernández-Llebrez et al., 
2004).  
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1.4 Aims  
 
The role of astrocytic RFX4_v3 in demyelination 
 
The present work was inspired by a study of Cahoy and colleagues from 2008, who 
found the transcription factor RFX4 highly enriched in astrocytes (Cahoy et al., 2008). 
Our group previously identified RFX4_v3 as a highly up-regulated factor in MS lesions. 
The astrocytic expression of RFX4 was further confirmed by double- 
immunohistochemistry for RFX4 and GFAP.  
Astrocytes are the most abundant cell type in MS lesions. In the last years it became 
increasingly clear that astrocytes do not only support neuronal functions, but - because of 
their immunological properties - also play an active role in the pathogenesis of MS 
lesions. On the one side, astrocytes support neurodegeneration and demyelination by 
promoting inflammation, but on the other side they can also create an environment 
conducive to regeneration and remyelination by secretion of pro-remyelinating factors 
(Williams et al., 2007; Nair et al., 2008; Brosnan and Raine, 2013).  
Previous studies showed that members of the RFX family regulate genes important for 
the immune response (Gajiwala et al., 2000; Morotomi-Yano et al., 2002). RFX4_v3 
directly targets and regulates the expression of CX3CL1 - a chemokine highly expressed 
in the brain and implicated in regulation of leukocyte migration and recruitment to MS 
lesions (Sunnemark et al., 2005; Zhang et al., 2006a; Broux et al., 2012; Blauth et al., 
2015).  
This raised the question whether an up-regulation of RFX4 in astrocytes acts as 
regulator of neuroinflammation, thereby influencing de- and remyelination in MS.  
Therefore, the main aim of this thesis was to investigate the astrocytic role of RFX4 in 
de- and remyelination. For that purpose I used GFAP cell specific RFX4 conditional 
knockout mice to study the effect of RFX4_v3-deficiency on myelin loss and myelin repair 
in the cuprizone mouse model.  
 
Characterization of the GFAP cell specific RFX4 conditional knockout mice 
 
To generate GFAP cell specific RFX4 conditional knockout mice the RFX4 flox/flox 
strain was crossed with a GFAP-driven Cre transgenic strain. During the generation of 
the conditional knockout strain a substantial fraction of these animals developed a 
hydrocephalus.  
Therefore, the second aim of this thesis was the phenotypic characterization of the 
newly generated GFAP cell specific RFX4 conditional knockout mice. To explain the 
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pathological and functional basis of the hydrocephalus in RFX4 conditional knockout 
mice I performed histological and immunohistochemical analyses with a focus on the 
subcommissural organ, an ependymal brain gland that is important for the patency of the 
Sylvian aqueduct. To further understand the molecular mechanisms of the hydrocephalus 
formation I studied the expression of developmental genes which regulate dorsal midline 
structuring and the development of the SCO. 
 
In the following, the first part of the thesis describes the characterization of the GFAP cell 
specific RFX4 conditional knockout mice, and the second part concerns the astrocytic 
role of RFX4_v3 in MS and the cuprizone mouse model. 
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2 Materials & methods 
2.1 Materials  
2.1.1 Reagents 
Table 1: Reagents 
Reagents  Source of supply 
Agarose  StarLab GmbH, Hamburg, Germany 
Crystal violet Sigma Aldrich, St. Louis, MO, USA 
dNTP (desoxynucleoside triphosphate) mix Thermo Scientific 
EDTA (ethylenediamine tetraacetic acid 
disodiumsalt dihydrate) 
Carl Roth, Karlsruhe, Germany 
GeneRuler™, 1 kb Plus DNA ladder  Thermo Scientific, Waltham, MA, USA 
HBSS (Hank‘s buffered salt solution) with Ca2+ 
and Mg2+ 
PAA,Pasching, Germany 
Isopropyl alcohol Merck Millipore, Darmstadt, Germany 
PBS (phosphate buffered salt solution), sterile      Gibco, Germany 
Penicillin, 10,000 units / streptomycin, 10mg/ml Gibco, Germany 
Trypan blue Sigma Aldrich, St. Louis, MO, USA 




DAB (3,3'-diaminobenzidine) Sigma Aldrich, Germany 
DAPI (4',6-diamidino-2-phenylindole) Molecular Probes, life technologies,   
Germany 
Percoll Sigma Aldrich, Germany  
DePex mounting medium Serva Electrophoresis GmbH, Germany 
Dako Fluorescent Mounting Medium Dako Deutschland GmbH, Germany 
Ethanol, 96% Merck, Millipore, Germany 
PLL (poly-L-lysine hydro bromide), powder Sigma Aldrich, Germany 
Formalin (37% solution, free from acid) Merck, Millipore, Germany 
Horse serum  PAA,Pasching, Germany 
LFB (Luxol Fast Blue) Sigma-Aldrich, Germany 
Mayer’s hemalum solution Merck, Millipore, Germany 
Methylene blue Merck, Millipore, Germany 
NaOH Merck, Millipore, Germany 
NaOH (1mol/ l, 0,1mol/ l) Merck KGaA, Germany 
NaCl Merck KgaA, Germany 
PBS (Dulbecco’s PBS, 10x powder) Applichem, Germany 
Periodic acid Merck KgaA, Germany 
ExtrAvidin-Peroxidase Sigma Aldrich, Germany 
PFA (paraformaldehyde) Sigma Aldrich, Germany 
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Reagents  Source of supply 
Qiazol Lysis Reagent  Qiagen, Germany 
Random Hexamers  Invitrogen, life technologies, Germany 
Triton X 100 MP Biomedicals, Germany 
Trizma base Sigma Aldrich, Germany 
PCR buffer, 5x Green GoTaq Reaction Buffer Promega, Germany 
FCS (fetal calf serum) Sigma Aldrich, St. Louis, MO, USA 
H2O2 (30% solution) Merck, Millipore, Germany 
BME Medium (Eagle′s Basal Medium) Gibco, Germany 
GlutaMax    Gibco, Germany 
Ground mouse chow (complete feed for rat   
& mice maintenance, ground) 
Ssniff Spezialdiäten GmbH, Germany 
HCl (25%, 1mol/ l, 0.1mol/ l) Merck, Millipore, Germany 
DMEN-Dulbecco’s Modified Eagle Medium  Gibco, Germany 
HEPES (4-(2-hydroxyethyl)-1-      Sigma Aldrich, St. Louis, MO, USA 
Naphthol AS  phosphate Sigma Aldrich, St. Louis, MO, USA 
Levamisole  MP Biomedicals, LLC, Germany 
Fast blue BB salt Sigma Aldrich, St. Louis, MO, USA 
Abbreviations: 
PCR: Polymerase chain reaction 
2.1.2 Solutions, buffers and cell culture media 
Table 2: Solutions, buffers and cell culture media  
Solution  Composition 





MACS (magnetic-activated cell sorting) buffer PBS, sterile 
0.05% BSA 
2 mM EDTA 
pH 7.2 
 
DMEMFACS buffer DMEM  
2% FCS 
 
Tris-EDTA buffer 10 mM Tris  
1 mM EDTA 
pH 9.0 
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Solution  Composition 
LFB working solution 0.1% LFB (w/ v)  
0.5% acetic acid in Ethanol 
 
Tail lysis buffer Bidistilled water 
5 mM EDTA      
200 mM NaCl    
0.1 M Tris-HCl pH 8.5       
0.2% SDS  
pH 8.5  
 
TAE buffer Bidistilled water  
40 mM Tris acetate 
1 mM EDTA  
pH 8.0  
 
PFA, 4% solution 40 g PFA  
1000 ml 1-fold PBS  
NaOH  
pH 7.4  
 
HCl-Isopropanol 70% Isopropyl alcohol 
0.25% HCl 
 








Levamisole (stock solution) 
49 ml PBS  
1 ml DAB  
20 μl hydrogen peroxide 
 
1 M Levamisole 
bidistilled water 
 
Tris HCL buffer  1 M Tris HCL 
1 M HCL  
pH 8.2 
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Solution  Composition 
Naphthol AS phosphate mix (stock solution) 10 mg/ml Naphthol AS phosphate mix  
N,N-di-methylformamide 
 
Fast blue  0.5 mg/ml Fast Blue BB salt 
0.2 mg/ml Naphthol AS  phosphate  
1 mM Levamisole 
0.1 M Tris HCL buffer, pH 8.2 
 
Chloral hydrate, 14% solution 14 g Chloral hydrate  





10% Horse serum  
100 units Penicillin  
0.1 mg/ml Streptomycin   
2 mM GlutaMax 
 
Dispase II (stock solution) 10 mg/ml Dispase II 
50 mM HEPES 
 
Collagenase D (stock solution) 100 mg/ml Collagenase D 
Steril HBSS 
 
DNase I (stock solution) 5 mg/ml DNase I  
Steril HBSS 
Abbreviation: 
BME: Eagle′s Basal Medium; DAB: 3,3'-diaminobenzidine BSA: bovine serum albumin; EDTA:     
ethylenediamine tetraacetic acid disodiumsalt dehydrate; PBS: phosphate buffered salt solution; 
Tris: tris(hydroxymethyl)aminomethane; LFB: Luxol Fast Blue; PFA: paraformaldehyde; 
DNase: desoxyribonuclease; TAE: Tris-acetate-EDTA 
2.1.3 Enzymes/ proteins 
Table 3: Enzymes/ proteins 
Enzymes/ proteins Source of supply 
ExtrAvidin-Peroxidase (0.01% solution) Sigma Aldrich, Germany 
Proteinase K Sigma Aldrich, St. Louis, MO, USA 
Trypsin-EDTA (0.05%) Gibco, life technologies, Germany 
BSA (bovine serum albumin) SERVA Electrophoresis GmbH, Heidelberg,      
Germany 
Collagenase D Roche, Basel, Switzerland 
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Enzymes/ proteins Source of supply 
Dispase Roche, Basel, Switzerland 
DNase I Worthington, Lakewood, USA 
N-glycosylase Eurogentic, Germany 
2.1.4 Kits 
Table 4: Kits 
Kits  Source of supply 
qPCR Core Kit  Eurogentic, Germany 
RNeasy Mini Kit  Qiagen, Germany 
TaqMan MicroRNA Reverse Transcription   
Kit 
Applied Biosystems, life technologies,   
Germany 
TopTaq Master Mix Kit Qiagen, Germany 
Abbreviations: 
RNA: ribonucleic acid 
2.1.5 Monoclonal antibodies for flow cytometry 
Table 5: Monoclonal antibodies for flow cytometry 
Specificity Fluorochrome Clone Dilution Source of supply 
CD86 APC Cy7 GL1 1:200 Biolegend  
H-2Kb (MHCI) FITC AF6-88.5 1:200 BD Pharmagen  
CD45 PerCP 30-F11 1:200 BD Pharmagen 
CD11b BV421 M1/70 1:200 Biolegend 
CD80 PE 16-10A1 1:200 Biolegend 
CD16/32 - 93 1:100 Biolegend 
Abbreviations: 
CD: cluster of differentiation; MHCI: major histocompatibility complex class I molecule; FITC: 
fluorescein isothiocyanate; PE: phycoerythrin; PerCP: peridinin chlorophyll protein APC: 
allophycocyanin; BV: brilliant violet; APC Cy7: allophycocyanin cyanine 7 
 
2.1.6 Primary antibodies for immunohistochemistry and fluorescence 
immunohistochemistry 
Table 6: Primary antibodies for immunohistochemistry and fluorescence 
immunohistochemistry 
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MBP myelin protein Rabbit/ Poly-
clonal/ 62301  
 




GFAP: glial fibrillary acidic protein; CNPase: 2',3'-Cyclic-nucleotide 3'-phosphodiesterase; Olig: 
oligodendrocyte transcription factor; p25/TPPP: brain-specific 25-kDa protein; Ki: Kiel; Mac: macrophage; 
APP: amyloid precursor protein; FRU: fiber reissner urea; AFRU: antiserum against fiber reissner urea; 
MBP: myelin basic protein  
2.1.7 Secondary antibodies for immunohistochemistry and fluorescence 
immunohistochemistry 
Table 7: Secondary antibodies for immunohistochemistry and fluorescence 
immunohistochemistry 
Antibody Conjugation Host Dilution Source of supply 
Anti rabbit IgG  Cy3 conjugated goat 1:100 Jackson 
ImmunoResearch 
Anti mouse  IgG Cy2 conjugated goat 1:100 Jackson 
ImmunoResearch 
Anti-rabbit IgG biotinylated goat 1:200 Jackson 
ImmunoResearch 
Anti-mouse IgG biotinylated sheep 1:200 GE Healthcare 
Anti-rat IgG biotinylated goat 1:500 DCS Innovative 
diagnostic system 
Anti-mouse IgG Alkaline 
phosphatase  
Goat 1:50 DAKO 
Abbreviations:     
IgG: immunoglobulin G; Cy3: cyanine 3; Cy2: cyanine 2 
2.1.8 Oligonucleotide primers 
Table 8: Oligonucleotide primers 
Primer  Sequence Function  Used for  
N43NeodelCKOF 5’-TCT GGA TGG 
CCT TTC CTT CAG 
TCA C-3’ 
Forward primer to 






5’-AAC GGT GTG 
AGG GTT GTG GCA 
G-3’ 
Reverse primer to 
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Primer  Sequence Function  Used for  
GFAPCRE TG  
oIMR1084 
 
5‘-GCG GTC TGG 
CAG TAA AAA CTA 
TC-3‘ 
 
Forward primer to 
detect cre  
GFAP cre mice 
73.12Mvs/J 
 
GFAPCRE TG   
oIMR1085 
 
5’-GTG AAA CAG 
CAT TGC TGT CAC 
TT-3’ 
 
Reverse primer to 
detect cre 
GFAP cre mice 
73.12Mvs/J 
 
RFX4 variant v3 Fw 
 
 
5’-ATG CAT  TGT 
GGG TTA CTG GAG-3′ 
Forward primer to 
detect RFX4_v3 
 
RFX4 variant v3 
 
RFX4 variant v3 Rev 5‘-TGA ATA TGC CAC 
TGT CTG TTT G-3’ 
Reverse primer to 
detect RFX4_v3 
 
RFX4 variant v3 
RFX4 variant v2/v4 FW 5‘-GGG CTT CTC CAA 
ACT CCT GT-3′ 
 
Forward primer to 
detect RFX4 v2/v4 
RFX4 variant v2/v4 
 
RFX4 variant v2/v4 Rev 5’-AGC CAC TTT TAG 
CCA CTC ATC-3′ 
Reverse primer to 
detect RFX4 v2/v4 
 
RFX4 variant v2/v4 
 
RFX4 variant v1 FW 5‘-GCA GAA ATA TCA 
CGG AAT GGT-3′ 
 
Forward primer to 
detect RFX4 v1 
RFX4 variant v1 
RFX4 variant v1 Rev 5‘-AGC CAC TTT TAG 
CCA CTC ATC-3′ 
Reverse primer to 
detect RFX4 v1 
RFX4 variant v1 
Source of supply:  
Oligonucleotide primers were ordered from Metabion, Planegg/Steinkirchen, Germany. 
2.1.9 TaqMan Expression Assays 
Table 9: TaqMan Expression Assays 
Gene symbol Gene name Source of supply 
GapDH Glyceraldehyde-3-phosphate 
dehydrogenase 
Applied Biosystems, life technologies/ 
Mm99999915_g1 
RFX4 Regulatory factor X 4 Applied Biosystems, life technologies/ 
Mm01240658_m1 
GFAP  Glial fibrillary acidic protein Applied Biosystems, life technologies/ 
Mm01253033_m1 
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Gene symbol Gene name Source of supply 
TNF-α Tumor necrosis factor alpha Applied Biosystems, life   
technologies/ Mm00443258_m1 
CXCL10 Chemokine (C-X-C motif) ligand 
10 
Applied Biosystems, life   
technologies/ Mm00445235_m1 
CCL2 Chemokine (C-C motif) ligand 2 Applied Biosystems, life      
technologies/ Mm00441242_mI 
CCL3 Chemokine (C-C motif) ligand 3 Applied Biosystems, life      
technologies/ Mm00441259_gI 
CXCL12 Chemokine (C-X-C motif) ligand 
12 
Applied Biosystems, life 
technologies/Mm00445553_m1 
IL-1ß Interleukin 1 beta Applied Biosystems, life 
technologies/Mm00434228_m1 
Wnt3 Wingless-type MMTV integration 
site family, member 3 
Applied Biosystems, life 
technologies/Mm00437336_m1 
Wnt3a Wingless-type MMTV integration 
site family, member 3a 
Applied Biosystems, life 
technologies/Mm00437337_m1 
Foxa2 Forkhead box A2 Applied Biosystems, life 
technologies/Mm01976556_s1 
Ctnnb1 Beta-catenin-1 Applied Biosystems, life 
technologies/Mm00495976_m1 
Fzd10 Frizzled class receptor 10 Applied Biosystems, life 
technologies/Mm00558396_s1 
Rspo1 R-spondin 1 Applied Biosystems, life 
technologies/Mm00507077_m1 
Vtn Vitronectin  Applied Biosystems, life      
technologies/ Mm00483039_m1 
CX3CL1 Chemokine (CX3C motif) ligand 1 Applied Biosystems, life 
technologies/Mm00436454_m1 
FAM labeled primers/probes were selected to be intron spanning. 
2.1.10 Consumables 
Table 10: Consumables 
Consumable Source of supply 
96 PCR Plate Biosphere Plus Sarstedt 
Tubes (50 ml, 15 ml, 2 ml, 1,5 ml, 0.2 ml) Sarstedt, Nuembrecht, Germany 
Cell culture flask, 25 cm2 Greiner bio-one, Kremsmuenster, Austria 
MS columns Miltenyi Biotec, Bergisch Gladbach,     
Germany 
Bottle top filter, 0.2 µm Sarstedt, Nuembrecht, Germany 
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Consumable Source of supply 
Bottle top filter, 0.2 µm Sarstedt, Nuembrecht, Germany 
Cryogenic tubes Thermo Scientific, Waltham, MA, USA 
FACS tube, 5 ml BD Biosciences, Franklin Lakes, NJ, USA 
Needles BD Biosciences, Franklin Lakes, NJ, USA 
Syringes BD Biosciences, Franklin Lakes, NJ, USA 
Syringes  B Braun, Melsungen, Germany  
Nunc™ MicroWell™ Plates, 96 well round 
bottom 
Thermo Scientific, Waltham, MA, USA 
Bottle top filter, 0.2 µm Sarstedt, Nuembrecht, Germany 
Glass microscope slides (Superfrost Plus) Thermo Scientific, USA 
24-well tissue culture plates,  sterile Greiner bio-one, Kremsmuenster, Austria 
BD FalconTM tube, 50 ml BD Biosciences, Germany 
BD FalconTM tube, 15 ml BD Biosciences, Germany 
70 µm cell strainer  BD Biosciences, Germany 
Abbreviations 
FACS: fluorescence-activated cell sorting 
2.1.11 Technical devices 
Table 11: Technical devices  
Device Source of supply 
Cell incubator CWJ300DABA Cellstar, Nunc GmbH, Germany 
Neubauer chamber Superior Marienfeld, Lauda-Koenigshofen,   
Germany 
Centrifuge 5415 R Eppendorf, Hamburg, Germany 
Centrifuge 5810 R Eppendorf, Hamburg, Germany 
FACS Aria™ II BD Biosciences, Franklin Lakes, NJ, USA 
Ocular counting grid, WHSZ 10X-H Olympus, Germany 
Microtome SM2000R Leica, Germany 
Microwave NN E201 WM Panasonic, Germany & Austria 
Light microscope BX41 Olympus, Germany 
iQ5 Real-Time PCR Detection System Bio-Rad, Germany 
Thermo mixer comfort Eppendorf, Hamburg, Germany 
UV transluminator Vilber Lourmat, Eberhardzell, Germany  
T3 Thermocycler Biometra, Germany 
Speed vacuum Concentrator 5301 Eppendorf, Hamburg, Germany 
Fluorescence microscope BX51 Olympus, Germany 
OctoMACS™ separator Miltenyi Biotec, Bergisch Gladbach,   
Germany 
Camera for fluorescence microscope XM10 Olympus, Germany 
Camera for light microscope DP71 Olympus, Germany 
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Device Source of supply 
Mastercycler gradient  Eppendorf, Hamburg, Germany 
Excelsior AS tissue processor Thermo scientific 
Microscop IX51 Olympus, Germany 
Abbreviations: 
FACS: fluorescence-activated cell sorting; MACS: magnetic-activated cell sorting 
 
2.1.12 Software 
Table 12: Software 
Software   Source of supply 
GraphPad Prism 5.01 GraphPad, USA 
FlowJo 7.6.1 Tree Star Inc., Ashland, OR, USA 
BD FACSDiva Software 6.1.2 BD Biosciences, Franklin Lakes, NJ, USA 
PSRemote 1.6.5 Breeze systems limited, Camberley, UK 
AnalysisTM Olympus, Germany 
CellSensDimension 1.7 Olympus, Germany 
iQ5 Optical System Software Bio-Rad, Germany 
 
2.1.13 Tissue from MS patients  
Table 13: Tissue from MS patients 
Case-number Age Sex MS lesion 
B515/10K-2 31 m Early active 
A20/12 63 f Chronic inactive 
The types of MS lesions were determined by Dr. Andreas Junker and Prof. Christine Stadelmann. 
2.2 Animals 
2.3 Mouse strains  
All mutant mice were generated from in house breeding colonies at the animal facility 
of the University Medical Center Goettingen. 
C57Bl/6J mice 
 
Seven- to eight-week-old C57Bl/6J mice were purchased from Charles River 
laboratories, Sulzfeld, Germany or from the animal facility of the University Medical 
Center Goettingen. C57BL/6J P0 mice were provided by the animal facility of the 
University Medical Center Goettingen. 
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RFX4 flox/flox 
 
The RFX4 flox/flox mice were generated and provided by Dr. Perry Blackshear. This 
line was backcrossed to C57BL/6 animals. This strain contains LoxP sites flanking the 
exon 4 of the RFX4 gene.  
 
GFAP-Cre 73.12 mice 
 
The GFAP cre line 73.12 was purchased from Charles River, Germany.  
GFAP cre 73.12 mice are generated and characterized by Michael V Sofroniew in 2004 
(Garcia, A Denise R et al., 2004). This line was backcrossed to C57BL/6 animals for at 
least 14 generations. Cre recombinase activity under control of the GFAP promoter is 
targeted to ependymal cells and to most astrocytes in the healthy and injured brain and 
spinal cord. 
 
GFAP cell specific RFX4 conditional knockout mice  
 
To generate GFAP cell specific RFX4 conditional knockout mice, the GFAP cre line 
73.12 was crossed with the RFX4 flox/flox mice, which results in RFX4 deletion under 
control of the GFAP promoter. The exon 4 of RFX4 is shared with variant 2, and variant 3 
of RFX4. Variant 2 of RFX4 has been identified in the testis, while the RFX4 variant 3 has 
been only identified in the brain (Blackshear et al., 2003; Matsushita et al., 2005). 
Therefore and due to the hydrocephalus phenotype of the GFAP cell specific conditional 
RFX4 knockout mice the strain was designated as RFX4_v3 conditional knockout mice in 
the discussion of the phenotype of GFAP cell specific conditional RFX4 knockout mice 
and in the second part of my thesis.  
2.3.1 Housing 
Animals were housed in the animal facility of the University Medical Center 
Goettingen. Up to 7 mice were housed together on 12/12h light/ dark cycle and had 
access to food and water ad libitum under SPF conditions. Animals were adapted to the 
new environment for at least one week before the experiments were started. All animal 
experiments were performed in accordance with the European Communities Council 
Directive of 24 November 1986 (86/EEC) and were authorized by the Government of 
Lower Saxony, Germany. 
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2.4 Methods 
2.4.1 Genotyping  
DNA extraction 
 
For genotyping, genomic DNA was extracted from tail biopsies of RFX4 flox/flox mice, 
GFAP cre 73.12 mice and GFAP cell specific RFX4 knockout mice. Therefore, the tail 
biopsies were lysed in 350 µl tail lysis puffer with proteinase K (1:100) for at least 2.5 
hours in a thermo mixer (350 rpm, 56°C). The digested tissue was centrifuged for 10 min 
at maximum speed to remove remaining tissue. The genomic DNA in the supernatant 
was precipitated with 350 µl isopropyl alcohol and centrifuged for 10 min at maximum 
speed. The pellet was washed with 700 µl 70% ethanol and centrifuged for 5min at 
maximum speed. The supernatant was discarded and the pellet was dried in a speed 
vacuum concentrator. The dried pellet was resuspended in 100 µl bidistilled water.  
 
Genotyping of RFX4 flox/flox and GFAP specific RFX4 conditional knockout mice  
 
PCR reaction was performed with the TopTaq buffer and TopTaq DNA Polymerase.  
 
Each PCR reaction included:   
 
Volume  Component  
10 µl genomic DNA 
0.5 µl 10 mM dNTP mix 
2.5 µl 10 x TopTaq buffer 
0.5 µl 10 pmol oligonucleotide primer (N43NeodelCKOF/ 
N43NeodelCKOR) 
0.125 µl TopTaq DNA polymerase 
10,9 µl bidistilled water 
 
PCR reactions were run in the Eppendorf thermocycler (Mastercycler gradient) at the 
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Temperature Time Step 
94°C     3 min Initial denaturation  
94°C     30 s Denaturation  
60°C     30 s       35 cycles Annealing 
72°C     1 min Extension 
72°C 10 min Final extension  
4°C     ∞ storage 
   
To analyze the amplified PCR product, the samples (10 µl) were loaded on an agarose gel in 
TAE buffer containing ethidium bromide. The endogenous allele was characterized by a 
band at 280 bp, while the floxed allele was detected by a band at 420 bp. Both bands were 
detected in heterozygous animals. 
 
Genotyping of GFAP cre 73.12 mice and GFAP specific RFX4 conditional knockout 
mice  
 
Each PCR reaction included:   
 
Volume  Component  
2 µl genomic DNA 
0.125 µl 10 mM dNTP mix 
2.5 µl 5 x Go-Taq DNA polymerase buffer 
0.25 µl 100 pmol oligonucleotide primer (GFAPCRE TG oIMR1084, 
GFAPCRE TG oIMR1085) 
0.2 µl PfuS DNA polymerase 
7,2 µl bidistilled water 
PCR reactions were run in the T3 thermocycler at the following cycling conditions: 
 
Temperature Time Step 
98.5°C     3 min Initial denaturation  
98.5°C     30 s Denaturation  
65°C     30 s        35 cycles Annealing 
72°C     1 min Extension 
72°C 2 min Final extension  
4°C     ∞ storage 
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To analyze the amplified PCR product, the samples (10 µl) were loaded on an agarose gel in 
TAE buffer containing ethidium bromide. The cre recombinase allele was detected by a band 
at 100 bp. 
2.4.2 PCR for the analysis of RFX4 transcript variants in MS 
The PCR analysis to determine the specific RFX4 variant in MS lesions was performed 
by Andreas Junker. We received a cDNA sample from an active MS lesion from the 
Netherlands brain bank. About 30 ng of the synthesized cDNA was used for each PCR 
reaction. The primers sequence for the specific variant 1, 2/4 and 3 are listed in Table 8.  
Each PCR reaction included:   
 
Volume  Component  
3 µl cDNA 
0.5 µl 10 mM dNTP mix 
2.5 µl 10 x TopTaq buffer 
0.2 µl 100 pmol oligonucleotide primer (Primer pair for RFX4_v1, RFX4_v2/4 or   
RFX4_v3) 
0.125 µl Taq DNA polymerase 
15.6 µl bidistilled water 
 
PCR reactions were run in the Eppendorf thermocycler at the following cycling conditions: 
 
Temperature Time Step 
95°C     5 min Initial denaturation  
95°C     1 min Denaturation  
55°C     30 s        35 cycles Annealing 
72°C     45 s Extension 
72°C 10 min Final extension  
10°C     ∞ Storage 
 
To analyze the amplified PCR product, the samples (10 µl) were loaded on an agarose gel in 
TAE buffer containing ethidium bromide. The RFX4 variant 1 was characterized by a band at 
260 bp, the RFX4 variant 2 and 4 by a band at 270 bp and RFX4 variant 3 by a band at 
about 500 bp.  
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2.4.3 Cuprizone mouse model 
To analyze demyelination seven to eight week old GFAP cell specific RFX4 conditional 
knockout mice and C57BL/6J mice were fed with the cupper chelator cuprizone in normal 
chow (0.25%) for 4 weeks. To analyze remyelination the 0.25% cuprizone diet was 
removed after 4 weeks and mice were fed with a normal diet for either 7 or 14 days. After 
de- and remyelination brains of mice were prepared for analysis by histochemistry, 
immunohistochemistry, flow cytometry and real time quantitative PCR. 
2.4.4 Histology 
To perform histology mice were transcardially perfused with a 4% PFA solution in 
PBS. Therefore mice were intraperitoneally injected with a lethal dose of a 14% chloral 
hydrate solution. Perfusion was performed through the left heart ventricle briefly with PBS 
and followed by 4% PFA solution. For post- fixation brain, liver and spleen from each 
mouse were removed and collected in 4% PFA for at least 2 days. After post fixation the 
tissue was transferred to PBS and embedded in paraffin. Therefore brains were cut into 
2-3 mm coronal sections, washed in water, dehydrated over night 
(alcohol/xylene/paraffine series) and then embedded into paraffin. For histological 
analysis embedded coronal brain sections were cut using a sliding microtome to obtain 1 
µm thick sections. These 1 µm sections were mounted onto glass slides. The tissue 
sections were then deparaffinized and rehydrated. For deparaffinization sections were 
prior incubated for one hour at 60°C and then transferred to xylene. The deparaffinization 
and rehydration steps were performed as follows:  
 
4x  10min  xylene  
1x    5min  xylene/ isopropyl alcohol 
2x    5min  100% isopropyl alcohol  
1x    5min   90% isopropyl alcohol  
1x    5min   70% isopropyl alcohol  
1x    5min    50% isopropyl alcohol  
   distilled water 
 
After histochemistry or immunohistochemistry sections were dehydrated by performing 
the xylene/ isopropyl series above in a reversed direction. Finally, sections were mounted 
with DePex mounting medium. 
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2.4.5 Luxol Fast Blue - Periodic Acid Schiff (LFB-PAS) staining 
LFB-PAS staining was performed to determine the extent of demyelination in RFX4 
conditional knockout mice and C57BL/6J mice. Therefore brain sections were 
deparaffinized, rehydrated to 90% isopropyl alcohol and incubated in LFB working 
solution over night at 60°C. The following day sections were washed with 90% isopropyl 
alcohol. For the differentiation step, sections were shortly incubated in 0.05% lithium 
carbonate, 70% isopropyl alcohol and finally washed in distilled water to stop the 
differentiation. These 3 steps were repeated until only the myelin appeared deep blue. 
For the PAS staining sections were transferred in 1% periodic acid for 5 min, washed in 
distilled water and incubated in Schiff’s reagent for 30 min. Then the sections were 
washed for 20 min with tap water. To counterstain the nuclei the sections were incubated 
for 2 min in Mayers Hämalaun, washed in distilled water and shortly incubated in 1% 
HCL-isopropyl alcohol for the differentiation. Finally the sections were shortly washed in 
distilled water and subsequently transferred for 10 min to tap water. 
2.4.6 Hematoxylin and eosin (H&E) staining 
H&E staining was performed to analyze the hydrocephalus and in particular the SCO 
of RFX4 conditional knockout mice. Therefore sections were deparaffinized, rehydrated 
and incubated for 8 min in Mayers Hämalaun. For differentiation the sections were 
transferred to 1% HCL-isopropyl alcohol, shortly washed in distilled water and transferred 
for 10 min to tap water. Then the sections were transferred to a 1% eosin solution for 1 
min and finally dehydrated and mounted with DePex.  
2.4.7 Immunohistochemistry and fluorescence immunohistochemistry 
Primary and secondary antibodies used for immunohistochemistry (IHC) and 
fluorescence immunohistochemistry are listed in Table 6 and Table 7.  
2.4.7.1 Immunohistochemistry 
Many epitopes are masked in formalin fixed tissue. For de-masking epitopes sections 
were heated in a microwave with either 10 mM citric acid buffer or 1 mM Tris-EDTA buffer 
(5 times for 3 min). The epitope retrieval buffer used for each primary antibody is listed in 
Table 6. After epitope retrieval the sections cooled down at RT and were washed with 
bidistilled water. In the next step the sections were transferred to 3% H2O2 in PBS for 20 
min at 4°C to block the endogenous peroxidase. The sections were then washed with 
PBS and subsequently incubated with blocking buffer for at least 20 min to reduce 
unspecific antibody binding (Table 6). After these procedures the sections were prepared 
for primary and secondary antibody incubation. All primary antibodies were diluted in 
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blocking buffer and incubated over night at 4°C and then washed three times with PBS. 
Primary antibody binding was visualized by using biotin conjugated secondary antibodies, 
ExtrAvidin-Peroxidase and DAB. Therefore the sections were incubated for 1 h with the 
secondary antibody diluted in blocking buffer, another 1 h with the ExtrAvidin-Peroxidase 
1:1000 in blocking buffer and subsequently washed with PBS. Finally DAB working 
solution was used to visualize the antibody binding. Thereby DAB is oxidized by the 
peroxidase, which produces a dark brown reaction. In the double IHC for RFX4 and 
GFAP, GFAP was visualized with an alkaline phosphatase conjugated secondary 
antibody and Fast blue. The counterstain of the nuclei was performed with Mayers 
Hämalaun as described above.  
2.4.7.2  Fluorescence immunohistochemistry 
Fluorescence double IHC was performed for RFX4 and GFAP (monoclonal mouse 
antibody). For that purpose the sections were incubated consecutively with the primary 
and secondary antibodies. Between each antibody incubation step, the sections were 
washed for three times with PBS. The primary antibodies were visualized with cyanine 
Cy3-conjugated goat-anti-rabbit IgG (RFX4) and Cy2-conjugated goat-anti-mouse IgG 
(GFAP). 
Finally sections were incubated with DAPI (1:10,000) for 10-15 min at RT to 
counterstain the nuclei.  
2.4.8 Morphometry and data aquisition 
LFB-PAS stained sections and myelin proteins MBP, CNPase  
 
To evaluate the extent of demyelination in the corpus callosum of RFX4 conditional 
knockout mice and C57BL/6J mice after 1, 2, 3, 4 weeks of demyelination and after 7 or 
14 days remyelination a semi quantitative score was used as follows: 
 
Score  Extent of demyelination  
0 No demyelination 
1 0-33% demyelination  
2 33%-66% demyelination  
3 >66% demyelination  
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      Mac3+ microglia/ macrophages  
 
The density of Mac3 positive cells after 1, 2, 3 weeks cuprizone treatment and 14 days 
of remyelination in the corpus callosum was determined at 400x magnification with an 








Mac3 positive cells after 1, 2, 3 weeks cuprizone treatment and 14 days of remyelination 
in the corpus callosum were counted at 400x magnification with an ocular counting grid. 
 
APP+ spheroids and glial cells 
 
To assess the number of APP+ spheroids and GFAP+, Olig2+, p25+ cells in corpus 
callosum of RFX4 conditional knockout mice and control mice, cells were counted at 400x 
magnification with an ocular counting grid 
 
Caspase3+ cells  
 
Caspase3 positive cells were counted at 400x with an ocular counting grid after 1 
week of cuprizone treatment. 
 
     Double immunohistochemistry of RFX4 and GFAP in MS lesions 
 
Double immunohistochemistry of RFX4 and GFAP were analyzed in a chronic inactive 
MS lesion and in a early active lesion. The types of MS lesions were determined by Dr. 
Andreas Junker and Prof. Christine Stadelmann. 
  
Score  Extent of microgliosis   
0 few microglia 
1 0-33% moderate microgliosis 
2 33%-66% marked microgliosis  
3 >66% severe microgliosis  
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2.4.9 Isolation of astrocytes from newborn mice 
For isolation of astrocytes newborn (P0) RFX4 conditional knockout mice and 
C57BL/6J mice were decapitated. The skulls were immediately opened and the brains 
were removed and transferred into pre-warmed HBSS (37°C). To minimize fibroblast 
interference to glia cell growth meninges were removed from the brain with a forceps. 
After these procedures brains were collected and washed in HBSS. In a following step 
brains were dissected and digested with a 0.05% Trypsin EDTA solution (500 µl per 
brain) for 10 min at 37°C. The reaction was stopped by adding BMEcomplete and a cell 
suspension was produced by pipetting up and down with a sterile pipette (10 ml).  After a 
centrifugation step (200 x g for 10 min) the supernatant was exchanged by fresh 
BMEcomplete and the pellet was resuspended. The cell suspension was then transferred 
into a PLL coated flask and incubated at 5% CO2 and 37°C in the tissue culture incubator 
(1 brain/ 25 cm2 flask). After 3-5 h medium was exchanged with fresh BMEcomplete and the 
primary cell culture was cultured until the cells build a 100% confluent layer. Every 3 to 4 
days medium was exchanged with fresh BMEcomplete.  
Oligodendrocytes and microglia cells were removed by vigorously agitating and 
washing the cells several times with PBS. The remaining astrocytes were detached with 
0.05% Trypsin-EDTA (2-3 min). To stop Trypsin-EDTA reaction BMEcomplete was added to 
the cell suspension and then centrifuged at 200 x g for 10 min. The pellet was 
resuspended in BMEcomplete and the number of astrocytes was calculated using a 
Neubauer counting chamber. For the quantitative PCR and the migration assay 
astrocytes were plated in PLL coated 24 well plates at a density of 120,000 cells per well 
in BME medium containing 10% FCS and were cultured for another 48 h. 
2.4.10 In vitro migration assay 
A cell migration assay was performed to test if astrocyte functions differ between 
RFX4 conditional knockout mice and C57BL/6J mice. Thereby the ability of astrocytes to 
migrate into a cell- free area was investigated. In a confluent astrocyte monolayer a 
scratch (straight line) was set with a 10 µl pipet tip. To remove cellular debris the cell 
culture was washed with BME media. In order to always catch the same area during 
image acquisition, a reference point on the bottom of the 24-well plate was made with a 
tip marker. Images were taken after 0, 24, 33 and 48 h. Images acquired for each well 
were further analyzed using the software AnalysisTM. Migration assays were performed 
twice with at least 3 animals (at least 3 wells/ animal) per group. 
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2.4.11 Quantitative PCR analysis 
Quantitative PCR analysis of the transcript RFX4 in MS lesions 
 
The quantitative PCR analysis of RFX4 in MS lesions was performed by Dr. Andreas 
Junker. Frozen 10 µm thick sections were mounted on membrane-covered polyethylene 
naphthalate slides (Zeiss, Jena, Germany). Parallel sections were stained with LFB to 
allow identification of the lesions. Tissue blocks were classified according to defined 
criteria: active lesions contained abundant macrophages with early (LFB and Oil Red O 
positive) myelin degradation products, either throughout the whole lesion or in a broad 
rim at the lesion edge. Inactive demyelinated lesions were sharply demarcated from the 
periplaque white matter, lacked a rim of microglia activation and were devoid of LFB or 
Oil Red O-reactive myelin degradation products in immune cells. 
For the analysis of mRNA transcripts, white matter MS lesions or control white matter 
specimens were dissected from the slides with a scalpel and 15 sections were pooled for 
RNA extraction. This mRNA analysis was restricted to white matter tissue samples to 
limit possible confounding effects of neuronal mRNAs. The qPCR was performed on the 
ABI 7900 (Applied Biosystems) using the qPCR Core Kit and uracyl N-glycosylase to 
determine the expression level of RFX4 and other transcripts.  
 
Quantitative PCR analysis of transcripts in P0 astrocytes  
 
Quantitative PCR was performed from cultured P0 astrocytes of RFX4 conditional 
knockout mice and C57BL/6J mice to characterize hydrocephalus involved genes. 
Therefore cultured astrocytes were washed twice with PBS, lysed with QIAzol Lysis 
Reagent and used for RNA isolation. 
 
Quantitative PCR analysis of transcripts in corpora callosa  
 
The transcript levels of RFX4, GFAP, cytokines and chemokines in the corpora callosa 
were measured by quantitative PCR. GFAP cell specific RFX4 conditional knockout mice 
and C57BL/6J mice were perfused with PBS after one week of 0.25% cuprizone 
treatment. The brains were removed and cut into 2-3 mm coronal sections. Brain slices 
with corpora callosa were briefly frozen in liquid nitrogen and the corpus callosum was 
immediately excised and transferred in QIAzol Lysis Reagent for the RNA isolation 
procedure. The experiment was repeated twice and one representative experiment is 
depicted in the results. 
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2.4.11.1 Isolation of RNA 
RNA was isolated from the corpus callosum and primary astrocyte cultures using the 
RNeasy Mini Kit according to the manufacturer’s instructions.  
2.4.11.2 cDNA Synthesis 
The complementary DNA (cDNA) synthesis was performed with the TaqMan 
MicroRNA Reverse Transcription Kit and Random Hexamers. Each reaction included 
300-500ng of the isolated RNA, 1 x RT buffer, 4 mM dNTPs, 10 µM Random Hexamers, 
1 U/µl RNase Inhibitor and 2.5 U/µl MultiScribe Reverse Transcriptase. Reverse 
transcription reactions were run in the Eppendorf thermocycler (Mastercycler gradient) at 
the following cycling conditions: 
 
Temperature Time Step 
25°C     10 min Annealing 
37°C     120 min Reverse transcription 
85°C     5 s              Inactivation of reverse 
transcriptase 
2.4.11.3 Quantitative PCR 
The quantitative PCR was performed with the qPCR Core Kit and TaqMan gene 
expression Assays according to the manufacturer´s instructions. For the quantitative PCR 
reaction the cDNA was first diluted to a concentration of 3 ng/µl. From the diluted cDNA 4 
µl (12 ng) was used per qPCR reaction. Quantitative PCR reactions were run in the iQ5™ 
Real Time PCR Detection System at the following cycling conditions: 
 
Temperature  Time Step 
98.5°C      3 min Initial denaturation  
98.5°C      30 s      40 cycles Denaturation  
65°C      30 s              Annealing/elongation 
 
The expression level of each transcript is indicated as the percentage of the 
housekeeping gene Gapdh.  
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2.4.12 Isolation of murine microglia cells from the corpus callosum for flow 
cytometry 
The isolation of phagocytes from the corpus callosum was established by and 
performed together with Dr. Martina Ott.  
To isolate phagocytes from the corpus callosum, mice were intraperitoneally injected 
with a lethal dose of a 14% chloral hydrate solution and transcardially perfused with cold 
PBS. The brains were immediately removed and cut in 2-3 mm coronal sections with a 
razor blade. The corpus callosum was immediately excised and transferred to a 70 µm 
cell strainer, homogenized in cold DMEM medium and centrifuged for 10 min at 300 x g, 
4°C. In the next step the enzyme mix was prepared with a final concentration of 1 mg/ml 
Dispase II, 2.5 mg/ml Collagenase D and 1 mg/ml DNase I in DMEM medium (2 ml/ 
corpus callosum). Each corpus callosum pellet was resuspended in 2 ml of the enzyme 
mix and pre-incubated for 10 min at 37°C. The incubation was continued with rotation for 
40 min at 37°C. To stop the reaction 10 ml of DMEMFACS buffer was added to the digest, 
mixed and centrifuged for 10 min at 300 x g, 20°C. The pellet was then washed by 
resuspending the cell suspension in 10 ml DMEMFACS buffer and spinning 10 min at 300 x g, 
20°C.  
During the centrifugation step the Percoll gradient was prepared. Therefore a 38% 
percoll solution containing 2.8 ml percoll and 1.2 ml DMEMFACS buffer and a 70% percoll 
solution containing 1.9 ml percoll and 3.1 ml DMEMFACS buffer was prepared for each 
corpus callosum. The 70% percoll solution was transferred to a 15 ml canonical tube (5 
ml per corpus callosum).  
After the centrifugation the supernatant was discarded and the pellet was resuspended 
in the 38% percoll solution (4 ml per corpus callosum) and transferred to the 15 ml 
canonical tube by slowly pipetting the 4 ml 38% percoll solution on top of the 70% percoll 
solution. The gradient was centrifuged for 25 min at 500 x g, 20°C. The centrifuge 
stopped with no brake so that the interphase was not disturbed. From the 70%-38% 
interphase 2.0 - 2.5 ml was collected into a clean 15 ml canonical tube. To wash the cells 
10 ml FACS buffer was added, mixed and centrifuged for 10 min at 300 x g, 4°C. The cell 
pellet was then resuspended in FACS buffer and used for the FACS staining. 
2.4.12.1 FACS staining of phagocytes 
After the gradient, cells from each animal were resuspended in FACS buffer (200 µl/ 
FACS antibody), distributed on a 96 well plate and centrifuged for 5 min at 300 x g and 
4°C. After the washing step the cell pellets were resuspended in 100 µl blocking buffer 
and incubated for 10 min at 4°C. The blocking buffer included anti-CD16/CD32 antibody 
diluted 1:100 in FACS buffer. To prepare the fluorochrome-labeled antibody mix, 
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antibodies were diluted 1:100 in FACS buffer. From the antibody mix 100 µl were added 
to each well to obtain a final dilution of 1:200. The cells were then incubated for another 
20 min at 4°C. After these procedure cells were centrifuged (5 min, 300 x g, 4°C), and 
washed with 100 µl FACS buffer. Finally cells were resuspended in 200 µl FACS buffer 
and analyzed by flow cytometry.  
2.4.12.2 Flow cytometry analysis 
Microglia cell sorting and flow cytometry analysis were performed by Sabrina Becker 
of the Flow cytometry core facility at the University Medical Center Goettingen. 
2.4.13 Statistical analysis 
All statistics were calculated using the GraphPad Prism5.01 software. The data were 
first tested for normal distribution with the Kolmogorov-Smirnov test with Dallal-Wilkinson-
Lilliefor p-value. For two experimental groups, unpaired t test was performed for 
parametric values, while the Mann-Whitney test was performed for non-parametric 
values. For comparison of more than 2 groups, one way ANOVA with Bonferroni post test 
was used for parametric data, while the Kruskal-Wallis test with Dunn’s post test was 
carried out for non-parametric data. Statistical significance was defined by p<0.05. 
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3 Results  
3.1 Part 1: Characterization of the GFAP cell specific RFX4 
conditional knockout mice  
3.1.1 Hydrocephalus and mortality of RFX4 conditional knockout mice  
 
Figure 2: Hydrocephalus and mortality of GFAP cell specific RFX4 conditional knockout mice. 
(A-B) Appearance of wild type (A) and mutant (B) mice at the age of 5 weeks. (C) H&E stained 
sagittal sections from RFX4 +/+ mice, RFX4 +/- and RFX4 -/- mice with extensive dilatation of the 
lateral ventricle. (D) Kaplan-Meier survival curve of RFX4 +/- mice , RFX4 -/- mice and RFX4 +/+ mice 
(littermate control mice). Lv, lateral ventricle, IVv, fourth ventricle. Scale bar = 1 mm 
To generate GFAP cell specific RFX4 conditional knockout mice, GFAP cre mice, 
expressing the Cre recombinase under control of the GFAP regulatory sequence 
(promoter), were crossed with RFX4 LoxP (floxed) mice. GFAP cell specific RFX4 
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conditional knockout mice were born at the expected Mendelian ratio, were normal in size 
and appearance at birth. Several of the heterozygous mice and a large percentage of the 
homozygous mice exhibited head swelling (Figure 2 A, B) followed by neurological 
deficits like convulsions and loss of balance, that ended in death in young adulthood. 
Heterozygous mice died at an age of 6 weeks and most RFX4 homozygous mice died 
between 4 to 6 weeks as shown in the Kaplan-Meier survival curve (Figure 2 D). The 
mortality rate at an age of 6 weeks was about 20% for RFX4 +/- mice, whereas RFX4 -/- 
mice died with a rate of about 50% at the same age. This implies a gene dosage effect. 
Mice which did not develop a hydrocephalus had a normal phenotype. Histological 
examination of the brains of symptomatic adult mice manifested severe hydrocephalus, 
with extensive dilatation of the lateral ventricles, but no distention of the fourth ventricle 
(Figure 2 C). Investigation of transgenic mice at the time of birth or few days after birth 
showed that the hydrocephalus was already present, indicating that the hydrocephalus is 
congenital (Figure 3). This suggested a congenital blockage in the aqueduct of Sylvius as 
has been reported for RFX4_v3 transgenic mice generated by Blackshear and 
colleagues, which leads to disruption of RFX4_v3 (Blackshear et al., 2003).  
 
 
Figure 3: Hydrocephalus of newborn RFX4 conditional knockout mice.  
H&E stained sections from rostral (r) to caudal (c), from both P1 and P3 RFX4 homozygous 
conditional knockout mice and P3 wild type animals. Lv, lateral ventricle. Scale bar = 1 mm 
3.1.2 Hydrocephalus in RFX4 conditional knockout mice is associated with 
abnormalities of the subcommissural organ  
The primary cause of a congenital hydrocephalus is stenosis or narrowing of the 
Sylvian aqueduct in the midbrain. The origin of the stenosis is not well understood, but it 
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has been reported that maldevelopment and resulting dysfunction of the SCO is involved 
in the cause of aqueductal stenosis (Overholser et al., 1954; Vio et al., 2000). The SCO 
is a small gland that secretes glycoproteins of high molecular mass into the ventricles to 
form Reissner’s fiber (Nualart et al., 1991; Rodríguez et al., 1998). The SCO is situated in 
the dorsocaudal region of the third ventricle at the entrance of the Sylvian aqueduct 
(Rodríguez et al., 1998). 
Part of the thesis was to explain the reason for the hydrocephalus formation in RFX4 
conditional knockout mice. For that purpose, the severity of the hydrocephalus in 
symptomatic adult RFX4 conditional knockout mice was assessed in serial sections from 
caudal to rostral. In addition, the presence of the SCO and the severity of SCO 
hypoplasia was investigated (Table 14). 10 homozygous and 8 heterozygous mice with 
hydrocephalus were analyzed. 













Severity of SCO 
hypoplasia 
 Moderate Marked  Severe  Moderate Marked Severe 
RFX4 +/- 8 4 2 2 8 4 3 1 
RFX4 -/- 10 3 3 4 10 2 4 4 
Sections from caudal to rostral were studied from RFX4 heterozygous and homozygous conditional 
knockout mice with hydrocephalus. The severity of the hydrocephalus, the presence of the SCO and the 
severity of the SCO hypoplasia were assessed. Two representative animals for each genotype are 
presented in Figure 4. 
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3.1.3 GFAP cell specific RFX4 conditional knockout mice suffer from 
congenital hydrocephalus of variable severity 
 
Figure 4: GFAP cell specific RFX4 conditional mice suffer from congenital hydrocephalus of 
variable severity accompanied by SCO hypoplasia.  
H&E histochemistry from wild type and RFX4 deficient mice with hydrocephalus of variable severity 
and SCO hypoplasia of each presented animal. (A,B,C) reflects a wild type mouse, (D,E,F) a RFX4 +/- 
mouse with a moderate hydrocephalus and marked SCO hypoplasia, (G,H,I) a RFX4 +/- mouse with 
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marked hydrocephalus and moderate SCO hypoplasia, (J,K,L) a RFX4 -/- mouse with marked 
hydrocephalus and severe SCO hypoplasia and (M,N,O) shows a RFX4 -/- mouse with severe 
hydrocephalus with severe SCO hypoplasia. SCO, subcommissural organ, Lv, lateral ventricle, IIIv, 
third ventricle, S.aq., Sylvian aqueduct, PC, posterior commissure. Scale bar = (A,D,G;J;M) 1 mm, 
(B,C,E,F,H,I,K,L,N,O) 50 µm 
All analyzed mice developed a hydrocephalus, while the severity of the hydrocephalus 
was variable (Figure 4). Most of the RFX4 +/- mice had a moderate to marked 
hydrocephalus, while the majority of the homozygous animals showed hydrocephalus of 
a marked to severe degree. This may indicate an effect of gene dosage on the severity of 
hydrocephalus. In the most marked to severe cases, hydrocephalus was characterized by 
extensive dilatation of the lateral and third ventricles (Figure 4 G, M), while less severe 
cases showed only a mild dilatation of the lateral ventricles and no distention of the third 
ventricle (Figure 4 D).  
3.1.4 Subcommissural organ hypoplasia 
The SCO was present in all analyzed animals. However all animals studied exhibited 
different degrees of SCO hypoplasia. The degree of SCO hypoplasia correlated well with 
the severity of the hydrocephalus as is shown in Table 14 and Figure 4 G-I and M-O. In 
wild type animals, ependymal cells of the SCO are elongated and their apical poles 
protrude in the direction of the third ventricle, where they secrete glycoproteins (Figure 4 
A-C). In contrast RFX4 conditional knockout mice showed a reduced number of 
ependymal cells (Figure 4 F, I, L, O). Remaining cells in the posterior commissure were 
flattened (Figure 4 I, L), arranged in a disordered fashion (Figure 4 F, O) and their apical 
borders no longer protruded into the lateral ventricle (Figure 4 F; I; L; O). The highly 
specialized ependymocytes of the SCO are either absent or inappropriately differentiated 
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3.1.4.1 Dysfunction of the SCO 
 
Figure 5: Expression of SCO RF glycoprotein is deregulated in RFX4 conditional knockout 
animals.  
IHC with an antibody specific for RF glycoproteins (AFRU) of young adult brain sections of wild type 
and RFX4 deficient mice. (A) represents a wild type mouse, (B-C) a RFX4 +/- mouse and (D-E) shows 
a RFX4 -/- mouse. Scale bar = 50 µm 
Due to maldevelopment of the SCO in RFX4 deficient mice I assumed that the SCO 
may be dysfunctional. A well developed SCO secretes glycoproteins of high molecular 
mass (Nualart et al., 1991). The majority of the glycoproteins are released in the ventricle 
where they aggregate to form a threadlike structure, known as Reissner’s fiber (Sterba 
and Wolf, 1969). To investigate whether the SCO of RFX4 conditional knockout mice is 
functional, adult brain section were stained with an antibody specific for RF glycoproteins 
(AFRU). 
In wild type mice strong RF glycoprotein expression was restricted to the SCO. This 
conspicuous glycoprotein expression was lacking in RFX4 conditionally deficient mice. It 
was replaced by a lower level of SCO glycoprotein production in RFX4 +/- or was 
completely absent in several cases of RFX4 -/- mice (Figure 5). 
3.1.5 Loss of developmental factors impairs SCO formation and function 
The SCO is derived from neuroepithelial cells that line the lumen of the dorsocaudal 
aspect of the diencephalon (Huh et al., 2009). These neuroepithelial precursors of the 
SCO differentiate into specialized secretory ependymocytes in response to the induction 
of Wnt and Bmp signals (Huh et al., 2009). Components of the Wnt and Bmp signaling 
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pathway were reported to be potential targets for RFX4_v3 in E10.5 brains (Blackshear et 
al., 2003; Zhang et al., 2006a). Due to the observed hypoplasia of the SCO of RFX4 
conditional knockout mice I assumed a similar deregulation of the Wnt and Bmp signaling 
pathways in our conditional knockout mouse. In order to test this hypothesis I cultured 
astrocytes of P0 mice and characterized them morphologically. In a second step I 
isolated RNA from P0 astrocytes and measured the expression levels of components 
involved in the Wnt and Bmp signaling pathway by qPCR. A selection of critical genes for 
early brain development, based on a microarray of heads from RFX4_v3 -/- mice at 
E10.5, were measured by qPCR (Zhang et al., 2006a).   
3.1.5.1 Characterization of RFX4 deficient P0 astrocytes in vitro 
 
Figure 6: Characterization of RFX4 deficient P0 astrocytes in vitro.  
(A) Representative IHC for GFAP and RFX4 of wild type and RFX4 deficient astrocytes. (B) 
Quantitative real time PCR for RFX4 from P0 astrocytes obtained from individual wild type and RFX4 
deficient animals (*p<0.01, ***p<0.001, one way ANOVA with Bonferroni post test). (C) Migration 
scratch assay of wild type, RFX4 +/- and RFX4 -/- mice. A scratch was made in an astrocyte 
monolayer from wild type, RFX4 +/- and RFX4 -/- mice. The ability to migrate was compared after 24h, 
33h and 48h. (n(wt)= 4; n(RFX4 +/-)= 3; n(RFX4 -/-)= 5) (C). Data are presented as mean ± SEM. 
Scale bar = 50 µm 
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Astrocytes were isolated and cultured from GFAP cell specific RFX4 conditional 
knockout mice and wild type mice at time of birth. To measure the expression level of 
RFX4 RNA was isolated from astrocytes of RFX4 +/-, RFX4 -/- and wild type mice. 
Quantitative real time PCR showed a significant reduction of RFX4 transcripts in P0 
astrocytes obtained from RFX4 conditional knockout mice compared to wild type mice 
(Figure 6 B). The transcript level of RFX4 showed a reduction of about 3- fold for RFX4 
+/- and about 7- fold for RFX4 -/- compared to wild type astrocytes. 
Immunohistochemistry for GFAP showed characteristically shaped astrocytes 
comparable to the wild type. Immunohistochemistry for GFAP and RFX4 of RFX4 
conditional knockout mice and wild type astrocytes illustrates expression of RFX4 in the 
nucleus, perinucleus and in the cytoplasm of wild type astrocytes. In astrocytes obtained 
from RFX4 -/- mice reduced expression was observed (Figure 6 A).  
A migration assay was performed to test whether RFX4 deficiency affects astrocyte 
functions. A scratch was made in an astrocyte cell monolayer from wild type, RFX4 +/- 
and RFX4 -/- mice and the ability to migrate was compared after 24h, 33h, and 48h. The 
ability to migrate into a cell free area was similar for RFX4 conditional knockout mice and 
wild type animals. In vitro astrocytes from RFX4 conditional knockout mice did not display 
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3.1.5.2 Regulation of hydrocephalus associated genes in RFX4 conditional 
knockout astrocytes. 
 
Figure 7: Regulation of hydrocephalus associated genes in RFX4 conditional knockout 
astrocytes.  
Based on Zhang and colleagues 2006 selected genes relevant for the development of congenital 
hydrocephalus (A) and factors critical for early brain development (B) were analyzed by quantitative 
real time PCR. (A-B) qPCR was performed from mRNA of cultured P0 astrocytes of RFX4 conditional 
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knockout mice and control mice (p>0.05, *p<0.05, **p<0.01, Mann Whitney test). The mean of each 
group is indicated.  
Based on Zhang and colleagues, 2006, which identified potential target genes of the 
brain specific variant 3 of RFX4, the expression levels of selected genes were measured 
by qPCR of RNA from P0 astrocytes isolated from the brains of RFX4 -/- and wild type 
mice. For the Wnt pathway Wnt3, Wnt3a, R-spondin, Frizzeled 10 (Fzd10) and ß-catenin 
were measured. For the Bmp signaling pathway Msx3 and cytochrome P450 26A1 
(Cyp26a) were studied. Furthermore, other factors critical for early brain development 
Foxa2, vitronectin (Vtn), IGF1 and CX3CL1 were measured. The expression levels of 
Wnt3a, Msx3 and Cyp26a were not measurable (too low) in P0 astrocytes with a raw CT 
> 35. Hence a difference between wild type and RFX4 conditional knockout animals was 
not measurable. However mRNA levels of all other transcripts were detectable and were 
evaluated. 
3.1.5.2.1 Transcript changes of Wnt signaling 
The Wnt signaling pathway is an evolutionary conserved pathway that regulates 
important aspects of cell fate determination, cell migration, cell polarity, neural patterning 
and embryonic development (Komiya and Habas, 2014). Zhang and colleagues studied 
potential target genes in RFX4_v3 deficient mice at embryonic stage 10.5 and identified 
four genes which belonged to the Wnt signaling pathway. Their transcript levels were 
dramatically down- regulated in heads from RFX4_v3 -/- mice. The levels of the secreted  
Wnt3 and Wnt3a glycoproteins were decreased by approximately 5- and 16- fold (Zhang 
et al., 2006a). In our RFX4 conditional knockout mice the level of Wnt3 was reduced by 
approximately 3- fold at the time of birth (Figure 7 A). The expression level of Wnt3a was 
not detectable at this time point.  
Fzd10 belongs to the frizzled gene family and was decreased by 2.4- fold in E10.5 
brains of RFX4_v3 -/- mice (Zhang et al., 2006a). In this study it was found to be reduced 
6- fold compared to astrocytes of wild type mice (Figure 7 A). R-spondin was decreased 
by 1.5- fold at E10.5 (Zhang et al., 2006a). The factor is a transmembrane protein that 
acts as activator of the canonical/wnt ß-catenin signaling pathway (de Lau, Wim B M et 
al., 2012). The gene was reduced by about two fold in RFX4 conditional knockout 
astrocytes compared to wild type (Figure 7 A). ß-catenin was not detected by Zhang and 
colleagues in E10.5 heads, but it has been reported that it acts as an intracellular signal 
transducer in the Wnt signaling pathway (Clevers and Nusse, 2012). Further, the gene 
was found to be crucial for proper midbrain development, and mutation of ß-catenin led to 
hydrocephalus (Ohtoshi, 2008). In conditional RFX4 knockout mice, ß-catenin was 
significantly down-regulated by about 1.5- fold (Figure 7 A).  
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3.1.5.2.2 Expression of factors critical for early brain development and neuronal 
regulators  
During neuroblastoma cell differentiation Foxa2 up-regulates Vtn expression (Shimizu 
et al., 2002). Both genes were found to be down-regulated in E10.5 RFX4_v3 -/- heads. 
Vtn was decreased by about 1.7- fold and Foxa2 by about 1.5- fold (Zhang et al., 2006a). 
In RFX4 conditional mice mRNA levels of Vtn were still significantly reduced whereas 
transcript levels of the transcription factor Foxa2 were not significantly changed at the 
time of birth (Figure 7 B). CX3CL1 has been reported as direct target gene, because 
RFX4_v3 binds to the CX3CL1 promoter (Zhang et al., 2006a). CX3CL1 is a chemokine 
that was decreased by approximately 3- fold in E10.5 heads of RFX4_v3 -/- mice (Zhang 
et al., 2006a; Zhang et al., 2008). RFX4 conditional knockout animals showed a reduction 
by approximately 1.7- fold at P0 (Figure 7 B). IGF1 was increased by two fold in E10.5 
heads of RFX4_v3 deficient mice (Zhang et al., 2006a). Insulin like growth factor has 
been shown to play role in regulating neural development including neurogenesis and 
myelination (Beck et al., 1995). Conditional RFX4 knockout mice did also up-regulate 
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3.2 Part 2: The role of astrocytic RFX4_v3 in demyelination 
3.2.1 RFX4 in MS 
3.2.1.1 RFX4 is produced by astrocytes and up-regulated in MS lesions 
 
Figure 8: RFX4 is up-regulated in MS lesions.  
RFX4 expression levels in individual tissue samples were determined by quantitative PCR. The mean 
of each group is indicated. (** p<0.01, Mann Whitney U test).  
MS is an inflammatory, demyelinating, neurodegenerative disorder of the CNS. A wealth 
of data describe that astrocytes play an active and possibly dual role in CNS 
inflammatory diseases such as MS. On the one side they have the ability to increase 
immune responses and inhibit myelin repair, on the other side they can also be protective 
and limit CNS inflammation while supporting oligodendrocyte and axonal regeneration 
(Nair et al., 2008). To determine astrocyte functions during inflammatory demyelination in 
MS lesions, Andreas Junker did a quantitative PCR study of MS lesions, together with 
normal brain white matter as control. 96 astrocyte specific genes, which were identified 
by Cahoy and colleagues 2008, were measured (Cahoy et al., 2008).  
This approach revealed RFX4 as a highly up-regulated factor in MS lesions. The 
transcript level of RFX4 was about 6-fold higher in MS lesions compared to normal brain 
white matter (**p<0.01) (Figure 8). The expression level of RFX4 in normal brain white 
matter was clearly detectable with a mean of 2.5% Gapdh. 
To determine astrocytic RFX4 expression in MS lesions double IHC for RFX4 and 
GFAP was performed on an actively demyelinating MS lesion, chronic inactive MS lesion 
and on normal appearing white matter (NAWM) as control (Figure 9). MS lesions were 
characterized using LFB-PAS histochemistry (Figure 9 A-E). RFX4 was detectable in 
NAWM and in both active and chronic inactive MS lesions (Figure 9). The transcription 
factor showed nuclear localization in various cell types including immune cells and glia 
cells of NAWM (Figure 9 A,F,K) and MS lesions of different activity status (Figure 9 G-J). 
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Double labeling for GFAP and RFX4 exhibited RFX4-expressing astrocytes in both acute 
(Figure 9 G) and chronic MS lesions (Figure 9 H-J). In the presented active lesion RFX4 
positive astrocytes were detected in the perivascular area and at the lesion border 
(Figure 9 G). In the chronic inactive lesion RFX4 positive astrocytes were located in the 
lesion center and more prominently at the lesion border (Figure 9 I, J). 
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Figure 9: RFX4 is expressed by astrocytes and up-regulated in MS. 
Histochemistry and immunohistochemistry using sections of normal appearing white matter, an active 
MS lesion and a chronic inactive MS lesion as indicated. (A-E) Histochemistry using LFB-PAS. (F-J) 
Double immunohistochemistry using anti-RFX4 (brown) and anti-GFAP (blue) antibodies. (K-O) Close-
up of anti-RFX4 and anti-GFAP IHC shown in F-J. Scale bars = (C,H,M) 500 µm; 
(A,F,K,B,G,L,D,I,N,E,J,O) 50 µm 
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3.2.1.2 RFX4 variant 3 is expressed in MS lesions 
 
Figure 10: Only RFX4_v3 is expressed in MS lesions.  
Expression of the transcript variants RFX4_v1,_v2, _v3, _v4  in MS lesions was measured by RT PCR 
using variant-specific primer pairs for v1, v2/v4 and v3. (A) Schematic representation of RFX4 
genomic structure and its main splice variants. The exons are depicted as boxes, and open reading 
frames are shown as green boxes. Primer pairs used for RT PCR are presented as red arrows and 
red dashed lines. Expected lengths of RT PCR products are indicated. (B) Agarose gel 
electrophoresis of RT PCR reactions. Gel was stained with ethidium bromide. M=DNA size marker 
 
In humans four main alternatively spliced variants of RFX4 have been described in 
normal tissue, which include RFX4_v1,_v2, _v3 and _v4 (Figure 10 A). In the testis 
variants v1, v2 and v4 are expressed and in the brain only RFX4_v3 has been detected 
(Matsushita et al., 2005).  
To investigate the expression of transcript variants RFX4_v1, _v2, _v3 and _v4 in MS 
lesions RT PCR was performed using published variant specific primer pairs (Matsushita 
et al., 2005). In MS lesions no RFX4_v1, _v2 and _v4 mRNA was detectable. RT PCR 
detected only variant 3 with the expected length of 500 base pairs in MS lesions (Figure 
10 B). RFX4_v3, was identified by the binding of the forward primer to exon 1 which is 
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3.2.2 Role of astrocytic RFX4_v3 during de- and remyelination in the 
cuprizone mouse model  
Pathologically, MS is characterized by the presence of areas of demyelination and 
inflammation in the white and gray matter of the CNS. Demyelination denominates a 
selective loss of myelin with relative axonal preservation. The natural response to 
demyelination is remyelination, the process of rebuilding the myelin sheaths including the 
generation of new oligodendrocytes. Unfortunately extensive remyelination of MS lesions 
is only rarely observed (Franklin, Robin J M and ffrench-Constant, 2008; Stadelmann and 
Brück, 2008; Kierdorf et al., 2013). Astrocytes are implicated to play a crucial role in 
regulating de- and remyelination in MS (Nair et al., 2008).  
 Regarding the finding of astrocytic RFX4_v3 in MS lesions, I assumed a possible role 
for the factor in the process of de- and remyelination. Therefore, the cuprizone mouse 
model was used to investigate the role of astrocytic RFX4_v3 during de- and 
remyelination.  
Demyelination was studied using 7 to 8 week old GFAP cell-specific RFX4_v3 
conditional knockout mice without hydrocephalus and control mice (C57Bl/6). Both were 
treated for 4 weeks with a 0.25% cuprizone diet. To analyze remyelination cuprizone was 
removed from the diet after 4 weeks and mice were kept on a cuprizone-free diet for 
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3.2.2.1 Cuprizone intoxication for 4 weeks induces strong demyelination in 
the corpus callosum of RFX4_v3 conditional knockout mice 
 
Figure 11: Cuprizone feeding for 4 weeks induces strong demyelination in the corpus callosum 
of RFX4_v3 conditional knockout mice.  
RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice were treated for 4 weeks with a 0.25% cuprizone 
diet. (A) Schematic representation of cuprizone treatment. (B) LFB-PAS staining of representative 
sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice after 4 weeks of cuprizone ingestion. 
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(C-D) Quantification of demyelination by scoring LFB-PAS staining in the medial and lateral corpus 
callosum. A score of 0 represents complete myelination and a score of 3 represents complete 
demyelination. Statistical significance was determined by Kruskal-Wallis test with Dunn’s post test (*** 
p<0,001, ** p<0,01). Data are presented as mean ± SEM. Scale bar = 500 µm 
 
Figure 12: Cuprizone-induced demyelination correlates with reduced myelin proteins in the 
corpus callosum of RFX4 deficient animals.  
Brain sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice were stained for myelin proteins 
MBP and CNPase. Extent of demyelination was quantified by scoring (A-B) MBP and (C-D) CNPase 
in corpus callosum medial (A,C) and corpus callosum lateral (B,D). Score of 0 represents complete 
myelination and score of 3 represents complete demyelination. Statistical significance was determined 
by Kruskal-Wallis test with Dunn´s post test (*p<0.05, ** p<0.01). Data are presented as mean ± SEM. 
Brain sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice were examined 
and scored for demyelination by LFB-PAS staining (Figure 11). Thereby, a score of 0 
represents complete myelination and a score of 3 represents complete demyelination in 
the corpus callosum. The corpus callosum of RFX4_v3 deficient mice was almost 
completely demyelinated after cuprizone treatment, while the myelin of wild type animals 
appeared to be still intact especially in the medial part of the corpus callosum after week 
4 of cuprizone intoxication. No difference was observed between RFX4_v3 +/- and 
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RFX4_v3 -/- mice. Compared to wild type animals RFX4_v3 +/- conditional knockout 
animals showed a significantly increased demyelination in the medial (score medial 
RFX4_v3: +/- 2.6 ± 0.1 vs RFX4_v3 +/+: 0.8 ± 0.2, ***p<0.001) and lateral (score lateral 
RFX4_v3: +/- 2.7 ± 0.1 vs. 1.9 ± 0.2 **p<0.01) part of the corpus callosum on LFB-PAS 
stained sections. 
In addition, enhanced demyelination after week 4 of cuprizone diet was confirmed by 
the reduced presence of myelin proteins in the corpus callosum of RFX4 deficient 
animals (Figure 12). The extent of demyelination was evaluated by scoring sections from 
RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice stained for myelin proteins MBP and 
CNPase. MBP as well as CNPase were significantly diminished mainly in the medial part 
of the corpus callosum of RFX4_v3 +/- compared to control mice (MBP score medial 2.2 
± 0.14 vs. 0.9 ± 0.2, **p<0.01) (CNPase score medial 2 ± 0.16, score medial 1 ± 0.23, 
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3.2.2.1.1 Increased axonal damage in RFX4 deficient mice 
 
Figure 13: Increased demyelination was accompanied by enhanced acute axonal damage in the 
corpus callosum of RFX4_v3 deficient mice. 
(A) APP IHC of brain sections from wild type and RFX4_v3 conditional knockout mice after cuprizone 
treatment. A representative medial section from corpus callosum is shown. (B-C) Quantification of 
APP positive spheroids in corpus callosum medial (B) and lateral (C) sections of indicated mice after 4 
weeks of cuprizone intoxification (** p<0,01, *** p<0,001, Kruskal-Wallis test with Dunn´s post test). 
Data are presented as mean ± SEM. Scale bar = 50 µm 
Substantial demyelination, as seen in the corpus callosum of RFX4_v3 deficient mice 
after cuprizone treatment, can lead to axonal damage. I thus investigated axonal 
transport disturbance in corpus callosum sections from wild type and RFX4_v3 
conditional knockout animals by IHC for APP (Figure 13). 
APP IHC revealed increased numbers of APP positive spheroids in RFX4_v3 deficient 
mice after week 4 of cuprizone intoxication. The quantitative analysis showed a 
significant increase of acute axonal damage in the medial and lateral parts of the corpus 
callosum for RFX4_v3 +/- mice compared to RFX4_v3 +/+ mice (medial 1295 ± 138 vs. 
176 ± 72 positive APP spheroids per mm2, ***p<0.001; lateral 924 ± 149 vs. 343 ± 51 
positive APP spheroids per mm2, **p<0.01) (Figure 13).  
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3.2.2.1.2 Extensive microglia accumulation in the corpus callosum of RFX4_v3 
conditional knockout mice after 4 weeks of cuprizone treatment  
 
Figure 14: Extensive accumulation of microglia/macrophages in the corpus callosum of 
RFX4_v3 conditional knockout mice during demyelination.  
(A) Mac3 IHC of corpus callosum sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice 
after cuprizone treatment. Representative sections are shown. (B-C) Quantification of Mac3 IHC in 
corpus callosum medial (B) and lateral (C) of indicated mice after 4 weeks of cuprizone intoxication. A 
score of 0 represents the presence of few microglia/macrophages with low immune reactivity and 
score of 3 represents high density of microglia/macrophages with intense immune reactivity in the 
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corpus callosum. (** p<0.01, *** p<0.001, Kruskal-Wallis test with Dunn’s post test). Data are 
presented as mean ± SEM. Scale bar = 500 µm 
Beside enhanced demyelination and axonal damage increased cellularity in the 
demyelinated corpus callosum was observed in RFX4 deficient mice after week 4 of 
cuprizone challenge (Figure 11 and Figure 13). Earlier studies demonstrated an 
increased response of microglia/ macrophages in the demyelinated corpus callosum to 
clear myelin debris (Hiremath et al., 1998). Therefore, I analyzed microglia/macrophage 
accumulation by Mac3 staining in the corpus callosum. 
Mac3 signals were scored in brain sections of RFX4_v3 +/+, RFX4_v3 +/- and 
RFX4_v3 -/- mice. Score of 0 represents the presence of few microglia/ macrophages 
with low immune reactivity and score of 3 represents high density of microglia/ 
macrophages with intense immune reactivity in the corpus callosum. After week 4 of 
cuprizone treatment extensive microglia/ macrophage accumulation was observed in 
RFX4_v3 deficient mice compared to wild type (Figure 14 A). Quantitative analysis 
revealed that microglia/ macrophages significantly accumulated in larger numbers in the 
corpus callosum from RFX4 deficient animals compared to wild type animals (score 
medial 2.4 ± 0.16 vs. 0.5 ± 0.2, ***p<0,001; score lateral 2 ± 0.18 vs. 1 ± 0.18, **p<0.01) 
(Figure 14 B/C). 
3.2.2.1.3 Blood brain barrier is closed in RFX4_v3 deficient mice 
 
Figure 15: Blood brain barrier is closed in RFX4_v3 deficient mice w/o hydrocephalus.  
(A-B) Fibrinogen IHC of brain sections from RFX4_v3 +/+ and RFX4_v3 -/- mice after cuprizone 
treatment. (C) Fibrinogen staining of RFX4_v3 -/- mice with severe hydrocephalus and brain 
hemorrhage (positive control). Representative sections are shown. (D-E) CD3 staining of brain 
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sections from RFX4_v3 +/+ and RFX4_v3 -/- mice. Representative sections are shown. Scale bar 
(A,B,C)= 1 mm; (D,E)= 100 µm 
Previous studies have demonstrated that the BBB is closed in the cuprizone mouse 
model, which allows to study the processes of de- and remyelination without substantial 
influence of the peripheral immune system (Bakker and Ludwin, 1987; Kondo et al., 
1987). Because of increased numbers of phagocytes in the corpus callosum of RFX4_v3 
deficient mice during cuprizone exposure I investigated whether the BBB remained intact 
in RFX4_v3 deleted mice.  
Therefore, IHC for fibrinogen was performed in cuprizone treated wild type and 
RFX4_v3 conditional knockout mice (Figure 15). As positive control I used a RFX4_v3 -/- 
mouse with severe hydrocephalus and brain hemorrhage. A positive immunolabeling for 
fibrinogen was observed in the RFX4_v3 -/- mouse with severe hydrocephalus, but was 
not detected in RFX4_v3 deficient mice. Thus the BBB of RFX4_v3 deficient mice remain 
intact under cuprizone challenge, indicating that the Mac3 positive cells most likely 
represent microglia, but not blood-borne macrophages.  
To assess numbers of T lymphocytes in the corpus callosum of wild type and RFX4 
deficient mice IHC was performed with an antibody against CD3 (Figure 15). Very few 
CD3 positive T lymphocytes were detected in both RFX4_v3 +/+ and RFX4_v3 -/- mice. 
This provides further evidence that the BBB in RFX4_v3 deficient is closed under 
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3.2.2.1.4 RFX4_v3 deficiency in astrocytes increases the number of microglia in the 
corpora callosa without differential activation patterns 
 
Figure 16: RFX4_v3 deficiency in astrocytes increases the number of microglia in the corpus 
callosum after cuprizone feeding without induction of microglial activation markers.  
(A) Flow cytometry analysis of CD45 and CD11b-positive cells of dissociated corpora callosa of wild 
type and RFX4_v3 deficient animals after week 4 of cuprizone challenge. RFX4_v3 +/+: n=7, 
RFX4_v3 +/-: n=6, *p<0,05, (unpaired t-test). (B-F) Flow cytometry analysis of microglia from corpora 
callosa for activation markers after cuprizone treatment of RFX4_v3 +/+ or RFX4_v3 +/- mice. 
Microglia samples were gated on CD11b-positive, CD45-dim cells for microglia. The mean 
fluorescence intensity was examined for (B) CD11b (n=7 per group, p>0.05, unpaired t-test), (C) 
CD45 (n=7 per group, p>0.05, unpaired t-test), (D) CD86 (n=7 per group, p>0.05, unpaired t-test) (E) 
CD80 (n=7 per group, p>0.05, unpaired t-test) and (F) MHC cIass I (n=7 per group, p>0.05, unpaired 
t-test). Data are presented as mean ± SEM. 
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The histological characterization of microglia cells in cuprizone-treated mice 
demonstrated enhanced microglia/ macrophage accumulation in the corpus callosum of 
RFX4 deficient mice compared to control mice. To further characterize the microglia 
phenotype of the demyelinated corpus callosum of RFX4 conditional knockout animals 
and control mice I used flow cytometry analysis. 
In a first step dissociated corpora callosa were analyzed for CD45 and CD11b-positive 
cells by flow cytometry analysis to quantify the number of microglia in wild type and 
RFX4_v3 deficient animals after week 4 of cuprizone ingestion. Absolute numbers of 
microglia from RFX4_v3 +/- deficient animals were significantly increased after 4 weeks 
of cuprizone treatment compared to wild type animals (179 ± 25 vs. 494 ± 110, *p<0,05) 
(Figure 16 A).  
In a second step microglia from corpora callosa were analyzed for expression of 
activation markers using flow cytometry at week 4 after cuprizone treatment (Figure 16 B-
F). For analysis of expression of activation markers on microglia, samples were gated on 
CD11b-positive CD45 dim cells for microglia. The mean fluorescence intensity was 
examined for CD11b, CD45, CD86, CD80 and MHC cIass I. For none of the analyzed 
activation markers a significant difference between RFX4_v3 +/- deficient mice and 
control mice was observed.  
Loss of RFX4_v3 in astrocytes thus leads to an increase of microglia in the corpus 
callosum, but does not significantly alter the expression of activation markers on 
microglia during demyelination compared to wild type. 
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3.2.2.1.5 Higher numbers of proliferating cells are present in the corpus callosum of 
RFX4_v3 mutants 
 
Figure 17: Elevated numbers of proliferating cells in the corpora callosa of RFX4-deficient 
animals.  
(A) IHC for Ki-67 in wild type and RFX4_v3 conditional knockout mice brain sections after cuprizone 
treatment (B) Quantification of Ki-67 positive cells in the medial and lateral corpus callosum of 
indicated mice after cuprizone treatment (***p<0.001 Kruskal-Wallis test with Dunn´s post test). Data 
are presented as mean ± SEM. Scale bar = 200 µm. 
To explain the increased microglia numbers in the demyelinated area I considered 
whether higher numbers of proliferating cells are detectable in the corpus callosum of 
RFX4_v3 deficient mice. Therefore IHC for Ki-67 was performed from wild type and 
RFX4_v3 conditional knockout mice to assess numbers of proliferating cells (Figure 17 
A).  
Significantly higher numbers of Ki-67 positive cells could be detected in the medial 
part of RFX4_v3 +/- animals compared to control animals (score medial 459 ± 70 vs. 65 ± 
23 Ki-67 positive cells per mm2, ***p<0,001) (Figure 17 B).  
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3.2.2.1.6 Reduced numbers of oligodendrocytes in the corpus callosum of RFX4_v3 
deficient mice after cuprizone exposure 
 
Figure 18: Reduced numbers of oligodendrocytes in the corpus callosum of RFX4_v3 deficient 
mice after cuprizone exposure.  
(A) Immunostaining using the oligodendrocyte marker anti-Olig2 of brain sections from RFX4 deficient 
animals and wild type animals. Representative images are shown. (B) Quantification of Olig2 staining 
in corpus callosum medial of indicated mice (**p<0.01, unpaired t test). Data are presented as mean ± 
SEM. Scale bar = 100 µm 
To assess the total number of oligodendrocytes after week 4 of cuprizone treatment I 
stained sections from RFX4_v3 +/+ and RFX4_v3 +/- mice with an antibody against 
Olig2, a marker for oligodendrocyte precursor cells (OPCs) and mature oligodendrocytes 
(Figure 18). RFX4_v3 +/- mice showed significantly lower numbers of oligodendrocytes in 
the medial part of the corpus callosum after week 4 of cuprizone treatment (medial score 
RFX4_v3 +/- 540 ± 40 vs. RFX4_v3 +/+ 903 ± 98 Olig2 positive cells per mm2, *p<0.05).  
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3.2.2.2 RFX4_v3 conditional knockout mice show delayed remyelination  
In the cuprizone mouse model the removal of cuprizone from the diet permits rapid 
remyelination which is almost complete after 4 weeks.  
To analyze their potential for remyelination 7 to 8 week old wild type and GFAP cell 
specific conditional RFX4_v3 knockout mice were treated for 4 weeks with a 0.25% 
cuprizone diet to induce demyelination. For the induction of remyelination, cuprizone 
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3.2.2.2.1 RFX4_v3 conditional knockout mice remain demyelinated after induction of 
remyelination for 1 week 
 
Figure 19: RFX4_v3 conditional knockout mice remain demyelinated after induction of 
remyelination for 1 week. 
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(A) Schematic representation of experimental layout. RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- 
mice were treated for 4 weeks with a 0.25% cuprizone diet followed by one week of a cuprizone-free 
diet. (B) LFB-PAS staining of representative sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3   
-/- mice. (C-D) Quantification of demyelination by scoring LFB-PAS staining in (C) corpus callosum 
medial and (D) corpus callosum lateral. Score of 0 represents complete remyelination and score of 3 
represents complete demyelination (* p<0.05, ** p<0.01, one way ANOVA with Bonferroni post test; 
Kruskal-Wallis test with Dunn´s post test). Data are presented as mean ± SEM. Scale bar = 500 µm 
 
Figure 20: RFX4_v3 conditional knockout mice remain demyelinated after induction of 
remyelination for 1 week. 
Brain sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice were stained for myelin proteins 
MBP and CNPase. Extent of remyelination was quantified scoring (A-B) MBP and (C-D) CNPase 
signal intensity in corpus callosum medial (A,C) and corpus callosum lateral (B,D) (* p<0.05, ** 
p<0.01, Kruskal-Wallis test with Dunn´s post test). Score of 0 represents complete remyelination and 
score of 3 represents complete demyelination. Data are presented as mean ± SEM. 
Remyelination was first analyzed 1 week after cuprizone withdrawal. Sections from 
RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice were examined and scored for 
remyelination by LFB-PAS staining (Figure 19). A score of 0 represents complete 
remyelination and score of 3 represents complete demyelination. RFX4_v3 deficient 
animals remained demyelinated after 1 week cuprizone withdrawal. The corpus callosum 
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of RFX4_v3 deficient mice was still demyelinated, whereas the myelin of control mice 
appeared to be remyelinated after 1 week cuprizone cessation (Figure 19 B). Quantitative 
analysis of the medial and lateral part of the corpus callosum revealed a significantly 
lower level of remyelination in RFX4_v3 conditional knockout animals compared to 
control mice (medial score RFX4_v3 -/-: 2.8 ± 0.2; RFX4_v3 +/-: 2.4 ± 0.3 vs. RFX4_v3 
+/+: 0.7 ± 0.2; *p<0.05 **p<0.01) (lateral score RFX4_v3 -/-: 2.1 ± 0.4; RFX4_v3 +/-: 1.4 ± 
0.3 vs. RFX4_v3 +/+: 0.7 ± 0.2; *p<0.05 **p<0.01) (Figure 19 C/D).  
These results were confirmed by analyzing the content of myelin proteins in the corpus 
callosum of control mice and RFX4_v3 deficient animals. The extent of remyelination was 
evaluated by scoring sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice 
immunostained for myelin proteins MBP and CNPase. Myelin protein MBP was still 
significantly reduced in RFX4 deficient animals compared to wild type animals (medial 
score RFX4_v3 -/- 1.9 ± 0.3; RFX4_v3 +/- 1.4 ± 0.2 vs. RFX4_v3 +/+ 0.75 ± 0.2, *p<0.05, 
**p<0.01) (lateral score RFX4_v3 -/- 2 ± 0.3 vs. RFX4_v3 +/+ 0.7 ± 0.2, *p<0.05) (Figure 
20 A, B). However no significant difference between wild type and RFX4_v3 conditional 
knockout animals was observed for the myelin protein CNPase (p>0.05) (Figure 20 C, D), 
indicating that the process of remyelination was active also in RFX4_v3 deficient mice. 
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3.2.2.2.2 Microglia accumulation in the corpus callosum of RFX4_v3 conditional 
knockout animals is still increased after 1 week cuprizone withdrawal 
 
Figure 21: Microglia accumulation in RFX4_v3 conditional knockout animals is still increased 
after 7 days cuprizone withdrawal.  
(A) Mac3 IHC of brain sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice 1 week after 
cuprizone cessation. Representative sections are shown. (B-C) Quantification of Mac3 IHC in medial 
(B) and lateral (C) corpora callosa of the different genotypes after 4 weeks of cuprizone intoxification. 
A score of 0 represents the presence of few microglia/macrophages with low immune reactivity and 
score of 3 represents high density of microglia/macrophages with high immune reactivity in the corpus 
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callosum (* p<0,05, ** p<0,01, *** p<0,001, Kruskal-Wallis test with Dunn´s post test). Data are 
presented as mean ± SEM. Scale bar = 500 µm 
With the onset of remyelination after removal of cuprizone from the diet Mac3-positive 
microglia cells usually begin to decrease in the corpus callosum.  
I thus analyzed microglia/ macrophage accumulation during remyelination by anti-
Mac3 IHC of sections from RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice after one 
week of cuprizone cessation. As predicted, cuprizone removal led to a reduction of 
microglia/macrophage accumulation in wild type animals whereas RFX4_v3 deficient 
animals retained a high infiltration rate of microglia/macrophage cells. Quantitative 
analysis revealed a significant difference in the medial part of the corpus callosum for 
both RFX4_v3 +/- and RFX4_v3 -/- versus control mice (medial score RFX4_v3 -/-: 2.9 ± 
0.1; RFX4_v3 +/-: 2.1 ± 0.3 vs. RFX4_v3 +/+: 0.7 ± 0.3, **p<0.01, *p<0.05) (Figure 21 B). 
In the lateral part of the corpus callosum a significant difference was only observed 
between RFX4_v3 -/- mice and wild type mice (lateral score RFX4_v3 -/-: 2.3 ± 0.4 vs. 
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3.2.2.2.3 Loss of RFX4_v3 in astrocytes restricts oligodendrocyte differentiation 
without changing numbers of oligodendrocyte precursor cells 
 
Figure 22: Loss of RFX4_v3 in astrocytes restricts oligodendrocyte differentiation without 
changing numbers of oligodendrocyte precursor cells.  
(A) Immunostaining using the oligodendrocyte marker anti-Olig2 of brain sections from RFX4 deficient 
animals and wild type animals. Representative images are shown. (C) Quantification of Olig2 IHC in 
corpus callosum medial. (B) Immunostaining using the mature oligodendrocyte marker anti-p25 of 
brain sections from RFX4 deficient animals and wild type animals. Representative images are shown. 
(D) Quantification of p25 IHC in corpus callosum medial of indicated mice (* p<0.05, ** p<0.01, one 
way ANOVA with Bonferroni post test). Data are presented as mean ± SEM. Scale bar = 100 µm 
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The process of remyelination depends on the presence of OPCs which differentiate to 
mature oligodendrocytes to produce the myelin sheath around the axon. 
 I analyzed oligodendrocyte differentiation during remyelination, by immunostaining for 
Olig2, a marker for oligodendrocytes, and for p25, a marker for mature oligodendrocytes. 
Although a slight decrease in numbers of oligodendrocytes in the medial part was 
observed, loss of astrocytic RFX4_v3 had no significant effect on numbers of Olig2 
positive oligodendrocytes (Figure 22 A, C).  
However, mature oligodendrocytes were significantly reduced in the medial part of the 
corpus callosum during the process of remyelination as revealed by p25 IHC (medial 
score RFX4_v3 -/- 176 +/- 49; RFX4_v3 +/- 414 ± 131 vs. RFX4_v3 +/+ 956 ± 148 p25 
positive cells per mm2, **p<0.01, *p<0.05) (Figure 22 B, D). 
Thus, the majority Olig2 positive cells in RFX4_v3 deficient mice represented most 
likely OPCs and not mature oligodendrocytes. This indicates that RFX4_v3 deletion does 
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3.2.2.2.4 RFX4_v3 conditional knockout mice show delayed remyelination of the 
corpus callosum compared to wild type mice 
 
Figure 23: RFX4_v3 conditional knockout mice remyelinate in the corpus callosum with a delay 
compared to wild type mice.  
(A) Schematic representation of the experimental design. RFX4_v3 +/+ and RFX4_v3 +/- were treated 
for 4 weeks with a 0.25% cuprizone diet followed by 2 weeks of a cuprizone-free diet. (B) LFB-PAS 
staining of representative sections from RFX4_v3 +/+ and RFX4_v3 +/- mice. (C) Quantification of 
demyelination by scoring LFB-PAS staining in corpus callosum medial and lateral. Score of 0 
represents complete remyelination and score of 3 represents complete demyelination (** p<0.01, one 
way ANOVA with Bonferroni post test). Data are presented as mean ± SEM. Scale bar = 500 µm 
To resolve whether RFX4_v3 deficient mice remain demyelinated in the corpus callosum, 
remyelination was analyzed after 2 weeks of cuprizone withdrawal. Sections from 
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RFX4_v3 +/+, RFX4_v3 +/- were examined and scored for remyelination by LFB-PAS 
staining. LFB-PAS staining revealed intact myelin in RFX4_v3 deficient animals after 14 
days of cuprizone withdrawal. Quantitative analysis of the medial and lateral part of the 
corpus callosum revealed a significantly lower level of remyelination in RFX4_v3 
conditional knockout animals in the medial part compared to control mice (medial score 
RFX4_v3 +/-: 1.7 ± 0.2 vs. RFX4_v3 +/+: 0.9 ± 0.13; **p<0.01) (Figure 23 C). In the 
lateral part of corpus callosum no difference was observed 
3.2.2.2.5 Numbers of Mac3 positive stained microglia are comparable in the corpus 
callosum of RFX4_v3 mutants and wild type animals 2 weeks after 
cuprizone cessation 
 
Figure 24: Numbers of Mac3 positive microglia are comparable in the corpus callosum of 
RFX4_v3 mutants and wild type animals 2 weeks after of cuprizone cessation.  
(A) Mac3 IHC of brain sections from RFX4_v3 +/+ and RFX4_v3 +/- mice 2 weeks after cuprizone 
cessation. Representative sections are shown. (B) Quantification of Mac3 IHC in the corpus callosum 
medial and lateral of indicated mice 2 weeks after cuprizone withdrawal (p>0.05, Kruskal-Wallis test 
with Dunn´s post test) (B). Data are presented as mean ± SEM. Scale bar = 500 µm 
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Microglia accumulation after 2 weeks of remyelination was analyzed by Mac3 IHC of 
brain sections of RFX4_v3 +/+, RFX4_v3 +/- mice. 2 weeks of cuprizone cessation 
reduced the amount of microglia accumulation in wild type animals and RFX4_v3 
deficient mice (Figure 24 A). Quantitative analysis revealed no significant difference 
between RFX4_v3 deficient mice and wild type mice (Figure 24 B). 
3.2.2.3 Effects of astrocytic RFX4_v3 inhibition are present after 2 weeks of 
cuprizone challenge 
In order to better understand the cuprizone induced pathology in RFX4_v3 deficient 
mice I performed a time course experiment to study the course of demyelination based 
on LFB-PAS histochemistry, of astrogliosis based on GFAP IHC and of microglia 
activation based on Mac3 IHC. Therefore 7 to 8 week old GFAP cell-specific RFX4_v3 
conditional knockout mice without hydrocephalus and control mice (C57Bl/6) were treated 
with a 0.25% cuprizone diet for 1, 2, 3, and 4 weeks.  
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3.2.2.3.1 RFX4_v3 deficiency markedly accelerates demyelination in vivo 
 
Figure 25: RFX4_v3 deficiency accelerates demyelination in vivo.  
(A) Schematic representation of experimental layout. Time course analysis of demyelination was 
performed after 1, 2 or 3 weeks of cuprizone ingestion. (B) LFB-PAS histochemistry of representative 
sections from RFX4_v3 +/+ and RFX4_v3 +/- mice after indicated weeks of cuprizone treatment. (C-D) 
Quantification of demyelination by scoring LFB-PAS in corpus callosum medial and lateral after (C) 2 
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weeks and (D) 3 weeks of cuprizone ingestion. Score of 0 represents complete myelination and score 
of 3 represents complete demyelination (*p<0,05, Mann Whitney test). Data are presented as mean ± 
SEM. Scale bar = 500 µm. 
A time course experiment was performed to analyze demyelination after 1, 2 and 3 weeks 
of cuprizone ingestion (Figure 25 A). The extent of demyelination in sections from 
RFX4_v3 +/+, RFX4_v3 +/- mice was examined by scoring the extent of demyelination 
based on LFB-PAS staining. After 1 week of cuprizone treatment the myelin in both 
RFX4_v3 deficient mice and control mice appeared to be intact (Figure 25 B). First signs 
of demyelination were observed after 2 weeks of cuprizone ingestion with a higher score 
of demyelination in RFX4 deficient mice compared to wild type mice. The difference was 
more prominent after week 3 with a significant difference in the lateral part of the corpus 
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3.2.2.3.2 Astrocyte specific RFX4_v3 deficiency has no influence on the density of 
activated GFAP positive astrocytes in the corpus callosum. 
 
Figure 26: Astrocyte-specific RFX4_v3 deficiency has no influence on the density of activated 
GFAP-positive astrocytes in the corpus callosum.  
(A) Schematic representation of experimental layout. Time course analysis of astrocyte proliferation 
after 1, 2, 3 or 4 weeks of cuprizone ingestion. (B) Left panels: Representative brain sections of the 
medial corpus callosum of wild type and RFX4_v3 conditional knockout animals were stained for 
GFAP after 1-4 weeks of cuprizone treatment. Right panels: Quantification of GFAP positive cells 
(p>0.05, one way ANOVA with Bonferroni post test (week 1), Kruskal-Wallis test with Dunn´s post test 
(week 4), Mann Whitney test (weeks 2 and 3). Data are presented as mean ± SEM. Scale bar = 50 µm 
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It was reported that cuprizone intoxication leads to hyperplasia and an increase in 
numbers of astroglia, which starts from the second to third week and is most pronounced 
in the fourth week of cuprizone treatment (Hiremath et al., 1998). Hence I asked whether 
similar results can be obtained in response to RFX4_v3 inhibition in astrocytes.   
Therefore a time course experiment was performed to evaluate the density of GFAP 
positive astrocytes in the corpus callosum of wild type and RFX4 deficient mice after 1, 2, 
3 and 4 weeks of cuprizone diet (Figure 26 A). GFAP immunohistochemistry was used to 
assess the number of activated astrocytes in brain sections from wild type and RFX4_v3 
conditional knockout animals. The densities of activated GFAP positive astrocytes in the 
corpus callosum were comparable in RFX4 conditional knockout and wild type animals at 
all time points (Figure 26 B). In addition the morphology of astrocytes was comparable 
until week 3. RFX4_v3 conditional knockout mice showed a slight change in the 
morphology of the astrocytes after week 4. The astrocytes appeared to be less dense 
compared to wild type animals, presumably due to the high cellularity in the corpus 
callosum of RFX4 +/- animals compared to wild type animals, which may leads to a 
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3.2.2.3.3 Astrocyte specific RFX4_v3 deletion leads to accelerated microglia/ 
macrophage infiltration into the corpus callosum 
 
Figure 27: Astrocyte-specific RFX4_v3 deletion leads to accelerated microglia infiltration into 
the corpus callosum.  
(A) Schematic representation of experimental layout. Time course analysis of Mac3-positive 
phagocytes in the corpus callosum of wild type and RFX4 deficient mice after 1, 2 or 3 weeks of 
cuprizone diet. (B) Left panels: Mac3 immunostaining of brain sections at given time points after 
cuprizone treatment. Representative sections are shown. Right panels: Quantification of Mac3-positive 
cells for each week respectively (**p<0.01, unpaired t test (B, week 2), *p<0.05, Mann Whitney test (B, 
week 3), p>0,05, one way ANOVA with Bonferroni post test (B, week 1)). Data are presented as mean 
± SEM. Scale bar = 50 µm. 
Due to the considerably enhanced infiltration of the corpus callosum by 
microglia/macrophage after four weeks of cuprizone challenge, I was interested to study 
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the course of microglia activation during the process of demyelination in RFX4_v3 
deficient mice compared to control mice. 
Therefore a time course experiment was set up to evaluate the density of Mac3 
positive microglia in the corpus callosum of wild type and RFX4 deficient mice 1, 2, and 3 
weeks after cuprizone ingestion (Figure 27 A). The number of activated phagocytes was 
assessed by immunostaining sections from wild type and RFX4_v3 conditional knockout 
animals for Mac3. The numbers of Mac3 positive stained microglia/ macrophages were 
comparable after 1 week of treatment between wild type and RFX4_v3 conditional 
knockout mice. However, RFX4_v3 deletion led to a faster phagocyte infiltration into the 
corpus callosum after 2 and 3 weeks with significantly higher numbers of Mac3 positive 
stained phagocytes in the corpus callosum (week 2 RFX4_v3 +/-: 605 ± 60 vs. RFX4_v3 
+/+: 336 ± 21 positive Mac3 stained cells per mm2, **p<0.01), (week 3 RFX4_v3 +/-: 1717 
± 176 vs. RFX4_v3 +/+: 926 ± 42 positive Mac3 stained cells per mm2, *p<0.05).  
The morphology of microglia cells in RFX4_v3 deficient mice and control mice was 
comparable at all time points. In the first and second week the microglia cells appeared 
to be ramified, while in week 3 the microglia cells appeared to be larger and obtained an 
amoeboid morphology. 
3.2.2.4 Deletion of RFX4_v3 in astrocytes increases oligodendrocyte 
apoptosis and increased mRNA levels of cytokine and chemokines in 
the corpus callosum 
The time course experiment demonstrated that the first differences in demyelination 
and microgliosis appear after two weeks of cuprizone challenge in RFX4_v3 deficient 
mice compared to wild type mice. I concluded that significant differences may take place 
as early as after 1 week of cuprizone diet in RFX4_v3 deficient mice compared to wild 
type mice.  
Accordingly I decided to treat RFX4_v3 deficient mice for one 1 week with a 0.25% 
cuprizone diet and further investigated oligodendroglial apoptosis, which is typically 
observed at this time point (Figure 28). Furthermore I measured chemokine and cytokine 
mRNA levels in the corpus callosum of RFX4_v3 deficient mice, which contribute to 
microglia recruitment and oligodendrocyte toxicity in the cuprizone mouse model (Figure 
29).  
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3.2.2.4.1 Increased oligodendroglial apoptosis under loss of RFX4_v3 in astrocytes 
 
Figure 28: Increased oligodendroglial apoptosis in RFX4_v3 deficient mice.  
(A) Experimental layout. RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice were treated for one week 
with 0.25% cuprizone diet. (B) Apoptotic cells were stained with caspase 3 using brain sections of 
indicated mice. Representative images are shown. (C) Quantification of caspase 3-positive cells in 
corpora callosa of indicated mice (* p<0,05, ** p<0,01 one way ANOVA with Bonferroni post test). 
Data are presented as mean ± SEM. Scale bars = 50 µm 
Evaluation of apoptotic cells took place after one week of 0.25% cuprizone treatment. 
Sections of RFX4_v3 +/+, RFX4_v3 +/- and RFX4_v3 -/- mice were stained for caspase 
3, a marker for cells undergoing apoptosis.  
Compared to wild type animals, RFX4 deficient mice show more apoptotic cells in the 
corpus callosum (Figure 28). Quantitative analysis revealed a significant difference of 
RFX4_v3 deficient mice compared to wild type mice (RFX4_v3 +/- 140 ± 11 RFX4_v3 -/- 
134 ± 10 vs. RFX4_v3 +/+ 92 ± 6 positive caspase 3 stained cells per mm2, * p<0.01 
**p<0.01). 
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3.2.2.4.2 Inhibition of astrocytic RFX4_v3 substantially increases transcripts for pro-
inflammatory cytokines and chemokines in response to cuprizone 
treatment in the corpus callosum 
 
Figure 29: Loss of RFX4_v3 increases the pro-inflammatory response in the corpus callosum.  
Transcript levels were measured using quantitative real-time PCR for (A) RFX4,(B) GFAP and (C) 
cytokines/ chemokines in RNA isolated from freshly prepared corpus callosum of untreated and 
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cuprizone treated RFX4_v3 +/+ and RFX4_v3 -/- mice. One representative experiment is shown. For 
each gene the mean of each group is indicated. RFX4: ** p<0,01, Kruskal-Wallis test with Dunn´s post 
test. GFAP: p>0,05, one way ANOVA with Bonferroni post test. CXCL10: ** p<0.01, *** p<0.001, IL-
1β: ** p<0.01, *** p<0.001, CCL2: * p<0.05, *** p<0.001, TNF-α: ** p<0.01, *** p<0.001, CCL3: ** 
p<0.01, *** p<0.001, CXCL12: *** p<0.001, one way ANOVA with Bonferroni post test. 
To measure transcript levels after 1 week of cuprizone intoxication quantitative real-
time PCR was used. The transcript levels of RFX4 (Figure 29 A), GFAP (Figure 29 B) 
and cytokines/ chemokines (Figure 29 C) from samples isolated from freshly prepared 
corpus callosum of untreated and cuprizone treated RFX4_v3 +/+, and RFX4_v3 -/- mice 
were measured (Figure 29).  
Cuprizone treatment itself had no significant influence on mRNA levels of RFX4 and 
GFAP after 1 week of cuprizone challenge. However there is a significant difference in 
RFX4 mRNA levels between wild type and RFX4_v3 -/- under similar mRNA levels of 
GFAP in the corpus callosum (Figure 29 A, B). RFX4 transcript levels of RFX4_v3 -/- 
mice were decreased about 4-fold (**p<0.01) compared to wild type animals (Figure 29 
A). 
Cuprizone treatment itself had an impact on measured cytokine and chemokine levels 
(Figure 29 C). Transcript level of CCL2 was significantly increased (about 40-fold 
*p<0.05), whereas transcript levels of CXCL12 (about 3-fold ***p<0.001) were 
significantly decreased (Figure 29 C). Transcript levels of CXCL10 (about 27 fold, p> 
0.05) and CCL3 (about 3 fold, p> 0.05) increased, but not significantly (Figure 29 C).  
RFX4_v3 deficiency in astrocytes significantly enhanced transcript levels of all 
measured cytokines and chemokines, except CXCL12, after 1 week cuprizone challenge 
(Figure 29 C). The mRNA levels of CCL2 were significantly increased at about 2-fold for 
RFX4_v3 -/- mice (*p<0.05) compared to wild type. Transcript levels of IL-1β were 
significantly increased at about 4-fold for RFX4_v3 -/- mice (**p<0.01) compared to wild 
type. CXCL10 mRNA levels were significantly increased at approximately 3-fold for 
RFX4_v3 -/- mice (**p<0.01) compared to wild type. The transcript levels of TNF-α were 
significantly increased at approximately 3-fold for RFX4_v3 -/- mice (**p<0.01), compared 
to wild type. The same was measured for CCL3 with significant increased mRNA levels at 
approximately 3-fold for RFX4_v3 -/- mice (**p<0.01) compared to wild type mice. 
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4 Discussion 
4.1 Part 1: Characterization of the GFAP cell specific RFX4 
conditional knockout mice  
4.1.1 GFAP specific loss of RFX4 leads to congenital hydrocephalus  
Hydrocephalus is characterized by an abnormal accumulation of CSF in the brain. CSF is 
produced and secreted by the epithelial cells of the choroid plexus (Ortloff et al., 2013). It 
circulates through the ventricular system from the lateral to the third ventricle and then 
via the cerebral aqueduct into the fourth ventricle. From the fourth ventricle the CSF flows 
via the median aperture of Magendie and the lateral apertures of Luschka into the 
subarachnoid space before being drained into the venous circulation. Hydrocephalus can 
be caused by overproduction of CSF, a failure to drain the CSF at the subarachnoid 
space or reduced reabsorption of the CSF (Pérez-Fígares et al., 2001; Linninger et al., 
2009). However, it has been reported that the main cause of congenital hydrocephalus is 
the obstruction of CSF flow through the narrow Sylvian aqueduct. The Sylvian aqueduct 
is located between the third and fourth ventricles (Pérez-Fígares et al., 2001; Huh et al., 
2009). It is suggested that genetic factors play a role in the pathogenesis of 
hydrocephalus. So far only one gene, the X-linked L1CAM, has been identified in 
humans. (Sztriha et al., 2002). This gene is responsible for about 5% of the congenital 
cases with genetic cause (Bruni et al., 1988a; Zhang et al., 2006b). The analysis of 
genetically modified animal models has led to the identification of more than 15 genes 
resulting in hydrocephalus in rodents (Rolf et al., 2001; Blackshear et al., 2003; Baas et 
al., 2006; Dietrich et al., 2009; Huh et al., 2009; Benadiba et al., 2012). 
In 2003, Blackshear and colleagues described that RFX4_v3 is crucial for early brain 
development and that its absence leads to congenital hydrocephalus (Blackshear et al., 
2003). Disruption of both RFX4_v3 alleles leads to severe brain deformation with failure 
of dorsal midline formation. All pups homozygous for RFX4_v3 died shortly before or 
after birth (Blackshear et al., 2003). RFX4_v3 +/- mice survived, but suffered from 
congenital hydrocephalus associated with hypoplasia or absence of the SCO. The fact 
that lack of one allele already leads to congenital hydrocephalus was explained by either 
autosomal dominance or gene dosage effects (Blackshear et al., 2003; Zhang et al., 
2007). 
In this study I demonstrate that GFAP cell specific RFX4 conditional knockout mice 
exhibit a very similar phenotype. GFAP cre driven cell specific disruption of RFX4 led to 
agenesis of the SCO and congenital hydrocephalus resulting in death in young 
adulthood.  
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The RFX4 flox/flox strain contains LoxP sites flanking the exon 4 of the RFX4 gene. 
RFX4 conditional knockout mice were generated by crossing the RFX4 flox/flox strain 
with a GFAP driven Cre transgenic strain, which results in RFX4 gene inactivation by 
deletion the exon 4 in vivo. Three variants of RFX4 have been described in mice, which 
includes variants 1, 2 and 3. Only RFX4_v2 and RFX4_v3 include the exon 4 in their 
sequence. Using transcript specific probes Blackshear and colleagues determined, that 
RFX4_v2 as well as RFX4_v1 are expressed in the testis, but they could not observe 
hybridization for either variant in the fetal and adult brain (Blackshear et al., 2003). 
However, RFX4_v3 has been identified in the fetal and adult brain and was not found in 
the testis (Blackshear et al., 2003; Matsushita et al., 2005). Therefore and due to the 
phenotype of the GFAP cell specific RFX4 conditional knockout mice I conclude that 
RFX4 variant 3 is deleted in our strain. In the following parts of my thesis the GFAP cell 
specific RFX4 conditional knockout mice are therefore termed GFAP cell specific 
RFX4_v3 conditional knockout mice.  
 
The mortality rate at an age of 6 weeks was about 20% for heterozygous RFX4_v3 
conditional knockout mice, while homozygous RFX4_v3 conditional knockout mice died 
at a rate of about 50% at the same age. This implies that the phenotype of RFX4_v3 
conditional knockout mice is also due to either autosomal dominance or more likely to 
gene dosage effects. This was further confirmed by the fact that RFX4_v3 +/- conditional 
mice had a moderate to marked hydrocephalus, whereas the majority of the homozygous 
animals analyzed showed a marked to severe hydrocephalus. In newborn transgenic 
mice hydrocephalus was already present at birth, indicating that the hydrocephalus is 
congenital. This suggested a blockage in the aqueduct of Sylvius that has also been 
reported for RFX4_v3 transgenic animals (Blackshear et al., 2003). 
 
4.1.2 Hydrocephalus in RFX4_v3 conditional knockout mice is caused by 
SCO hypoplasia  
As mentioned above the primary cause of congenital hydrocephalus is stenosis or 
narrowing of the Sylvian aqueduct (Perez Figares, 2001). The etiopathogenesis of 
aqueductal stenosis is not well understood, but it has been reported that maldevelopment 
and resulting dysfunction of the SCO is involved in the genesis of aqueductal stenosis 
(Vio et al., 2000). The SCO also known as Reissners fiber complex is a small brain gland 
of the circumventricular system (Vio et al, 2000). The SCO is built by secretory 
ependymal cells, which secrete glycoproteins into the ventricles, where they aggregate 
and form the so called Reissner fiber. These aggregates grow at a constant rate and 
extend along the aqueduct, fourth ventricle and central canal of the spinal cord (Vio et al., 
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2000). The secretion of glycoproteins into the rostral end of the cerebral aqueduct may 
prevent the closure of the cerebral aqueduct. This would hinder stenosis of the aqueduct 
and prevent hydrocephalus formation (Vio et al, 2000). A direct prove for this theory was 
given by the fact that immunizing pregnant rat with RF glycoproteins induced SCO 
defects, stenosis and hydrocephalus (Sara Rodriguez et al, 1999).  
RFX4 variant 3 is described to play an important role for the development of the SCO 
(Blackshear et al., 2003). Hypoplasia or absence of the SCO in RFX4_v3 +/- mice was 
described as the main cause for the hydrocephalus (Blackshear et al., 2003).  
In our study, the SCO was present in all analyzed RFX4_v3 conditional knockout 
animals. However, all symptomatic mice exhibited SCO hypoplasia. RFX4_v3 
conditionally deficient mice showed a reduced number of SCO ependymocytes. The 
remaining cells were flattened, unstructured and their apical borders no longer extended 
into the lateral ventricle. Thus the specialized ependymocytes of the SCO were either 
absent or inappropriately differentiated in RFX4_v3 conditional knockout mice.  
Moreover, residual ependymal cells of the SCO showed reduced immunoreactivity or 
were not immunoreactive with anti-Reissner’s fiber serum (AFRU), implicating a 
dysfunctional glycoprotein secretion.  
This observation is consistent with the findings of Blackshear and colleagues and 
supports the hypothesis that hydrocephalus in conditional knockout animals is caused by 
maldevelopment of the SCO. 
 
The SCO originates from neuroepithelial cells that line the lumen of the dorsocaudal 
aspect of the diencephalon. These epithelial precursors of the SCO differentiate to 
specialized secretory ependymocytes in response to the induction of Wnt and Bmp 
signals (Liem et al., 1995; Liem et al., 1997). Blackshear and colleagues showed by in 
situ hybridization that RFX4_v3 is expressed in early development. From E12.5 to birth, 
levels of RFX4_v3 mRNA were detected in the neuroepithelium and the ependyma of the 
neural tube. In addition from E14.5 to birth RFX4_v3 transcripts were found in the 
ependymocytes of the developing SCO (Blackshear et al., 2003).  
In our conditional knockout mice, RFX4_v3 is deleted under control of the GFAP 
promoter. GFAP is the major intermediate filament protein of mature astrocytes. Sousa 
and colleagues described that the expression of GFAP is regulated under developmental 
and pathological conditions (Sousa, Vivian de Oliveira et al., 2004). GFAP is also 
expressed in neural progenitors like the neuroepithelium during embryogenesis and in 
nearly all adult neural stem cells (Garcia, A Denise R et al., 2004). It has been reported 
that in adult rat and mouse, the circumventricular organs are rich in GFAP positive cells 
(Bennett et al., 2009). Moreover an immunohistochemical study of rat SCO-
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ependymocytes illustrates that these cells express GFAP from E19 until P3 (Chouaf et 
al., 1991). For adult RFX4_v3 conditional knockout mice it can be assumed that RFX4_v3 
will be absent in astrocytes and neural stem cells. During embryogenesis RFX4_v3 will 
be deleted in neural progenitors including the neuroepithelium (Goldman, 2003; Garcia, A 
Denise R et al., 2004), suggesting that deletion of RFX4_v3 in conditional and transgenic 
mice which leads to interruption of RFX4_v3 is in many aspects congruent during 
embryogenesis. This implicates that similar processes in response to the development of 
the hydrocephalus occur. 
 
4.1.3 Regulation of developmental factors by RFX4_v3 impairs SCO 
formation and function 
Maldevelopment of the SCO is associated with a number of genetic mutations 
including the Wnt and Bmp signaling pathways. These morphogens influence the 
establishment of dorsolateral patterning of the CNS and the development and function of 
the SCO and the ventricular ependymal cells (Liem et al., 1995; Liem et al., 1997). A 
transcriptional repressor of these pathways is the Msx1 protein. Homozygous Msx1 
knockout mice were not able to maintain Wnt1 and Bmp6 in the dorsal midline of P1 mice 
(Bach, 2003). The loss of morphogens reduced the transcript levels of the cell fate 
markers paired box 6 and 7 (Pax6/7). As a consequence Msx1 mutants developed a 
hydrocephalus and had a dysfunctional SCO together with neuroependymal denudation 
(Bach, 2003; Ramos et al., 2004). In addition to that Wnt1 and Pax6 mutants revealed 
similar hydrocephalic or SCO phenotypes (Louvi A and Wassef M, 2000; Estivill-Torrús et 
al., 2001). Similarly, 2009 Dietrich and co-workers published that inactivation of 
Huntington’s disease gene in Wnt1 cell lineages display reduced growth, dismorphic SCO 
and congenital hydrocephalus as reflected by expansion of the lateral ventricle and loss 
of cortical tissue (Dietrich et al., 2009). From these studies, Wnt and Bmp signaling seem 
to be important regulatory mechanisms necessary for the correct differentiation of 
ependymocytes of the SCO and for preventing the initiation of hydrocephalus formation. 
Two members of the RFX family RFX3 and RFX4_v3 are found in the dorsal neural tube 
and seem to be crucial for regular SCO development (Blackshear et al., 2003; Baas et 
al., 2006). Homozygous RFX4_v3 complete knockout mice were embryonically lethal due 
to ruinous midline defects (Blackshear et al., 2003). These defects were accompanied by 
down regulation of Msx2 and a loss of Wnt7a and Wnt7b in the cortical hem at E12.5 
(Blackshear et al., 2003). Furthermore a microarray of E10.5 heads of RFX4_v3 -/- mice 
identified components of Wnt and Bmp signaling as potential targets for RFX4_v3 
(Blackshear et al., 2003; Zhang et al., 2006a).  
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Because the Wnt and Bmp signaling pathways play an important role in early and late 
stages of brain development (Zhang et al., 2007) I investigated these genes in a qPCR 
study of P0 astrocytes from conditional knockout mice. The study revealed that genes 
implicated in Wnt and Bmp signaling pathways are regulated in RFX4_v3 conditional 
knockout mice. I was able to show that mRNA levels of Wnt3, Rspondin and Frizzeled10 
are reduced at the time of birth as was shown before at E10.5 in RFX4_v3 -/- mice. In 
addition to established factors regulated by RFX4_v3, I could show that ß-catenin, an 
important regulator of Wnt signaling, is down-regulated at P0. This gene was found to be 
crucial for proper midbrain development. Conditional mutation of ß-catenin led to 
hydrocephalus (Ohtoshi, 2008). Other transcripts quantified like IGF1, vitronectin and 
CX3CL1 confirmed and supported our hypothesis that genes in conditional RFX4_v3 
knockout animals are similarly modulated as in the complete RFX4_v3 knockout mice.  
Although not all genes studied were detectable at P0 (i.e. Msx3, Wnt3a) these findings 
imply that RFX4_v3 deleted astrocytes regulate early morphogens that are relevant for 
dorsal midline structuring including the development of the SCO. Additionally this 
supports the idea that hydrocephalus in our RFX4 conditional knockout strain is mainly 
caused by SCO agenesis and resulting stenosis of the aqueduct, which is in line with the 
work of Blackshear, 2003 and Zhang, 2006.  
 
In summary, our results indicate that astrocytic and ependymal RFX4_v3 is highly 
relevant for early brain development and the pathogenesis of congenital hydrocephalus in 
rodents. 
Congenital hydrocephalus in humans occurs with an incidence of 0.1-0.3% of live 
births (Perez Figares et al., 2001). So far, only the gene L1CAM has been linked to 
congenital hydrocephalus in humans (Sztriha et al., 2002). Further research is required to 
investigate if different expression levels of RFX4_v3 are involved in the pathogenesis of 
human congenital hydrocephalus. 
 
                                                                                                Discussion 93 
4.2 Part 2: The role of astrocytic RFX4_v3 in demyelination 
4.2.1 RFX4 is produced by astrocytes and up-regulated in MS lesions 
MS is a chronic demyelinating, inflammatory autoimmune disease, typically affecting 
multiple regions within the CNS. MS lesions are characterized by demyelination, 
inflammation, axonal loss and gliosis (Brück, 2005; Milo and Kahana, 2010; Lassmann, 
2011; Kutzelnigg and Lassmann, 2014). The mechanisms leading to tissue injury in MS 
are complex and not fully understood. A specific inflammatory environment, 
predominantly consisting of pro- and anti-inflammatory molecules, appears to play a 
central role in regulating CNS inflammation and regeneration. On the one hand, active 
MS lesions display a mainly pro-inflammatory environment, which probably causes 
inflammation-associated demyelination. On the other hand at later stages MS lesions can 
exhibit a more anti-inflammatory and protective environment to support remyelination and 
neuroregeneration (Kerschensteiner et al., 2003). Different cell types have been 
described to secrete cytokines, chemokines and neurotoxins, which contribute to the 
inflammatory milieu. These cell types comprise infiltrating peripheral immune cells like 
auto-reactive T cells and macrophages as well as CNS-resident cells like microglia and 
astrocytes (Nair et al., 2008). 
Astrocytes have been deemed to play a secondary role in MS. However, it is now 
believed that astrocytes play an active role in MS due to their immunomodulatory 
capacity (Williams et al., 2007; Nair et al., 2008). Astrocytes have been shown to 
modulate de- and remyelination through the production and secretion of pro- and anti-
inflammatory cytokines and chemokines (Dong and Benveniste, 2001; Nair et al., 2008).  
They may promote demyelination by enhancing the immune response by antigen 
presentation or secretion of chemotactic molecules (Dong and Benveniste, 2001; 
McFarland and Martin, 2007). Conversely, astrocytes also inhibit aspects of immune 
response pathways, thereby downmodulating demyelination for example by production of 
anti-inflammatory cytokines (Schönrock et al., 2000; Valerio, 2002).   
Based on Cahoy and colleagues 2008, Dr. Andreas Junker did a quantitative PCR 
study to measure 96 astrocyte-specific genes in MS lesions to determine astrocyte 
functions during inflammatory demyelination in MS lesions. This approach revealed RFX4 
as a highly up-regulated factor in MS lesions. The work presented here demonstrates that 
RFX4 is expressed in various cell types of actively demyelinating MS lesions and chronic 
inactive MS lesions. In addition double IHC of RFX4 and GFAP displayed prominent 
expression of RFX4 in astrocytes. This confirmed the work of Cahoy and colleagues, 
which find RFX4 highly enriched in astrocytes (Cahoy et al., 2008).  
In humans four main splice variants of RFX4 have been described, but only variant 3 
was detected in brain tissue (Matsushita et al., 2005). Likewise, RT PCR with variant 
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specific primers (Matsushita et al., 2005) demonstrated that only the mRNA of RFX4_v3 
is present in MS lesions. 
RFX4 belongs to the protein family of regulatory factor x (RFX), which share a highly 
conserved winged helix DNA binding domain (Morotomi-Yano et al., 2002). Interestingly, 
members of the RFX family are known as regulators of immune response (Moreno et al., 
1997) and RFX4_v3 modulates the expression of CX3CL1, a chemokine gene which is 
highly expressed in brain and implicated in MS (Zhang et al., 2006a).  
Together, these facts raised the possibility that astrocytic RFX4_v3 may act as 
regulator of neuroinflammation, thereby influencing de- and remyelination in MS. To 
further investigate the role of the astrocytic RFX4_v3 in MS, GFAP cell-specific RFX4_v3 
conditional knockout mice were used to study de- and remyelination in the cuprizone 
mouse model.  
4.2.2 RFX4_v3 expression is important for regulation of myelination and 
activation of phagocytes in the cuprizone mouse model 
4.2.2.1 Increased demyelination in the corpus callosum of RFX4_v3 deficient 
mice after 4 weeks of cuprizone treatment 
To investigate the effects of astrocyte specific RFX4_v3 deletion on demyelination, 
conditional RFX4_v3 knockout animals and wild type controls were fed with cuprizone for 
4 weeks. In this toxic experimental MS model, the copper chelator cuprizone is classically 
fed for 4 to 6 weeks, which induces a significant and reproducible demyelination in a 
variety of CNS regions, including the corpus callosum (Matsushima and Morell, 2001; 
Gudi et al., 2009; Koutsoudaki et al., 2009; Silvestroff et al., 2010, Gudi et al., 2014, 
2014). Because of the high mortality rate in the conditional RFX4_v3 -/- knockout mice, 
the animals were treated with cuprizone for 4 weeks. Demyelination was subsequently 
analyzed in the corpus callosum.   
Compared to wild type, RFX4_v3 deficient mice displayed reduced LFB-PAS and 
myelin protein staining after 4 weeks of the cuprizone diet. A time course experiment 
revealed first signs of demyelination after 2 weeks of cuprizone ingestion with a higher 
score of demyelination in RFX4 deficient mice compared to wild type mice. The difference 
was even more pronounced after week 3 with a significant difference in the lateral part of 
the corpus callosum. Additionally, compared to wild type, RFX4_v3 deficient mice 
showed more axonal damage and a reduced total number of oligodendrocytes in the 
corpus callosum after 4 weeks of cuprizone treatment. 
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4.2.2.2 Remyelination in RFX4_v3 deficient mice is delayed 
In the model of cuprizone induced demyelination, acute demyelination is followed by 
spontaneous remyelination upon cuprizone withdrawal. Typically, remyelination in wild 
type mice is already marked in the 1st and 2nd week after cuprizone withdrawal and is 
almost complete after 4 weeks (Lindner et al., 2008; Torkildsen et al., 2008). Mason and 
colleagues reported that remyelination already starts during continued cuprizone 
ingestion (Mason et al., 2001a). Remyelinated axons are detectable with antibodies 
against myelin proteins CNPase and MBP (Matsushima and Morell, 2001; Lindner et al., 
2008; Gudi et al., 2009) and show pale staining with LFB. 
In this study cuprizone withdrawal revealed that RFX4_v3 deficient mice failed to 
remyelinate in the corpus callosum after week 1 of cuprizone cessation. Very low levels 
of remyelination were detected by analyzing LFB-PAS and MBP in mutant mice. However 
semiquantitatively, a significant difference between the RFX4_v3 deficient mice and the 
control mice was not observed for the myelin protein CNPase. This indicates an active 
ongoing remyelination process, which was further confirmed by a similar density of 
remyelinated fibers after 14 days in RFX4_v3 deficient and wild type mice. I thus 
concluded that remyelination is delayed, but not completely failing in RFX4_v3 deficient 
mice. 
The process of remyelination includes migration, proliferation and differentiation of 
OPCs and a reduction of microglia/macrophages in the demyelinated corpus callosum 
(Matsushima and Morell, 2001; Stangel and Hartung, 2002). OPCs start to migrate and 
proliferate in week 3-5 during cuprizone exposure, while microglia cells remove myelin 
debris in the corpus callosum (Mason et al., 2000). OPC proliferation is followed by 
differentiation into mature oligodendrocytes to restore the myelin sheath (Koutsoudaki et 
al., 2010).  
Immunohistochemical analyses were performed to evaluate OPC proliferation and 
differentiation in RFX4 deficient animals during the period of remyelination. Based on 
Olig2, a marker for precursor and mature oligodendrocytes, a reduced number of 
oligodendrocytes in the corpus callosum of RFX4_v3 deficient mice was observed after 4 
weeks of cuprizone treatment. However, no significant difference in the density of Olig2-
positive oligodendrocytes was observed after 7 days of remyelination between RFX4_v3 
deficient and wild type mice. Thus, OPC proliferation is occurring in both wild type and 
RFX4 deficient mice, with a delayed onset in RFX4_v3 deficient mice, which shows that 
the process of regeneration is active and not failing after 7 days of cuprizone withdrawal. 
By assessing p25, a marker for mature oligodendrocytes, a significantly lower number of 
mature oligodendrocytes was observed in the corpus callosum of RFX4_v3 deficient mice 
demonstrating that Olig2-positive cells in RFX4_v3 deficient mice mainly represent OPCs 
and not mature oligodendrocytes. The fact that OPC proliferation was delayed and 
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remyelination was observed after 14 days of cuprizone withdrawal suggests that OPC 
differentiation is delayed and inefficient but not failing after 7 days of cuprizone 
withdrawal.  
4.2.2.3 Increased phagocyte activation and accumulation during de- and 
remyelination 
Increased demyelination and delayed remyelination were accompanied by massive 
microglia/macrophage accumulation in the corpus callosum of RFX4_v3 deficient mice. 
Microglia cells are the resident immune cells of the CNS. In healthy brains, resting 
microglia scan the parenchyma for injuries to neurons or macroglia such as 
oligodendrocytes or astrocytes (Ajami et al., 2007). CNS injuries induce activation of 
microglia cells (Kettenmann et al., 2011). The resting ramified microglia cells take on an 
amoeboid-like shape, which is characterized by retracted processes (Aguzzi et al., 2013). 
In the mouse cuprizone model microglia cells become activated within week 1 and 
significantly increase during week 3 and 4 to clear myelin debris (Hiremath et al., 1998).  
The presented work revealed comparable numbers of Mac3-positive microglia for wild 
type and RFX4_v3 conditional knockout mice after 1 week of cuprizone treatment. 
However, in week 2 to 4 RFX4_v3 deficient mice showed significantly higher numbers of 
Mac3-positive phagocytes. This increase in phagocyte accumulation correlated well with 
the course of demyelination in RFX4_v3 deficient mice.  
When demyelination is complete microglia cells reach a maximal number and then 
start to decline gradually (Mason et al., 2004). Therefore, phagocyte numbers were 
investigated during the remyelination phase. After 1 week of remyelination a large 
number of microglia/macrophages were still present in the corpus callosum of RFX4_v3 
deficient mice, while their numbers were significantly reduced in the corpus callosum of 
wild type mice. However, 2 weeks after cuprizone cessation the density of microglia cells 
in the corpus callosum of RFX4_v3 deficient and wild type mice was comparable. Given 
these findings, I propose that the massive infiltration of the corpus callosum by microglia 
postpones the process of regeneration. The large excess of phagocytes might require 
more time to decline, which in turn leads to a delay in spontaneous remyelination in 
RFX4_v3 deficient mice. 
 
These results raised two main questions: What is the reason for the massive 
microglia/macrophage accumulation and how does RFX4_v3 deficiency in astrocytes 
contribute to this? The second question is whether microglia/macrophage accumulation is 
the cause or consequence of increased demyelination and delayed remyelination in 
RFX4_v3 deficient mice. 
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4.2.3 The blood brain barrier is closed in RFX4_v3 deficient mice. 
The first step to answer these questions was to clarify the origin of the Mac3-positive 
cells in the corpus callosum of RFX4_v3 deficient mice. Therefore, we investigated the 
BBB integrity in RFX4_v3 deficient and control mice, as a leaky BBB could indicate and 
result in enhanced infiltration of phagocytes in the corpus callosum. An important function 
of astrocytes is maintaining the BBB, which is a selective permeable barrier that 
separates the circulating blood from the CNS parenchyma. The structure of the BBB 
consists of capillaries built by endothelial cells, a basement membrane and pericytes 
which are surrounded by astrocyte end-feet, (Ballabh et al., 2004). As astrocytes are 
involved in formation of the BBB, we questioned the BBB integrity in mice with astrocytic 
RFX4_v3 deficiency. 
Based on IHC for fibrinogen and CD3 we concluded that the BBB is intact in RFX4_v3 
deficient mice during cuprizone-induced demyelination. A positive IHC for the 
glycoprotein fibrinogen and CD3, a marker for lymphocytes, was not observed, which 
would indicate BBB disruption. 
Previous publications showed that the BBB is closed in the cuprizone mouse model 
(Kondo et al., 1987; Baker et al., 1991; McMahon et al., 2002). Peripheral monocytes 
were only present in the brains of cuprizone treated mice when the brain was 
preconditioned, for example through irradiation (Mildner et al., 2007; Remington et al., 
2007). Hence, increased numbers of activated microglia in the brain of cuprizone treated 
mice originate from local recruitment and proliferation of microglia and not from 
recruitment of monocytes from the blood. Therefore, the cuprizone model is suitable to 
study de- and remyelination without a significant influence of the peripheral immune 
system.  
In line with these data, the results of the present work indicate that Mac3-positive cells 
in RFX4_v3 deficient mice most likely represent microglia and not blood-borne 
macrophages. This further supports the hypothesis that RFX4_v3 deficiency leads to an 
increased recruitment, activation and proliferation of microglia.  
 
4.2.4 RFX4_v3 deficiency causes microglial cell proliferation without 
stimulation of microglial activation markers  
To further characterize microglia cells of RFX4 deficient mice the cells were analyzed 
by flow cytometry.  
Flow cytometry experiments demonstrated that the CD45-low and CD11b-positive cell 
population was the most abundant cell population in RFX4 deficient mice. In addition this 
population increased in absolute numbers after 4 weeks of cuprizone treatment, which 
was in agreement with elevated numbers of proliferating cells in the corpus callosum of 
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RFX4_v3 deficient mice. This leads to the assumption that RFX4_v3 deletion in 
astrocytes increases recruitment and proliferation of microglia cells.    
The data is in line with two previously published studies that reported activation, 
proliferation and migration of microglia into the corpus callosum in response to primary 
demyelination by cuprizone intoxication. Both studies demonstrated that after 4.5 or 5 
weeks of cuprizone intoxication the CD11b-positive and CD45-low population are the 
most abundant phagocytes in the demyelinated corpus callosum (Remington et al., 2007; 
Voss et al., 2012). The CD11b-positive and CD45-low population identifies parenchymal 
microglia. At this time point only 0.5-7% are infiltrating monocytes, which showed high 
expression of CD45 (Remington et al., 2007; Voss et al., 2012). 
The next question was whether microglia cells of RFX4_v3 deficient mice only 
increase in cell number due to recruitment and proliferation or whether they have a more 
“activated” phenotype thereby causing more severe demyelination and axonal damage. A 
study of Krauthausen and colleagues showed that CXCR3- deficient mice reveal a milder 
clinical course accompanied by significantly less microglia activation, which was shown 
by reduced expression levels of CD45 and CD11b (Krauthausen et al., 2014).  
Based on the activation markers described by Remington and co-workers (Remington 
et al., 2007), microglia cells were characterized in the corpus callosum of RFX4_v3 
deficient mice and control mice. No significant differences in the expression levels of 
CD11b, CD45, CD86, CD80 and MHC class I were observed between RFX4_v3 deficient 
mice and control mice. 
 
In summary these data indicate that astrocytic RFX4_v3 deficiency leads to increased 
microglia recruitment and proliferation in the corpus callosum in mice exposed to 
cuprizone. However, loss of RFX4_v3 does not significantly alter the expression of 
activation markers on microglia cells during demyelination. Therefore, enhanced 
demyelination and axonal damage cannot be explained by a more activated microglia 
phenotype, which could lead to increased phagocytic activity. It is more likely that 
increased numbers of microglia cells in the corpus callosum contribute to increased 
demyelination and axonal damage. Although it is not clear at this point whether increased 
microglia recruitment and proliferation is the cause or consequence of increased 
demyelination and axonal damage.  
 
Based on results from previous studies two possible explanations could account for 
increased microglia recruitment and proliferation.  
First, it was demonstrated that astrocytes regulate microglia recruitment and 
proliferation by secretion of chemokines and cytokines (Raasch et al., 2011; Skripuletz et 
al., 2013). In addition inhibition of nuclear factor kappa B activation in astrocytes resulted 
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in reduced demyelination, reduced expression of pro-inflammatory mediators and a 
significantly diminished glial response (Raasch et al., 2011). This led to the hypothesis 
that deletion of RFX4_v3 in astrocytes may change the astrocytic phenotype or astrocyte 
function, in particular the ability of astrocytes to secrete cytokines and chemokines.  
Second, it was described that less demyelination in the corpus callosum is associated 
with less oligodendrocyte apoptosis or a limited loss of oligodendrocytes in the corpus 
callosum. This results in reduced microglia/ macrophage accumulation (Li et al., 2008; 
Raasch et al., 2011). Therefore, I asked the question whether elevated levels of 
oligodendrocyte apoptosis contribute to enhanced microglia accumulation in RFX4_v3 
deficient mice. 
4.2.5 RFX4_v3 loss in astrocytes modulates chemokine and cytokine 
transcript levels, thereby attracting phagocytes into the demyelinated 
corpus callosum 
4.2.5.1 Astrocyte specific RFX4_v3 deficiency has no influence on numbers 
of activated GFAP positive astrocytes in the corpus callosum  
Previous studies indicate that astrocytes play a crucial role in the recruitment of 
microglia in the cuprizone mouse model. Deletion of IKB kinase 2 in astrocytes was 
sufficient to protect mice from myelin loss in the cuprizone mouse model (Raasch et al., 
2011). In addition Skripuletz and colleagues demonstrated that a loss of astrocytes in 
GFAP-thymidine kinase transgenic mice reduced removal of damaged myelin and also 
delayed the remyelination process in the cuprizone mouse model. These effects were 
combined with a decrease in microglial activation and recruitment (Raasch et al., 2011; 
Skripuletz et al., 2013). Due to RFX4_v3 loss in astrocytes I hypothesized that a possible 
malfunction of astrocytes could lead to the observed microglia phenotype in the 
cuprizone mouse model.  
Therefore P0 astrocytes were characterized from RFX4_v3 deficient mice and control 
mice in vitro. Despite the fact that RFX4 transcripts in P0 astrocytes were significantly 
reduced, P0 astrocytes from RFX4_v3 deficient mice showed no morphological changes 
by IHC for GFAP. In addition, P0 astrocytes from RFX4_v3 deficient mice behaved in the 
same way as wild type astrocytes in a scratch migration assay. Thus, in vitro astrocytes 
from RFX4_v3 conditional knockout mice did not display obvious morphological and 
functional deficits.  
As the next step astrocytes from RFX4_v3 deficient mice and wild type mice were 
analyzed in the cuprizone mouse model after 1, 2, 3 and 4 weeks.  
In the cuprizone mouse model astrocytes usually increase in number and obtain a 
changed morphology during demyelination. During the first two weeks of 0.2% cuprizone 
treatment the quantity of astrocytes remains on a basal level (Hiremath et al., 1998). 
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However, during the third week of cuprizone ingestion, when significant levels of 
demyelination are present, astrocytes significantly increase in numbers (Hiremath et al., 
1998). Astrocytes in untreated mice show few, delicate and short processes, while 
astrocytes from cuprizone treated mice become hypertrophic with thick processes already 
during the first 2 weeks (Hiremath et al., 1998). Apart from the typical morphological 
changes, activated astrocytes express high levels of the intermediate filament glial 
fibrillary acidic protein (GFAP) (Eng, 1985). Astrocytic proliferation is enhanced in 
response to the toxin cuprizone, which was demonstrated by double immunostaining with 
BrdU and GFAP (Hiremath et al., 1998; Gudi et al., 2009; Gudi et al., 2014).  
In the RFX4_v3 deficient mice the number of activated GFAP-positive astrocytes in the 
corpus callosum was comparable to wild type animals at all time points and thus was in 
line with the literature (Hiremath et al., 1998). In addition the morphology of astrocytes 
was comparable until week 3. After 4 weeks I observed slight changes in RFX4_v3 
deficient mice. At this time point astrocyte density decreased compared to the wild type 
animals. This is probably due to the high cellularity of the corpus callosum of RFX4_v3 
heterozygous animals, which may lead to a displacement of astrocytes. In addition after 1 
week the expression level of the astrocytic activation marker GFAP in the corpus 
callosum was comparable between RFX4_v3 deficient and control mice.  
Altogether no substantial differences were found in cell density, morphology, and 
function between astrocytes from RFX4_v3 deficient and control mice in vitro and in vivo 
after cuprizone treatment. Thus, microglia recruitment and proliferation in RFX4_v3 
deficient mice cannot be explained through changes in astrocyte phenotype or density. 
However, I assumed that astrocytic functions such as chemokine and cytokine production 
were modified in RFX4_v3 deficient mice upon cuprizone treatment. 
 
4.2.5.2 Inhibition of astrocytic RFX4_v3 substantially increases transcripts of 
pro-inflammatory cytokines and chemokines in response to cuprizone  
Astrocytes produce a bulk of chemokines in MS (Dong and Benveniste, 2001; Nair et 
al., 2008). Hence, it was suggested that chemokine secretion is important for 
demyelination to recruit inflammatory cells to the injured area, such as macrophages and 
microglia (Babcock et al., 2003; Remington et al., 2007; Bianchi et al., 2011; Qin and 
Benveniste, 2012).  
The present work demonstrates that RFX4_v3 deficient mice have elevated levels of 
demyelination, oligodendrocyte loss and axonal damage, which are accompanied by 
massive microglia activation, recruitment and proliferation. Based on the reports 
discussed above I wondered whether astrocytic RFX4_v3 is involved in regulating the 
cytokine and chemokine production in astrocytes after cuprizone treatment. Compared to 
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wild type mice the first noticeable differences in demyelination and microgliosis in 
RFX4_v3 deficient mice appeared after two weeks of cuprizone treatment. Hence, I 
assumed that differences between wild type and RFX4_v3 deficient mice would start to 
appear after approximately one week of cuprizone treatment. Therefore, mRNA 
expression levels of the chemokines and cytokines CCL2, CCL3, CXCL10, IL-1ß, TNF-α 
and CXCL12 were measured at this time point in the corpus callosum of RFX4_v3 
deficient and wild type mice. Some of these cytokines and chemokines have been 
reported in the context of altered astrocyte activation in the cuprizone mouse model. 
Besides decreased demyelination and reduced microglia cells, IKB kinase 2 deletion in 
astrocytes additionally reduces astrocytic production of chemokines and cytokines 
including CCL2, CCL3, CXCL10 and TNF-α (Raasch et al., 2011). Skripuletz and 
colleagues also demonstrated that reduced microglia recruitment is associated with a 
reduction of CXCL10 production in mice after astrocyte ablation (Skripuletz et al., 2013).  
Compared to wild type mice the mRNA levels of CCL2 in RFX4_v3 deficient mice were 
strongly up-regulated after 1 week of cuprizone diet. Up-regulated levels of CCL2 mRNA 
were particularly found during the first week of cuprizone ingestion (McMahon et al., 
2001; McMahon et al., 2002; Buschmann et al., 2012). This is in line with the results from 
cuprizone treated wild type mice compared to untreated wild type mice. In MS CCL2 
expression was found in the brain, CSF and blood (Mahad and Ransohoff, 2003). In the 
cuprizone mouse model and EAE this factor was shown to be produced by astrocytes 
(Ransohoff et al., 1993; Raasch et al., 2011; Kim et al., 2014). GFAP cell specific CCL2 
conditional knockout mice have less severe EAE and show lower numbers of 
macrophages and T cells recruited into the white matter of the spinal cord and lower 
numbers of microglia in both white and gray matter. Finally, reduced axonal loss and 
demyelination was observed in GFAP cell specific CCL2 conditional knockout mice (Kim 
et al., 2014). Hayashi and colleagues showed that CCL2 induces chemotaxis of 
microglia. In addition they reported that LPS, IL-1ß and TNF-α stimulation leads to CCL2 
secretion by astrocytes, but does not induce CCL2 secretion by microglia (Hayashi et al., 
1995). Based on these results, I deduced that up-regulation of CCL2 in astrocytes with 
RFX4_v3 deletion might be responsible for microglia activation and attraction to the 
demyelinated corpus callosum. 
Compared to wild type mice also CCL3 was significantly up-regulated in RFX4_v3 
conditional knockout mice after 1 week of cuprizone treatment. CCL3 has been reported 
to be present in the brain of mice after 2 days of cuprizone treatment, with increasing 
levels until week 4 and a slight decrease after week 5, which was in line with the data of 
untreated versus treated wild type mice (McMahon et al., 2001; Raasch et al., 2011; 
Buschmann et al., 2012; Krauthausen et al., 2014). CCL3 is produced by astrocytes and 
microglia cells in the cuprizone mouse model as well as in EAE (Nygårdas et al., 2000; 
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Raasch et al., 2011). Deletion of this chemokine leads to reduced recruitment of microglia 
and astrocytes, which results in delayed demyelination in the cuprizone mouse model 
(McMahon et al., 2001). Studies in EAE with neutralizing antibodies against CCL3 and 
CCL2 revealed that these chemokines regulate the mononuclear accumulation and 
infiltration, which enhances the severity of the disease (Karpus et al., 1995; Kennedy et 
al., 1998). In vitro it was demonstrated that CCL3 influences migration and activation of 
microglia (Hayashi et al., 1995; Cross and Woodroofe, 2001).  
The work from Skripuletz and colleagues implied that CXCL10 is involved in the 
process of activation and recruitment of microglia and macrophages (Skripuletz et al., 
2013). With IHC techniques Skripuletz and colleagues showed that the factor was 
expressed by reactive astrocytes, but not in reactive microglia (Skripuletz et al., 2013). In 
the present study CXCL10 was significantly up-regulated in RFX4_v3 -/- compared to 
wild type mice. Increased levels of CXCL10 were also observed in cuprizone treated wild 
type mice in contrast to untreated wild type mice, which was in line with previous studies 
(Skripuletz et al., 2013). CXCL10 expression was found in MS, where the factor was 
expressed in astrocytes in the lesion border of demyelinated plaques (Tanuma et al., 
2006). The authors speculated that the production of CXCL10 and CCL2 by astrocytes 
activates astrocytes and directs reactive gliosis followed by migration and activation of 
microglia/macrophage in demyelinated lesions (Tanuma et al., 2006). Astroglial CXCL10 
deletion in mice led to milder clinical deficits and reduced acute demyelination in EAE 
accompanied by a reduced accumulation of CD4-positive lymphocytes in the spinal cord 
perivascular space, while the overall composition of these cells was unchanged. In 
addition the IBA1-positive microglia/macrophage accumulation was not affected in these 
mice (Mills Ko et al., 2014). 
By contrast, the chemokine CXCL12 was not regulated by RFX4_v3 deletion. After 1 
week of cuprizone treatment the factor was significantly down-regulated in both wild type 
and RFX4_v3 deficient mice to comparable mRNA levels. Expression of CXCL12 in the 
cuprizone mouse model was shown at later time points during the cuprizone diet, 
implicating that astrocytic CXCL12 is not important for early microglia/macrophage 
attraction, but rather for the process of remyelination as was described by Patel and 
colleagues (Patel et al., 2012).  
Compared to wild type mice the pro-inflammatory cytokines IL-1ß and TNF-α were 
significantly increased in the corpus callosum of RFX4_v3 deficient mice. Previous 
studies showed that IL-1ß promotes astrocyte proliferation and is also required for 
reactive astrogliosis upon CNS injury, which is a typical feature in the cuprizone mouse 
model (Giulian and Lachman, 1985; Herx and Yong, 2001). The cytokine IL-1ß is mainly 
produced by microglia and macrophages, but was also found in a subpopulation of 
astrocytes and has been shown to activate TNF-α, IL-6 and nitric oxide, thereby 
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contributing to the inflammatory response (Lee et al., 1993; Mason et al., 2001b). It has 
been reported that the factor is up-regulated from the first week onwards of cuprizone 
intoxication, which was confirmed by our data. The factor strongly increased at week 3 
and stayed on this level until week 6 (Mason et al., 2001). IL-1ß deletion in the cuprizone 
mouse model reduced the differentiation of OPCs, which leads to inefficient remyelination 
(Mason et al., 2001b). The role of IL-1ß during the first week of cuprizone exposure is still 
unclear, but the factor was described to promote reactive astrogliosis and activation of 
astrocytic chemokine secretion such as CCL2 in vitro. Hence, in RFX4_v3 deficient mice 
IL-1ß might have an indirect effect on the activation and recruitment of 
microglia/macrophages by activating the secretion of other chemokines in the corpus 
callosum.  
The cytokine TNF-α has been described to play a dual role in the cuprizone mouse 
model. Mice lacking TNF-α showed a decreased loss of oligodendrocytes during the first 
3 weeks, but also displayed significantly delayed remyelination. Reduced remyelination 
was associated with a reduction of the pool of proliferating OPCs and thus a reduced 
number of mature oligodendrocytes (Arnett et al., 2001). Although TNF-α is produced by 
microglia cells and astrocytes, Raasch and colleagues showed with laser microdissection 
that astrocytes regulate the transcript level of TNF-α in the cuprizone mouse model 
(Raasch et al., 2011). TNF-α is involved in many inflammatory diseases such as MS and 
is mainly produced by microglia/macrophages in the central nervous system, which has 
been shown to influence leukocyte activation and invasion (Bradley, 2008). 
 
Altogether, I conclude that after cuprizone treatment of astrocytic RFX4_v3 deficient 
mice, up-regulated levels of CXCL10, CCL2, CCL3, IL-1ß and TNF-α are involved in the 
activation and recruitment of microglia/macrophages. The results suggest that the 
transcription factor RFX4_v3 controls the activation and response of astrocytes through 
production of chemokines and cytokines, thereby influencing the recruitment of 
phagocytes. Finally this could contribute to increased demyelination, oligodendrocyte loss 
and axonal damage in RFX4_v3 deficient mice.  
4.2.5.3 The transcription factor RFX4_v3 possibly acts as a regulator of 
cytokine and chemokine production in MS 
In the neuroinflammtory disorder MS RFX4_v3 was found to be up-regulated. The 
factor showed a prominent expression in the nucleus of astrocytes in active and inactive 
MS lesions. In addition, it was suggested that RFX4 acts rather as a transcriptional 
repressor than as a transcriptional activator (Morotomi-Yano et al., 2002; Zhang et al., 
2007). This could be an indication for a protective role of RFX4 in the context of 
neuroinflammation in MS. 
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MS lesions are characterized by inflammation, demyelination and axonal damage 
(Lassmann et al., 1998). It is thought that MS is driven by a T cell mediated autoimmune 
reaction against myelin proteins (Hohlfeld, 2004). In the context of neuroinflammation, 
astrocytes have been reported to regulate the infiltration of peripheral pro-inflammatory 
leukocytes into the CNS (Bush et al., 1999; Voskuhl et al., 2009; Toft-Hansen et al., 
2011; Kim et al., 2014). Ablation of reactive astrocytes in adult transgenic mice leads to 
an increased infiltration of leukocytes including monocytes, macrophages, neutrophils 
and lymphocytes, failure of the BBB repair and neuronal degeneration (Bush et al., 
1999). This was confirmed by Toft-Hansen and co-workers, who showed that inhibition of 
reactive astrocytosis after initiation of EAE causes increased macrophage, but not T cell 
infiltration and leads to enhanced severity of EAE (Toft-Hansen et al., 2011). Increased 
macrophage infiltration was reflected by increased levels of cytokines and chemokines 
such as TNF-α and CCL2 (Toft-Hansen et al., 2011). A recent publication by Mayo and 
colleagues showed that regulation of astrocyte activation by glycolipids drives chronic 
CNS inflammation (Mayo et al., 2014). In this study the authors reported that 
lactosylceramide (LacCer) and B4GALT6 are up-regulated in the CNS of mice during 
chronic EAE and MS lesions. In addition, they were able to show that LacCer in 
astrocytes controls the recruitment and activation of microglia and CNS infiltrating 
monocytes by regulation of the production of the chemokine CCL2 and granulocyte 
macrophage colony-stimulating factor (GM-CSF) (Mayo et al., 2014). Downregulation of 
LacCer synthesis decreased the local CNS innate immunity and neurodegeneration in 
EAE and also interfered with activation of human astrocytes (Mayo et al., 2014).  
 
All of these studies demonstrate that the production and release of chemokines by 
astrocytes play an important role in the progression of MS. The data presented in my 
study, using astrocytic RFX4_v3 deficient mice under cuprizone treatment, further 
indicate that astrocytes regulate neuroinflammation by controlling chemokine and 
cytokine release, thereby restricting leukocyte infiltration, which is an indication of a 
protective role of astrocytes in MS. Hence, our data point to a putative protective role of 
the transcription factor RFX4_v3 in MS by regulating cytokine and chemokine production 
and release to restrict neuroinflammation.  
4.2.6 Deletion of RFX4_v3 in astrocytes induces apoptosis of 
oligodendrocytes 
As mentioned before increased oligodendrocyte apoptosis in the corpus callosum of 
RFX4_v3 deficient mice versus wild type mice could be an explanation for enhanced 
microglia activation.  
Oligodendrocyte cell death is an early phenomenon during the first three weeks of 
cuprizone treatment (Hesse et al., 2010; Veto et al., 2010). The mechanism of 
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oligodendrocyte apoptosis in response to cuprizone is not well understood. It is thought 
that selective toxicity of cuprizone to oligodendrocytes through functional disturbances in 
mitochondria plays an important role during oligodendrocyte apoptosis and, thus, 
initiation of demyelination (Matsushima and Morell, 2001; Pasquini et al., 2007; 
Ransohoff, 2012; Bénardais et al., 2013). Within the first 10 days of cuprizone treatment 
dying oligodendrocytes can be identified by expression of caspase 3 (Hesse et al., 2010).  
Indeed, based on caspase 3 IHC, oligodendroglial apoptosis proved to be significantly 
increased in RFX4_v3 deficient mice compared to wild type mice one week after the start 
of cuprizone treatment. 
Several studies describe that reduced demyelination is associated with less 
oligodendrocyte apoptosis or reduced loss of oligodendrocytes and less microglia 
activation, which supports the data presented here (Li et al., 2008; Raasch et al., 2011; 
Brück et al., 2012). Brück and colleagues showed that treatment of wild type and RAG-1-
deficient mice with Laquinimod (an oral immunoregulatory compound) reduced 
oligodendrocyte apoptosis, demyelination and microglia activation upon cuprizone 
feeding (Brück et al., 2012). A similar scenario was observed in a work from Li and 
colleagues who showed that p53 knockout mice and wild type mice receiving a p53 
inhibitor demonstrated less demyelination and reduced numbers of apoptotic 
oligodendrocytes accompanied by reduced microglia recruitment in the demyelinating 
corpus callosum. 
Furthermore, Raasch and co-workers showed that astrocytic loss of IKB kinase 2 
protects mice from myelin loss, which was associated with reduced loss of 
oligodendrocytes in the corpus callosum. Actually, IHC for Olig2 after four weeks of 
cuprizone revealed reduced total numbers of oligodendrocytes in the corpus callosum of 
RFX4_v3 deficient mice, which – considering the data of Raasch and colleagues - could 
contribute to the increase in demyelination observed in these animals.  
 
In summary, the discussion above indicates that increased injury in the corpus 
callosum by enhanced oligodendrocyte apoptosis could contribute to increased microglia 
activation. It is most likely that a combination of both enhanced cytokine and chemokine 
secretion and increased oligodendrocyte apoptosis in RFX4_v3 deficient mice contributes 
to the observed microglia phenotype in the cuprizone mouse model, which is in line with 
the literature (Li et al., 2008; Raasch et al., 2011; Skripuletz et al., 2013). Still, it cannot 
be completely solved whether enhanced microglia recruitment and proliferation is the 
cause or consequence of the increased demyelination, reduced oligodendrocytes and 
increased axonal damage in the corpus callosum of RFX4_v3 deficient mice.   
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What could be the reason for increased oligodendrocyte apoptosis in RFX4_v3 
deficient mice? 
4.2.6.1 RFX4_v3 may indirectly influence oligodendrocyte apoptosis by 
changing the inflammatory environment in the corpus callosum 
The observed increase in oligodendrocyte apoptosis upon cuprizone treatment in 
RFX4_v3 deficient mice raises the question how apoptosis is triggered in these animals. 
One option could be a indirect influence of RFX4_v3 on oligodendrocyte apoptosis by up-
regulation of cytokines and chemokines. 
MS lesions are characterized by oligodendrocyte death, axonal damage, gliosis, 
activation of microglia, and perivascular and parenchymal accumulation of lymphocytes 
and macrophages (Lassmann et al., 2007; Compston and Coles, 2008). Primary death of 
oligodendrocytes, is one of the factors suggested to be central to MS (Barnett and 
Prineas, 2004; Barnett and Sutton, 2006; Locatelli et al., 2012). 
One mechanism that may cause injury to oligodendrocytes in MS is signaling via death 
receptors of the TNF receptor superfamily, such as the receptor FAS (D'Souza, 1996). 
Death receptors are cell surface receptors, which transmit apoptotic signals by specific 
ligands like TNF-α and FasL. They play an important role in apoptosis and can activate a 
caspase cascade within seconds of ligand binding. Members of these receptors have 
been found on oligodendrocytes in MS and their ligands were shown to induce cytotoxic 
effects (D'Souza, 1996). In vitro it was shown that exposure of human adult 
oligodendrocytes to TNF-α leads to oligodendrocyte injury (Souza, 1995). TNF-α induces 
caspase activation by interaction with specific caspase receptors that regulate the factor 
Bcl-2, a regulator of cell death. This can lead to mitochondrial dysfunction and OLG 
apoptosis (Pang et al., 2007). Inhibition of caspase 1 and caspase 3 was shown to 
protect OLGs against TNF-α- induced apoptosis (Selmaj and Raine, 1988; Louis et al., 
1993; Tchélingérian et al., 1995; Hisahara et al., 1997; Cudrici et al., 2006). 
In the CNS, TNF-α is primarily produced by microglia and astrocytes, but only 
microglia cells have been reported to mediate OLG death through TNF-α production 
(Merrill et al., 1993; Arnett et al., 2001).  
We found that TNF-α was significantly up-regulated in RFX4_v3 deficient mice after 
one week of cuprizone diet. At this time point oligodendrocyte apoptosis was also 
increased. This implicates involvement of RFX4_v3 in regulation of TNF-α release to 
control oligodendrocyte cell death in the cuprizone mouse model. A similar scenario is 
conceivable for MS since RFX4_v3 was up-regulated in various cell types and in 
particular in astrocytes of MS lesions. It is conceivable that the transcription factor 
RFX4_v3 controls astrocytes and possibly also microglia through down-regulation of 
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cytokine and chemokine levels such as TNF-α to prevent oligodendrocyte death and 
neurodegeneration in MS lesions.  
4.2.7 Delayed remyelination as a consequence of a dysregulated 
inflammatory environment by astrocytes in RFX4_v3 conditional 
knockout mice 
As described in detail above the process of remyelination in RFX4_v3 deficient mice is 
most likely delayed. Although the number of OPCs in mutant mice was comparable to 
wild type mice after 7 days of remyelination, the number of mature oligodendrocytes in 
RFX4_v3 deficient mice was significantly lower than the in wild type mice. The delay in 
remyelination was associated with enhanced microglia accumulation. I assumed that the 
increase in microglia cells in the corpus callosum postpones the process of regeneration, 
including proliferation and differentiation of OPCs into mature oligodendrocytes. It was 
described that the inflammatory milieu influences the process of remyelination (Franklin, 
Robin J M and ffrench-Constant, 2008). Therefore it is conceivable that dysregulation of 
pro-inflammatory cytokines and chemokines by RFX4_v3 in astrocytes cause delayed 
remyelination.  
In MS remyelination does occur, but is inefficient and inadequate (Franklin, Robin J M 
and ffrench-Constant, 2008). Failure of remyelination is mostly due to a failure or arrest 
of oligodendroglial differentiation, whereas OPC presence and their migratory capacity 
are not limiting factors for remyelination in MS (Franklin, Robin J M and ffrench-Constant, 
2008). A lack of a supportive cellular environment hinders OPCs to differentiate into 
mature oligodendrocytes (Franklin, Robin J M, 2002; Franklin, Robin J M and ffrench-
Constant, 2008). Therefore, modulation of the inflammatory environment of a lesion could 
be effective to increase remyelination. In addition to other chemokines TNF-α and IL-1ß 
were up-regulated one week after cuprizone exposure in RFX4_v3 deficient mice. 
Genetic deletion of TNF-α and IL-1ß in the mouse cuprizone model significantly reduced 
remyelination due to an inadequate recruitment and differentiation of OPCs, which 
indicates that pro- as well as anti-inflammatory factors play a role in remyelination in the 
mouse cuprizone model (Arnett et al., 2001; Mason et al., 2001b). Olah and colleagues 
found that in the mouse cuprizone model microglia show a phenotype associated with 
phagocytosis of myelin debris as well as with recruitment of OPCs through expression of 
cytokines and chemokines, which provided evidence for the capability of microglia to 
support remyelination. Therefore, dysregulation of pro-inflammatory cytokines and 
chemokines by RFX4_v3 in astrocytes may directly or indirectly, through increased 
microglia cells, postpone remyelination which supports our hypothesis that remyelination 
is delayed and not failing. In addition, increased phagocytes in the corpus callosum may 
change the cytokine and chemokine level at later time points in the cuprizone mouse 
model, and thereby influence the recruitment, proliferation and differentiation of OPCs. 
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Altogether the dysregulated pro-inflammatory environment due to RFX4_v3 deficiency 
in astrocytes may postpone the process of remyelination. I suppose that the increased 
numbers and prolonged presence of microglia cells are a direct or indirect consequence 
of the modulated pro-inflammatory environment caused by loss of RFX4_v3, which may 
impede OPC differentiation and remyelination.  
The fact that RFX4_v3 is up-regulated in MS lesions and may influence the 
inflammatory environment, leads to the suggestion that this factor impacts on OPC 
differentiation in MS.  
4.2.8 Outlook 
The present work demonstrates that compared to wild type, mice with astrocytic 
RFX4_v3 deletion show enhanced loss of oligodendrocytes, increased demyelination, 
and axonal damage. Furthermore, the process of remyelination was delayed. These 
observations in RFX4_v3 deficient mice were accompanied by increased microglia 
activation and proliferation, which can be explained by early changes in cytokine and 
chemokine levels as well as increased oligodendrocyte apoptosis. Further research is 
required to fully understand the function of the astrocytic RFX4_v3 in the cuprizone 
mouse model and in MS. 
First, based on the literature and due to astrocytic loss of RFX4_v3 I assume that 
increased cytokine and chemokine levels are produced by astrocytes. However, it cannot 
be completely excluded that these molecules are additionally produced by microglia cells 
(Gandhi et al., 2010). Laser capture microdissection could be used as a method to 
specifically isolate astrocytes and microglia from the corpus callosum of RFX4_v3 
deficient and control mice to specifically measure cytokine and chemokine transcript 
levels in these cells.  
Second, cytokine and chemokine levels should be measured at later time points in the 
cuprizone mouse model to clarify whether RFX4_v3 is mainly important for early changes 
regarding cytokine and chemokine levels and oligodendrocyte apoptosis in this model. 
Such analyses could explain whether delayed remyelination is indeed a consequence of 
a dysregulated pro-inflammatory environment. 
Third, delayed remyelination in RFX4_v3 deficient mice could be due a lack of 
secretion of pro-remyelinating factors by astrocytes. Limited remyelination in MS was 
linked to disturbed balance of growth factors that influence OPC differentiation (Webster, 
H. d. F, 1997; Franklin and Hinks, 1999). One of these astrocyte produced growth factors 
is IGF1, which has been demonstrated to influence oligodendrocyte differentiation. IGF1 
was shown to be up-regulated in homozygous RFX4_v3 knockout animals at the 
embryonic stage 10.5 (Zhang et al., 2006a). In the work presented here up-regulation of 
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IGF1 was shown in astrocytes of RFX4_v3 conditional knockout animals at the time of 
birth, indicating that RFX4_v3 is important for regulation of the pro-remyelinating factor 
IGF1. Therefore, it would be important to analyze IGF1 expression of RFX4_v3 deficient 
and control mice to investigate whether delayed remyelination is a consequence of 
dysregulated inflammatory environments and/or of a lack of secretion of pro-
remyelinating factors by astrocytes in the cuprizone mouse model. 
Fourth, members of the RFX family of transcription factors are thought to bind to the 
X-box consensus sequences in the promoters of targets to regulate gene expression. To 
investigate if the analyzed cytokines and chemokines are potential direct targets of the 
transcription factor RFX4_v3, promoter sequences should be scanned for the presence of 
X-box consensus sequences in silico. Furthermore, RFX4_v3 transcriptional activity on 
potential targets can be analyzed by reporter gene assays. 
Lastly, it was demonstrated that RFX4_v3 is important for myelination and activation 
and recruitment of microglia by secretion of cytokines and chemokine. Based on these 
data and on data available in the literature it only can be speculated that RFX4_v3 may 
control cytokines and chemokine levels and restricts neuroinflammation in MS. Further 
studies are needed to understand the role of RFX4_v3 in MS, which includes a detailed 
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5 Summary and conclusion 
5.1 Part 1: Characterization of the GFAP cell specific RFX4 
conditional knockout mice  
GFAP cell specific RFX4 conditional knockout mice were generated by crossing the 
RFX4 flox/flox strain with a GFAP driven Cre transgenic strain. This results in RFX4 gene 
inactivation by deletion of the exon 4 in vivo. In mice, the exon 4 of the RFX4 gene is 
shared by RFX4_v2 and RFX4_v3. Only RFX4_v3 was identified in the fetal and adult 
brain, while RFX4_v2 is expressed in the testis (Blackshear et al., 2003; Matsushita et 
al., 2005). Therefore I concluded that RFX4_v3 is deleted in GFAP cell specific RFX4 
conditional knockout mice, which was further supported by the obtained brain phenotype. 
A substantial proportion of the GFAP cell specific RFX4 conditional knockout mice 
developed severe head swelling followed by neurological deficits that led to death in 
young adulthood. Histological analysis of GFAP cell specific conditional knockout mice 
revealed a hydrocephalus with dramatic extension of the lateral ventricle. The 
hydrocephalus was present at birth, indicating that the hydrocephalus is congenital, 
which is in line with the literature (Blackshear et al., 2003). 
At an age of 6 weeks the mortality rate for heterozygous RFX4_v3 conditional 
knockout mice was about 20%, while homozygous RFX4_v3 conditional knockout mice 
died at a rate of about 50%. This implies that the phenotype of RFX4_v3 conditional 
knockout mice is most likely the result of a gene dosage effect. 
It has been reported that maldevelopment and resulting dysfunction of the SCO is 
involved in the genesis of aqueductal stenosis, which is the primary cause of a congenital 
hydrocephalus (Vio et al., 2000; Perez Figares, 2001). In transgenic RFX4_v3 +/- mice 
generated by Blackshear and colleagues maldevelopment and dysfunction of the SCO 
were described as the main cause for hydrocephalus formation (Blackshear et al., 2003). 
Thus I hypothesized that hydrocephalus in RFX4 conditional knockout mice is caused by 
maldevelopment and dysfunction of the SCO. 
The SCO was present in all analyzed RFX4 conditional knockout animals. However, all 
symptomatic mice exhibited SCO hypoplasia. In addition, the SCO of RFX4 conditional 
knockout animals showed reduced or no immunoreactivity with anti-Reissner´s fiber 
serum (AFRU), implicating a dysfunctional glycoprotein secretion of the SCO.  
Furthermore, early morphogens including the Wnt signaling pathway were differentially 
expressed in astrocytes from RFX4 conditional knockout mice. These genes are relevant 
for dorsal midline structuring including the development of the SCO. These observations 
were in line with the findings of Blackshear and colleagues and supported the hypothesis 
that hydrocephalus in RFX4 conditional knockout animals is caused by maldevelopment 
and dysfunction of the SCO. My data further show that RFX4_v3 depletion in GFAP cell 
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lineages including astrocytes and ependymal cells is sufficient to induce congenital 
hydrocephalus. 
Altogether our results indicate that astrocytic and ependymal RFX4_v3 is highly 
relevant for the development of the brain and the pathogenesis of congenital 
hydrocephalus in rodents. An alignment of the human and mouse RFX4_v3 amino acid 
sequences showed 96% sequence identity between the mouse and human RFX4_v3 
protein (Blackshear et al., 2003), which could point toward similar functions of RFX4_v3 
in mouse and human. Therefore RFX4_v3 may be involved in the pathogenesis of human 
congenital hydrocephalus, which will be part of future investigations. 
 
5.2 Part 2: The role of astrocytic RFX4_v3 in demyelination 
The transcription factor RFX4_v3 was identified in the fetal and adult brain 
(Blackshear et al., 2003; Matsushita et al., 2005). In 2008, Cahoy and colleagues 
identified the transcription factor RFX4 as an astrocyte enriched factor (Cahoy et al., 
2008). 
In the present work RFX4_v3 was highly up-regulated in brain lesions of the 
neuroinflammatory disorder MS. IHC of active and chronic inactive MS lesions showed 
that RFX4 is present in various cell types and shows a prominent nuclear localization in 
astrocytes.  
Astrocytes play an important role in modulating de- and remyelination in MS (Nair et 
al., 2008). They promote demyelination by enhancing the immune response through 
antigen presentation and secretion of chemotactic molecules (Dong and Benveniste, 
2001; McFarland and Martin, 2007). Conversely, astrocytes inhibit aspects of the immune 
response, for example through production of anti-inflammatory cytokines, thereby 
inhibiting demyelination (Schönrock et al., 2000; Valerio, 2002).  
To understand the astrocytic role of RFX4_v3 in MS, GFAP cell specific RFX4_v3 
conditional knockout mice were used to study de- and remyelination in the cuprizone 
mouse model. To analyze demyelination, RFX4_v3 deficient mice and wild type mice 
were fed with the copper chelator cuprizone for 4 weeks. Remyelination was analyzed 
either 7 or 14 days after cuprizone withdrawal. 
The data presented in this study demonstrate that astrocytic RFX4_v3 expression is 
important for regulation of myelination and activation of microglia during the process of 
de- and remyelination in the cuprizone mouse model. During the process of 
demyelination RFX4_v3 deficient mice displayed increased demyelination, reduced total 
numbers of oligodendrocytes and enhanced axonal damage. Remyelination in RFX4_v3 
deficient mice was delayed. These effects were accompanied by increased phagocyte 
density in RFX4_v3 deficient mice. Phagocyte density correlated well with the course of 
de- and remyelination in RFX4_v3 deficient mice. 
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The results raised two central questions. i) What is the reason for the massive 
phagocyte accumulation? and ii) is phagocyte accumulation the cause or consequence of 
increased demyelination and delayed remyelination in RFX4_v3 deficient mice? 
 
To answer these questions the origin of the Mac3-positive cells in the corpus callosum 
was investigated. In this study it was shown that the BBB in RFX4_v3 deficient mice is 
closed, which is in line with previous studies (Kondo et al., 1987; Baker et al., 1991; 
McMahon et al., 2002). This implicates that the Mac3-positive cells in RFX4_v3 deficient 
mice represent microglia and not blood-borne macrophages, which could enter via a 
disrupted BBB. 
 
Flow cytometry analysis showed that the CD45-low and CD11b-positive cell population 
that identifies parenchymal microglia cells, is the most abundant cell population in 
RFX4_v3 deficient mice, which was in line with previous studies (Remington et al., 2007; 
Voss et al., 2012). This population increased in absolute numbers after 4 weeks of 
cuprizone treatment without changing the expression of activation markers on microglia 
cells during demyelination. These results indicated that loss of RFX4_v3 in the astrocytes 
leads to increased microglia recruitment and proliferation in the corpus callosum in mice 
exposed to cuprizone, but does not significantly alter the expression of activation markers 
on microglia cells during demyelination.  
 
Further investigations during the early phase of cuprizone treatment showed increased 
transcript levels of pro-inflammatory chemokines and cytokines and enhanced 
oligodendrocyte apoptosis in the corpus callosum of RFX4_v3 deficient mice. Based on 
the literature most of these pro-inflammatory factors are produced by astrocytes and play 
an important role for leukocyte activation and recruitment in the cuprizone mouse model, 
EAE as well as in MS lesions. This implied that the transcription factor RFX4_v3 controls 
the activation and response of astrocytes by producing chemokines and cytokines and 
thereby influences the recruitment of phagocytes. However, in this study the observed 
microglia phenotype in the cuprizone mouse model of RFX4_v3 deficient mice seems to 
be a combination of both enhanced cytokine and chemokine secretion and increased 
oligodendrocyte apoptosis, which is in line with the literature (Li et al., 2008; Raasch et 
al., 2011; Skripuletz et al., 2013). In this work it cannot be completely solved whether 
enhanced microglia recruitment and proliferation is the cause or consequence of the 
increased demyelination, reduced oligodendrocytes and increased axonal damage in the 
corpus callosum of RFX4_v3 deficient mice.  
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Altogether these results indicate that RFX4_v3 in astrocytes plays a protective role in the 
cuprizone mouse model by regulating oligodendrocyte apoptosis and recruitment of 
microglia cells. Our data point towards a control of the inflammatory environment by the 
transcription factor RFX4_v3 to restrict the activation and recruitment of microglia cells as 
well as oligodendrocyte apoptosis, which eventually controls the extent of de- and 
remyelination in the cuprizone mouse model. 
 
Up-regulated levels of RFX4_v3 in astrocytes in MS lesions may implicate a protective 
role for RFX4_v3 in MS since the transcription factor was rather described as 
transcriptional repressor than as transcriptional activator. The transcription factor 
RFX4_v3 possibly acts as a regulator for the production and release of cytokines and 
chemokines and may have a protective role in MS by restricting neuroinflammation.  
 
 
 References 114 
 
References 
Aguzzi, A., Barres, B.A., and Bennett, M.L. (2013). Microglia: scapegoat, saboteur, or something else? 
Science (New York, N.Y.) 339, 156-161. 
Ajami, B., Bennett, J.L., Krieger, C., Tetzlaff, W., and Rossi, Fabio M V (2007). Local self-renewal can 
sustain CNS microglia maintenance and function throughout adult life. Nature neuroscience 10, 
1538-1543. 
Araki, R., Takahashi, H., Fukumura, R., Sun, F., Umeda, N., Sujino, M., Inouye, S.-I.T., Saito, T., and 
Abe, M. (2004). Restricted expression and photic induction of a novel mouse regulatory factor X4 
transcript in the suprachiasmatic nucleus. The Journal of biological chemistry 279, 10237-10242. 
Arnett, H.A., Mason, J., Marino, M., Suzuki, K., Matsushima, G.K., and Ting, J.P. (2001). TNF alpha 
promotes proliferation of oligodendrocyte progenitors and remyelination. Nature neuroscience 4, 
1116-1122. 
Ashique, A.M., Choe, Y., Karlen, M., May, S.R., Phamluong, K., Solloway, M.J., Ericson, J., and 
Peterson, A.S. (2009). The Rfx4 transcription factor modulates Shh signaling by regional control of 
ciliogenesis. Science signaling 2, ra70. 
Baas, D., Meiniel, A., Benadiba, C., Bonnafe, E., Meiniel, O., Reith, W., and Durand, B. (2006). A 
deficiency in RFX3 causes hydrocephalus associated with abnormal differentiation of ependymal 
cells. The European journal of neuroscience 24, 1020-1030. 
Babcock, A.A., Kuziel, W.A., Rivest, S., and Owens, T. (2003). Chemokine expression by glial cells 
directs leukocytes to sites of axonal injury in the CNS. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 23, 7922-7930. 
Bach, A. (2003). Msx1 is required for dorsal diencephalon patterning. Development 130, 4025-4036. 
Baker, D., O'Neill, J.K., and Turk, J.L. (1991). Cytokines in the central nervous system of mice during 
chronic relapsing experimental allergic encephalomyelitis. Cellular Immunology 134, 505-510. 
Bakker, D.A., and Ludwin, S.K. (1987). Blood-brain barrier permeability during Cuprizone-induced 
demyelination. Journal of the Neurological Sciences 78, 125-137. 
 References 115 
 
Ballabh, P., Braun, A., and Nedergaard, M. (2004). The blood-brain barrier: an overview: structure, 
regulation, and clinical implications. Neurobiology of disease 16, 1-13. 
Barnett, M.H., and Prineas, J.W. (2004). Relapsing and remitting multiple sclerosis: pathology of the 
newly forming lesion. Annals of neurology 55, 458-468. 
Barnett, M.H., and Sutton, I. (2006). The pathology of multiple sclerosis: a paradigm shift. Current 
opinion in neurology 19, 242-247. 
Barres, B.A., Schmid, R., Sendnter, M., and Raff, M.C. (1993). Multiple extracellular signals are 
required for long-term oligodendrocyte survival. Development (Cambridge, England) 118, 283-295. 
Bauer, J., Sminia, T., Wouterlood, F.G., and Dijkstra, C.D. (1994). Phagocytic activity of macrophages 
and microglial cells during the course of acute and chronic relapsing experimental autoimmune 
encephalomyelitis. Journal of neuroscience research 38, 365-375. 
Beck, K.D., Powell-Braxtont, L., Widmer, H.-R., Valverde, J., and Hefti, F. (1995). Igf1 gene disruption 
results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal 
parvalbumin-containing neurons. Neuron 14, 717-730. 
Benadiba, C., Magnani, D., Niquille, M., Morlé, L., Valloton, D., Nawabi, H., Ait-Lounis, A., Otsmane, 
B., Reith, W., and Theil, T., et al. (2012). The ciliogenic transcription factor RFX3 regulates early 
midline distribution of guidepost neurons required for corpus callosum development. PLoS genetics 
8, e1002606. 
Bénardais, K., Kotsiari, A., Skuljec, J., Koutsoudaki, P.N., Gudi, V., Singh, V., Vulinović, F., Skripuletz, T., 
and Stangel, M. (2013). Cuprizone [bis(cyclohexylidenehydrazide)] is selectively toxic for mature 
oligodendrocytes. Neurotoxicity research 24, 244-250. 
Bennett, L., Yang, M., Enikolopov, G., and Iacovitti, L. (2009). Circumventricular organs: a novel site of 
neural stem cells in the adult brain. Molecular and cellular neurosciences 41, 337-347. 
Benveniste, E.N. (1997). Role of macrophages/microglia in multiple sclerosis and experimental 
allergic encephalomyelitis. Journal of molecular medicine (Berlin, Germany) 75, 165-173. 
Bianchi, R., Kastrisianaki, E., Giambanco, I., and Donato, R. (2011). S100B protein stimulates microglia 
migration via RAGE-dependent up-regulation of chemokine expression and release. The Journal of 
biological chemistry 286, 7214-7226. 
 References 116 
 
Bjartmar, C., and Trapp, B.D. (2001). Axonal and neuronal degeneration in multiple sclerosis: 
mechanisms and functional consequences. Current opinion in neurology 14, 271-278. 
Blackshear, P.J., Graves, J.P., Stumpo, D.J., Cobos, I., Rubenstein, John L R, and Zeldin, D.C. (2003). 
Graded phenotypic response to partial and complete deficiency of a brain-specific transcript variant 
of the winged helix transcription factor RFX4. Development (Cambridge, England) 130, 4539-4552. 
Blauth, K., Zhang, X., Chopra, M., Rogan, S., and Markovic-Plese, S. (2015). The role of fractalkine 
(CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with 
relapsing-remitting multiple sclerosis. Clinical immunology (Orlando, Fla.). 
Boillat, C.A., Jones, H.C., and Kaiser, G.L. (1999). Aqueduct stenosis in hydrocephalus: ultrastructural 
investigation in neonatal H-Tx rat brain. European journal of pediatric surgery : official journal of 
Austrian Association of Pediatric Surgery … [et al] = Zeitschrift für Kinderchirurgie 9 Suppl 1, 44-46. 
Bradley, J.R. (2008). TNF-mediated inflammatory disease. The Journal of pathology 214, 149-160. 
Brosnan, C.F., and Raine, C.S. (2013). The astrocyte in multiple sclerosis revisited. Glia 61, 453-465. 
Broux, B., Pannemans, K., Zhang, X., Markovic-Plese, S., Broekmans, T., Eijnde, B.O., van Wijmeersch, 
B., Somers, V., Geusens, P., and van der Pol, Susanne, et al. (2012). CX(3)CR1 drives cytotoxic 
CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. Journal of autoimmunity 38, 10-19. 
Brück, W. (2005). Clinical implications of neuropathological findings in multiple sclerosis. Journal of 
neurology 252 Suppl 3, iii10-iii14. 
Brück, W., Pförtner, R., Pham, T., Zhang, J., Hayardeny, L., Piryatinsky, V., Hanisch, U.-K., Regen, T., 
van Rossum, D., and Brakelmann, L., et al. (2012). Reduced astrocytic NF-κB activation by laquinimod 
protects from cuprizone-induced demyelination. Acta neuropathologica 124, 411-424. 
Brück, W., Porada, P., Poser, S., Rieckmann, P., Hanefeld, F., Kretzschmar, H.A., and Lassmann, H. 
(1995). Monocyte/macrophage differentiation in early multiple sclerosis lesions. Annals of neurology 
38, 788-796. 
Brück, W., and Stadelmann, C. (2005). The spectrum of multiple sclerosis: new lessons from 
pathology. Current opinion in neurology 18, 221-224. 
Bruni, J.E., Del Bigio, M.R., Cardoso, E.R., and Persaud, T. (1988a). Hereditary hydrocephalus in 
laboratory animals and humans. Experimental pathology 35, 239-246. 
 References 117 
 
Bruni, J.E., del Bigio, M R, Cardoso, E.R., and Persaud, T.V. (1988b). Neuropathology of congenital 
hydrocephalus in the SUMS/NP mouse. Acta neurochirurgica 92, 118-122. 
Bsibsi, M., Persoon-Deen, C., Verwer, Ronald W H, Meeuwsen, S., Ravid, R., and Van Noort, Johannes 
M (2006). Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective 
mediators. Glia 53, 688-695. 
Bsibsi, M., Ravid, R., Gveric, D., and Van Noort, Johannes M (2002). Broad expression of Toll-like 
receptors in the human central nervous system. Journal of neuropathology and experimental 
neurology 61, 1013-1021. 
Buschmann, J.P., Berger, K., Awad, H., Clarner, T., Beyer, C., and Kipp, M. (2012). Inflammatory 
response and chemokine expression in the white matter corpus callosum and gray matter cortex 
region during cuprizone-induced demyelination. Journal of molecular neuroscience : MN 48, 66-76. 
Bush, T.G., Puvanachandra, N., Horner, C.H., Polito, A., Ostenfeld, T., Svendsen, C.N., Mucke, L., 
Johnson, M.H., and Sofroniew, M.V. (1999). Leukocyte infiltration, neuronal degeneration, and 
neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. 
Neuron 23, 297-308. 
Cahoy, J.D., Emery, B., Kaushal, A., Foo, L.C., Zamanian, J.L., Christopherson, K.S., Xing, Y., Lubischer, 
J.L., Krieg, P.A., and Krupenko, S.A., et al. (2008). A transcriptome database for astrocytes, neurons, 
and oligodendrocytes: a new resource for understanding brain development and function. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 28, 264-278. 
Calderon, T.M., Eugenin, E.A., Lopez, L., Kumar, S.S., Hesselgesser, J., Raine, C.S., and Berman, J.W. 
(2006). A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 
expression in astrocytes by soluble myelin basic protein. Journal of Neuroimmunology 177, 27-39. 
Cannella, B., and Raine, C.S. (1995). The adhesion molecule and cytokine profile of multiple sclerosis 
lesions. Annals of neurology 37, 424-435. 
Carpentier, P.A., Williams, B.R., and Miller, S.D. (2007). Distinct roles of protein kinase R and toll-like 
receptor 3 in the activation of astrocytes by viral stimuli. Glia 55, 239-252. 
Castañeyra-Perdomo, A., Meyer, G., Carmona-Calero, E., Bañuelos-Pineda, J., Méndez-Medina, R., 
Ormazabal-Ramos, C., and Ferres-Torres, R. (1994). Alterations of the subcommissural organ in the 
hydrocephalic human fetal brain. Brain research. Developmental brain research 79, 316-320. 
 References 118 
 
Chouaf, L., Didier-Bazes, M., Hardin, H., Aguera, M., Fevre-Montange, M., Voutsinos, B., and Belin, 
M.F. (1991). Developmental expression of glial markers in ependymocytes of the rat subcommissural 
organ: role of the environment. Cell Tissue Res 266, 553-561. 
Clevers, H., and Nusse, R. (2012). Wnt/β-catenin signaling and disease. Cell 149, 1192-1205. 
Compston, A., and Coles, A. (2008). Multiple sclerosis. The Lancet 372, 1502-1517. 
Cross, A.K., and Woodroofe, M.N. (2001). Immunoregulation of microglial functional properties. 
Microscopy research and technique 54, 10-17. 
Croxford, A.L., Kurschus, F.C., and Waisman, A. (2011). Mouse models for multiple sclerosis: historical 
facts and future implications. Biochimica et biophysica acta 1812, 177-183. 
Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., and 
Churakova, T., et al. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for 
autoimmune inflammation of the brain. Nature 421, 744-748. 
Cudrici, C., Niculescu, T., Niculescu, F., Shin, M.L., and Rus, H. (2006). Oligodendrocyte cell death in 
pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement. 
Journal of rehabilitation research and development 43, 123-132. 
de Lau, Wim B M, Snel, B., and Clevers, H.C. (2012). The R-spondin protein family. Genome biology 
13, 242. 
Didier, N., Romero, I.A., Créminon, C., Wijkhuisen, A., Grassi, J., and Mabondzo, A. (2003). Secretion 
of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on 
human brain microvascular endothelial cell permeability. Journal of neurochemistry 86, 246-254. 
Didon, L., Zwick, R.K., Chao, I.W., Walters, M.S., Wang, R., Hackett, N.R., and Crystal, R.G. (2013). 
RFX3 modulation of FOXJ1 regulation of cilia genes in the human airway epithelium. Respiratory 
research 14, 70. 
Dietrich, P., Shanmugasundaram, R., Shuyu, E., and Dragatsis, I. (2009). Congenital hydrocephalus 
associated with abnormal subcommissural organ in mice lacking huntingtin in Wnt1 cell lineages. 
Human molecular genetics 18, 142-150. 
Dong, Y., and Benveniste, E.N. (2001). Immune function of astrocytes. Glia 36, 180-190. 
 References 119 
 
Dotzlaw, H., Alkhalaf, M., and Murphy, L.C. (1992). Characterization of estrogen receptor variant 
mRNAs from human breast cancers. Molecular endocrinology (Baltimore, Md.) 6, 773-785. 
D'Souza, S.D. (1996). Multiple Sclerosis: Fas Signaling in Oligodendrocyte Cell Death. Journal of 
Experimental Medicine 184, 2361-2370. 
El Zein, L., Ait-Lounis, A., Morlé, L., Thomas, J., Chhin, B., Spassky, N., Reith, W., and Durand, B. 
(2009). RFX3 governs growth and beating efficiency of motile cilia in mouse and controls the 
expression of genes involved in human ciliopathies. Journal of Cell Science 122, 3180-3189. 
Emery, P., Durand, B., Mach, B., and Reith, W. (1996). RFX Proteins, a Novel Family of DNA Binding 
Proteins Conserved in the Eukaryotic Kingdom. Nucleic Acids Research 24, 803-807. 
Eng, L.F. (1985). Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments 
in differentiated astrocytes. Journal of Neuroimmunology 8, 203-214. 
Estivill-Torrús, G., Vitalis, T., Fernández-Llebrez, P., and Price, D.J. (2001). The transcription factor 
Pax6 is required for development of the diencephalic dorsal midline secretory radial glia that form 
the subcommissural organ. Mechanisms of development 109, 215-224. 
Feng, C., Zhang, Y., Yin, J., Li, J., Abounader, R., and Zuo, Z. (2014). Regulatory factor X1 is a new 
tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma. 
Neuro-oncology 16, 1078-1085. 
Fernández-Llebrez, P., Grondona, J.M., Pérez, J., López-Aranda, M.F., Estivill-Torrús, G., Llebrez-Zayas, 
P.F., Soriano, E., Ramos, C., Lallemand, Y., and Bach, A., et al. (2004). Msx1-deficient mice fail to form 
prosomere 1 derivatives, subcommissural organ, and posterior commissure and develop 
hydrocephalus. Journal of neuropathology and experimental neurology 63, 574-586. 
Franklin, R.J., and Hinks, G.L. (1999). Understanding CNS remyelination: clues from developmental 
and regeneration biology. Journal of neuroscience research 58, 207-213. 
Franklin, Robin J M (2002). Why does remyelination fail in multiple sclerosis? Nature reviews. 
Neuroscience 3, 705-714. 
Franklin, Robin J M, and ffrench-Constant, C. (2008). Remyelination in the CNS: from biology to 
therapy. Nature reviews. Neuroscience 9, 839-855. 
 References 120 
 
Furuta, Y., Piston, D.W., and Hogan, B.L. (1997). Bone morphogenetic proteins (BMPs) as regulators 
of dorsal forebrain development. Development (Cambridge, England) 124, 2203-2212. 
Gajiwala, K.S., Chen, H., Cornille, F., Roques, B.P., Reith, W., Mach, B., and Burley, S.K. (2000). 
Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature 403, 916-
921. 
Gandhi, R., Laroni, A., and Weiner, H.L. (2010). Role of the innate immune system in the pathogenesis 
of multiple sclerosis. Journal of Neuroimmunology 221, 7-14. 
Gangemi, M., Cavallo, L.M., Di Somma, A., Mazzucco, G.M., Bono, P.S., Ghetti, G., and Zambon, G. 
(2014). Hydrocephalus onset after microsurgical or endovascular treatment for acute subarachnoid 
hemorrhage. Retrospective italian multicenter study. Translational medicine @ UniSa 9, 50-55. 
Garcia, A Denise R, Doan, N.B., Imura, T., Bush, T.G., and Sofroniew, M.V. (2004). GFAP-expressing 
progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nature 
neuroscience 7, 1233-1241. 
Gensert, J.M., and Goldman, J.E. (1997). Endogenous Progenitors Remyelinate Demyelinated Axons 
in the Adult CNS. Neuron 19, 197-203. 
Gimenez, Mary Ann T, Sim, J.E., and Russell, J.H. (2004). TNFR1-dependent VCAM-1 expression by 
astrocytes exposes the CNS to destructive inflammation. Journal of Neuroimmunology 151, 116-125. 
Giulian, D., and Lachman, L. (1985). Interleukin-1 stimulation of astroglial proliferation after brain 
injury. Science 228, 497-499. 
Goldman, S. (2003). Glia as neural progenitor cells. Trends in neurosciences 26, 590-596. 
Grondona, J.M., Pérez, J., Cifuentes, M., López-Avalos, M.D., Nualart, F.J., Peruzzo, B., Fernández-
Llebrez, P., and Rodríguez, E.M. (1994). Analysis of the secretory glycoproteins of the 
subcommissural organ of the dogfish (Scyliorhinus canicula). Molecular Brain Research 26, 299-308. 
Gudi, V., Gingele, S., Skripuletz, T., and Stangel, M. (2014). Glial response during cuprizone-induced 
de- and remyelination in the CNS: lessons learned. Frontiers in cellular neuroscience 8, 73. 
Gudi, V., Moharregh-Khiabani, D., Skripuletz, T., Koutsoudaki, P.N., Kotsiari, A., Skuljec, J., Trebst, C., 
and Stangel, M. (2009). Regional differences between grey and white matter in cuprizone induced 
demyelination. Brain Research 1283, 127-138. 
 References 121 
 
Hayashi, K., Nakamura, S., Nishida, W., and Sobue, K. (2006). Bone morphogenetic protein-induced 
MSX1 and MSX2 inhibit myocardin-dependent smooth muscle gene transcription. Molecular and 
cellular biology 26, 9456-9470. 
Hayashi, M., Luo, Y., Laning, J., Strieter, R.M., and Dorf, M.E. (1995). Production and function of 
monocyte chemoattractant protein-1 and other β-chemokines in murine glial cells. Journal of 
Neuroimmunology 60, 143-150. 
Hébert, J.M., Mishina, Y., and McConnell, S.K. (2002). BMP signaling is required locally to pattern the 
dorsal telencephalic midline. Neuron 35, 1029-1041. 
Herx, L.M., and Yong, V.W. (2001). Interleukin-1 beta is required for the early evolution of reactive 
astrogliosis following CNS lesion. Journal of neuropathology and experimental neurology 60, 961-
971. 
Hesse, A., Wagner, M., Held, J., Brück, W., Salinas-Riester, G., Hao, Z., Waisman, A., and Kuhlmann, T. 
(2010). In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. 
Neurobiology of disease 37, 362-369. 
Hiremath, M.M., Saito, Y., Knapp, G.W., Ting, J.-Y., Suzuki, K., and Matsushima, G.K. (1998). 
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. 
Journal of Neuroimmunology 92, 38-49. 
Hisahara, S., Shoji, S., Okano, H., and Miura, M. (1997). ICE/CED-3 Family Executes Oligodendrocyte 
Apoptosis by Tumor Necrosis Factor. Journal of neurochemistry 69, 10-20. 
Huh, M.S., Todd, Matthew A M, and Picketts, D.J. (2009). SCO-ping out the mechanisms underlying 
the etiology of hydrocephalus. Physiology (Bethesda, Md.) 24, 117-126. 
Jack, C.S., Arbour, N., Manusow, J., Montgrain, V., Blain, M., McCrea, E., Shapiro, A., and Antel, J.P. 
(2005). TLR signaling tailors innate immune responses in human microglia and astrocytes. Journal of 
immunology (Baltimore, Md. : 1950) 175, 4320-4330. 
Jones, H.C., Dack, S., and Ellis, C. (1987). Morphological aspects of the development of hydrocephalus 
in a mouse mutant (SUMS/NP). Acta neuropathologica 72, 268-276. 
Jones, H.C., and Klinge, P.M. (2008). Hydrocephalus 2008, 17-20th September, Hannover Germany: a 
conference report. Cerebrospinal fluid research 5, 19. 
 References 122 
 
Kang, J., Jiang, L., Goldman, S.A., and Nedergaard, M. (1998). Astrocyte-mediated potentiation of 
inhibitory synaptic transmission. Nature neuroscience 1, 683-692. 
Karni, A., Abraham, M., Monsonego, A., Cai, G., Freeman, G.J., Hafler, D., Khoury, S.J., and Weiner, 
H.L. (2006). Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive 
Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response. The Journal of 
Immunology 177, 4196-4202. 
Karpus, W.J., Lukacs, N.W., McRae, B.L., Strieter, R.M., Kunkel, S.L., and Miller, S.D. (1995). An 
important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of 
the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. Journal of 
immunology (Baltimore, Md. : 1950) 155, 5003-5010. 
Kennedy, K.J., Strieter, R.M., Kunkel, S.L., Lukacs, N.W., and Karpus, W.J. (1998). Acute and relapsing 
experimental autoimmune encephalomyelitis are regulated by differential expression of the CC 
chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1. Journal of 
Neuroimmunology 92, 98-108. 
Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H., and Hohlfeld, R. (2003). Neurotrophic 
cross-talk between the nervous and immune systems: implications for neurological diseases. Annals 
of neurology 53, 292-304. 
Kettenmann, H., Hanisch, U.-K., Noda, M., and Verkhratsky, A. (2011). Physiology of microglia. 
Physiological reviews 91, 461-553. 
Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E.G., Wieghofer, P., Heinrich, 
A., Riemke, P., and Hölscher, C., et al. (2013). Microglia emerge from erythromyeloid precursors via 
Pu.1- and Irf8-dependent pathways. Nature neuroscience 16, 273-280. 
Kim, R.Y., Hoffman, A.S., Itoh, N., Ao, Y., Spence, R., Sofroniew, M.V., and Voskuhl, R.R. (2014). 
Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune 
encephalomyelitis. Journal of Neuroimmunology 274, 53-61. 
Komiya, Y., and Habas, R. (2014). Wnt signal transduction pathways. Organogenesis 4, 68-75. 
Kondo, A., Nakano, T., and Suzuki, K. (1987). Blood-brain barrier permeability to horseradish 
peroxidase in twitcher and cuprizone-intoxicated mice. Brain Research 425, 186-190. 
 References 123 
 
Kotter, M.R., Li, W.-W., Zhao, C., and Franklin, Robin J M (2006). Myelin impairs CNS remyelination by 
inhibiting oligodendrocyte precursor cell differentiation. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 26, 328-332. 
Koutsoudaki, P.N., Hildebrandt, H., Gudi, V., Skripuletz, T., Škuljec, J., and Stangel, M. (2010). 
Remyelination after cuprizone induced demyelination is accelerated in mice deficient in the polysialic 
acid synthesizing enzyme St8siaIV. Neuroscience 171, 235-244. 
Koutsoudaki, P.N., Skripuletz, T., Gudi, V., Moharregh-Khiabani, D., Hildebrandt, H., Trebst, C., and 
Stangel, M. (2009). Demyelination of the hippocampus is prominent in the cuprizone model. 
Neuroscience letters 451, 83-88. 
Krauthausen, M., Saxe, S., Zimmermann, J., Emrich, M., Heneka, M.T., and Müller, M. (2014). CXCR3 
modulates glial accumulation and activation in cuprizone-induced demyelination of the central 
nervous system. Journal of neuroinflammation 11, 109. 
Kutzelnigg, A., and Lassmann, H. (2014). Pathology of multiple sclerosis and related inflammatory 
demyelinating diseases. Handbook of clinical neurology 122, 15-58. 
Kwon, T., Chung, M.-I., Gupta, R., Baker, J.C., Wallingford, J.B., and Marcotte, E.M. (2014). Identifying 
direct targets of transcription factor Rfx2 that coordinate ciliogenesis and cell movement. Genomics 
data 2, 192-194. 
LaMantia, A.S., Colbert, M.C., and Linney, E. (1993). Retinoic acid induction and regional 
differentiation prefigure olfactory pathway formation in the mammalian forebrain. Neuron 10, 1035-
1048. 
Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedgwick, J.D., McClanahan, T., 
Kastelein, R.A., and Cua, D.J. (2005). IL-23 drives a pathogenic T cell population that induces 
autoimmune inflammation. The Journal of experimental medicine 201, 233-240. 
Lassmann, H. (2011). Review: the architecture of inflammatory demyelinating lesions: implications 
for studies on pathogenesis. Neuropathology and applied neurobiology 37, 698-710. 
Lassmann, H., Brück, W., and Lucchinetti, C.F. (2007). The immunopathology of multiple sclerosis: an 
overview. Brain pathology (Zurich, Switzerland) 17, 210-218. 
 References 124 
 
Lee, S.C., Dickson, D.W., Liu, W., and Brosnan, C.F. (1993). Induction of nitric oxide synthase activity 
in human astrocytes by interleukin-1 beta and interferon-gamma. Journal of Neuroimmunology 46, 
19-24. 
Lee, S.M., Tole, S., Grove, E., and McMahon, A.P. (2000). A local Wnt-3a signal is required for 
development of the mammalian hippocampus. Development (Cambridge, England) 127, 457-467. 
Li, J., Ghiani, C.A., Kim, J.Y., Liu, A., Sandoval, J., DeVellis, J., and Casaccia-Bonnefil, P. (2008). 
Inhibition of p53 transcriptional activity: a potential target for future development of therapeutic 
strategies for primary demyelination. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 28, 6118-6127. 
Liberto, C.M., Albrecht, P.J., Herx, L.M., Yong, V.W., and Levison, S.W. (2004). Pro-regenerative 
properties of cytokine-activated astrocytes. Journal of neurochemistry 89, 1092-1100. 
Liem, K.F., Tremml, G., and Jessell, T.M. (1997). A Role for the Roof Plate and Its Resident TGFβ-
Related Proteins in Neuronal Patterning in the Dorsal Spinal Cord. Cell 91, 127-138. 
Liem, K.F., Tremml, G., Roelink, H., and Jessell, T.M. (1995). Dorsal differentiation of neural plate cells 
induced by BMP-mediated signals from epidermal ectoderm. Cell 82, 969-979. 
Lindner, M., Heine, S., Haastert, K., Garde, N., Fokuhl, J., Linsmeier, F., Grothe, C., Baumgärtner, W., 
and Stangel, M. (2008). Sequential myelin protein expression during remyelination reveals fast and 
efficient repair after central nervous system demyelination. Neuropathology and applied 
neurobiology 34, 105-114. 
Linninger, A.A., Sweetman, B., and Penn, R. (2009). Normal and hydrocephalic brain dynamics: the 
role of reduced cerebrospinal fluid reabsorption in ventricular enlargement. Annals of biomedical 
engineering 37, 1434-1447. 
Liu, A., and Niswander, L.A. (2005). Bone morphogenetic protein signalling and vertebrate nervous 
system development. Nature reviews. Neuroscience 6, 945-954. 
Liu, Y., Helms, A.W., and Johnson, J.E. (2004). Distinct activities of Msx1 and Msx3 in dorsal neural 
tube development. Development (Cambridge, England) 131, 1017-1028. 
 References 125 
 
Locatelli, G., Wörtge, S., Buch, T., Ingold, B., Frommer, F., Sobottka, B., Krüger, M., Karram, K., 
Bühlmann, C., and Bechmann, I., et al. (2012). Primary oligodendrocyte death does not elicit anti-CNS 
immunity. Nature neuroscience 15, 543-550. 
Louis, J., Magal, E., Takayama, S., and Varon, S. (1993). CNTF protection of oligodendrocytes against 
natural and tumor necrosis factor-induced death. Science 259, 689-692. 
Louvi A and Wassef M (2000). Ectopic engrailed 1 expression in the dorsal midline causes cell de… - 
PubMed - NCBI. http://www.ncbi.nlm.nih.gov/pubmed/10952903. 26.11.2014. 
Lublin, F.D., Reingold, S.C., Cohen, J.A., Cutter, G.R., Sørensen, P.S., Thompson, A.J., Wolinsky, J.S., 
Balcer, L.J., Banwell, B., and Barkhof, F., et al. (2014). Defining the clinical course of multiple sclerosis: 
the 2013 revisions. Neurology 83, 278-286. 
Lucchinetti, C., Brück, W., and Noseworthy, J. (2001). Multiple sclerosis: recent developments in 
neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Current opinion 
in neurology 14, 259-269. 
Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., and Lassmann, H. (2000). 
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. 
Annals of neurology 47, 707-717. 
Lucchinetti, C.F., Brueck, W., Rodriguez, M., and Lassmann, H. (1998). Multiple sclerosis: lessons from 
neuropathology. Seminars in neurology 18, 337-349. 
Mahad, D.J., and Ransohoff, R.M. (2003). The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and 
experimental autoimmune encephalomyelitis (EAE). Seminars in Immunology 15, 23-32. 
Mason, J.L., Jones, J.J., Taniike, M., Morell, P., Suzuki, K., and Matsushima, G.K. (2000). Mature 
oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation 
and differentiation during demyelination/remyelination. Journal of neuroscience research 61, 251-
262. 
Mason, J.L., Langaman, C., Morell, P., Suzuki, K., and Matsushima, G.K. (2001a). Episodic 
demyelination and subsequent remyelination within the murine central nervous system: changes in 
axonal calibre. Neuropathol Appl Neurobiol 27, 50-58. 
 References 126 
 
Mason, J.L., Suzuki, K., Chaplin, D.D., and Matsushima, G.K. (2001b). Interleukin-1beta promotes 
repair of the CNS. The Journal of neuroscience : the official journal of the Society for Neuroscience 
21, 7046-7052. 
Mason, J.L., Toews, A., Hostettler, J.D., Morell, P., Suzuki, K., Goldman, J.E., and Matsushima, G.K. 
(2004). Oligodendrocytes and Progenitors Become Progressively Depleted within Chronically 
Demyelinated Lesions. The American journal of pathology 164, 1673-1682. 
Matsushima, G.K., and Morell, P. (2001). The Neurotoxicant, Cuprizone, as a Model to Study 
Demyelination and Remyelination in the Central Nervous System. Brain Pathology 11, 107-116. 
Matsushita, H., Uenaka, A., Ono, T., Hasegawa, K., Sato, S., Koizumi, F., Nakagawa, K., Toda, M., 
Shingo, T., and Ichikawa, T., et al. (2005). Identification of glioma-specific RFX4-E and -F isoforms and 
humoral immune response in patients. Cancer science 96, 801-809. 
Mayo, L., Trauger, S.A., Blain, M., Nadeau, M., Patel, B., Alvarez, J.I., Mascanfroni, I.D., Yeste, A., 
Kivisäkk, P., and Kallas, K., et al. (2014). Regulation of astrocyte activation by glycolipids drives 
chronic CNS inflammation. Nature medicine 20, 1147-1156. 
McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P., Lublin, F.D., McFarland, H.F., 
Paty, D.W., Polman, C.H., and Reingold, S.C., et al. (2001). Recommended diagnostic criteria for 
multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. 
Annals of neurology 50, 121-127. 
McFarland, H.F., and Martin, R. (2007). Multiple sclerosis: a complicated picture of autoimmunity. 
Nature immunology 8, 913-919. 
McMahon, E.J., Cook, D.N., Suzuki, K., and Matsushima, G.K. (2001). Absence of Macrophage-
Inflammatory Protein-1 Delays Central Nervous System Demyelination in the Presence of an Intact 
Blood-Brain Barrier. The Journal of Immunology 167, 2964-2971. 
McMahon, E.J., Suzuki, K., and Matsushima, G.K. (2002). Peripheral macrophage recruitment in 
cuprizone-induced CNS demyelination despite an intact blood–brain barrier. Journal of 
Neuroimmunology 130, 32-45. 
Merrill, J.E., Ignarro, L.J., Sherman, M.P., Melinek, J., and Lane, T.E. (1993). Microglial cell cytotoxicity 
of oligodendrocytes is mediated through nitric oxide. Journal of immunology (Baltimore, Md. : 1950) 
151, 2132-2141. 
 References 127 
 
Mildner, A., Schmidt, H., Nitsche, M., Merkler, D., Hanisch, U.-K., Mack, M., Heikenwalder, M., Brück, 
W., Priller, J., and Prinz, M. (2007). Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes 
only under defined host conditions. Nature neuroscience 10, 1544-1553. 
Miljkovic, D., Momcilovic, M., Stojanovic, I., Stosic-Grujicic, S., Ramic, Z., and Mostarica-Stojkovic, M. 
(2007). Astrocytes stimulate interleukin-17 and interferon-gamma production in vitro. Journal of 
neuroscience research 85, 3598-3606. 
Mills Ko, E., Ma, J.H., Guo, F., Miers, L., Lee, E., Bannerman, P., Burns, T., Ko, D., Sohn, J., and Soulika, 
A.M., et al. (2014). Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive 
axon loss in a murine autoimmune multiple sclerosis model. Journal of neuroinflammation 11, 105. 
Milo, R., and Kahana, E. (2010). Multiple sclerosis: geoepidemiology, genetics and the environment. 
Autoimmunity reviews 9, A387-94. 
Minagar, A., and Alexander, J.S. (2003). Blood-brain barrier disruption in multiple sclerosis. Multiple 
sclerosis (Houndmills, Basingstoke, England) 9, 540-549. 
Miranda-Angulo, A.L., Byerly, M.S., Mesa, J., Wang, H., and Blackshaw, S. (2014). Rax regulates 
hypothalamic tanycyte differentiation and barrier function in mice. The Journal of comparative 
neurology 522, 876-899. 
Moreno, C.S., Rogers, E.M., Brown, J.A., and Boss, J.M. (1997). Regulatory factor X, a bare 
lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex. Journal of 
immunology (Baltimore, Md. : 1950) 158, 5841-5848. 
Morotomi-Yano, K., Yano, K.-i., Saito, H., Sun, Z., Iwama, A., and Miki, Y. (2002). Human regulatory 
factor X 4 (RFX4) is a testis-specific dimeric DNA-binding protein that cooperates with other human 
RFX members. The Journal of biological chemistry 277, 836-842. 
Nair, A., Frederick, T.J., and Miller, S.D. (2008). Astrocytes in multiple sclerosis: a product of their 
environment. Cellular and molecular life sciences : CMLS 65, 2702-2720. 
Naumann, W. (1986). Immunhistochemische Untersuchungen zur Ontogenese des 
Subcommissuralorgans. Acta histochemica. Supplementband 33, 265-272. 
Nedergaard, M., Ransom, B., and Goldman, S.A. (2003). New roles for astrocytes: redefining the 
functional architecture of the brain. Trends in neurosciences 26, 523-530. 
 References 128 
 
Nelander, J., Hebsgaard, J.B., and Parmar, M. (2009). Organization of the human embryonic ventral 
mesencephalon. Gene expression patterns : GEP 9, 555-561. 
Newberne, P.M. (1962). The subcommissural organ of the vitamin B12-deficient rat. The Journal of 
nutrition 76, 393-413. 
Nualart, F., Hein, S., Rodríguez, E.M., and Oksche, A. (1991). Identification and partial 
characterization of the secretory glycoproteins of the bovine subcommissural organ-Reissner's fiber 
complex. Evidence for the existence of two precursor forms. Molecular Brain Research 11, 227-238. 
Nygårdas, P.T., Määttä, J.A., and Hinkkanen, A.E. (2000). Chemokine expression by central nervous 
system resident cells and infiltrating neutrophils during experimental autoimmune encephalomyelitis 
in the BALB/c mouse. European journal of immunology 30, 1911-1918. 
Ohtoshi, A. (2008). Hydrocephalus caused by conditional ablation of the Pten or beta-catenin gene. 
Cerebrospinal fluid research 5, 16. 
Ortloff, A.R., Vío, K., Guerra, M., Jaramillo, K., Kaehne, T., Jones, H., McAllister, J.P., and Rodríguez, E. 
(2013). Role of the subcommissural organ in the pathogenesis of congenital hydrocephalus in the HTx 
rat. Cell and tissue research 352, 707-725. 
Overholser, M.D., Whitley, J.R., O'Dell, B.L., and Hogan, A.G. (1954). The ventricular system in 
hydrocephalic rat brains produced by a deficiency of vitamin B12 or of folic acid in the maternal diet. 
The Anatomical record 120, 917-933. 
Pasquini, L.A., Calatayud, C.A., Bertone Uña, A L, Millet, V., Pasquini, J.M., and Soto, E.F. (2007). The 
neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory 
cytokines secreted by microglia. Neurochemical research 32, 279-292. 
Patel, J.R., Williams, J.L., Muccigrosso, M.M., Liu, L., Sun, T., Rubin, J.B., and Klein, R.S. (2012). 
Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor 
proliferation and differentiation within the adult CNS. Acta neuropathologica 124, 847-860. 
Pérez-Fígares, J.M., Jimenez, A.J., and Rodríguez, E.M. (2001). Subcommissural organ, cerebrospinal 
fluid circulation, and hydrocephalus. Microscopy research and technique 52, 591-607. 
Pérez-Fígares, J.M., Jiménez, A.J., Pérez-Martín, M., Fernández-Llebrez, P., Cifuentes, M., Riera, P., 
Rodríguez, S., and Rodríguez, E.M. (1998). Spontaneous congenital hydrocephalus in the mutant 
 References 129 
 
mouse hyh. Changes in the ventricular system and the subcommissural organ. Journal of 
neuropathology and experimental neurology 57, 188-202. 
Pittock, S.J., and Lucchinetti, C.F. (2007). The pathology of MS: new insights and potential clinical 
applications. The neurologist 13, 45-56. 
Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., 
Hutchinson, M., and Kappos, L., et al. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions 
to the McDonald criteria. Annals of neurology 69, 292-302. 
Qin, H., and Benveniste, E.N. (2012). ELISA methodology to quantify astrocyte production of 
cytokines/chemokines in vitro. Methods in molecular biology (Clifton, N.J.) 814, 235-249. 
Raasch, J., Zeller, N., van Loo, G., Merkler, D., Mildner, A., Erny, D., Knobeloch, K.-P., Bethea, J.R., 
Waisman, A., and Knust, M., et al. (2011). IkappaB kinase 2 determines oligodendrocyte loss by non-
cell-autonomous activation of NF-kappaB in the central nervous system. Brain : a journal of 
neurology 134, 1184-1198. 
Ramos, C., Fernández-Llebrez, P., Bach, A., Robert, B., and Soriano, E. (2004). Msx1 disruption leads 
to diencephalon defects and hydrocephalus. Developmental dynamics : an official publication of the 
American Association of Anatomists 230, 446-460. 
Ransohoff, R.M. (2012). Animal models of multiple sclerosis: the good, the bad and the bottom line. 
Nature neuroscience 15, 1074-1077. 
Ransohoff, R.M., Hamilton, T.A., Tani, M., Stoler, M.H., Shick, H.E., Major, J.A., Estes, M.L., Thomas, 
D.M., and Tuohy, V.K. (1993). Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 
in experimental autoimmune encephalomyelitis. FASEB journal : official publication of the Federation 
of American Societies for Experimental Biology 7, 592-600. 
Reith, W., and Mach, B. (2001). The bare lymphocyte syndrome and the regulation of MHC 
expression. Annual review of immunology 19, 331-373. 
Remington, L.T., Babcock, A.A., Zehntner, S.P., and Owens, T. (2007). Microglial recruitment, 
activation, and proliferation in response to primary demyelination. The American journal of 
pathology 170, 1713-1724. 
 References 130 
 
Rodriguez, S., Rodriguez, P., Banse, C., Rodriguez, E., and Oksche, A. (1987). Reissner's fiber, massa 
caudalis and ampulla caudalis in the spinal cord of lamprey larvae (Geotria australis). Cell Tissue Res. 
247. 
Rodríguez, E.M., Oksche, A., Hein, S., and Yulis, C.R. (1992). Cell biology of the subcommissural organ. 
International review of cytology 135, 39-121. 
Rodríguez, E.M., Rodríguez, S., and Hein, S. (1998). The subcommissural organ. Microscopy research 
and technique 41, 98-123. 
Rolf, B., Kutsche, M., and Bartsch, U. (2001). Severe hydrocephalus in L1-deficient mice. Brain 
Research 891, 247-252. 
Schoebitz, K., Garrido, O., Heinrichs, M., Speer, L., and Rodríguez, E.M. (1986). Ontogenetical 
development of the chick and duck subcommissural organ. An immunocytochemical study. 
Histochemistry 84, 31-40. 
Schönrock, L.M., Gawlowski, G., and Brück, W. (2000). Interleukin-6 expression in human multiple 
sclerosis lesions. Neuroscience letters 294, 45-48. 
Schwaninger, M., Sallmann, S., Petersen, N., Schneider, A., Prinz, S., Libermann, T.A., and Spranger, 
M. (1999). Bradykinin induces interleukin-6 expression in astrocytes through activation of nuclear 
factor-kappaB. Journal of neurochemistry 73, 1461-1466. 
Selmaj, K.W., and Raine, C.S. (1988). Tumor necrosis factor mediates myelin and oligodendrocyte 
damage in vitro. Annals of neurology 23, 339-346. 
Shimizu, S., Kondo, M., Miyamoto, Y., and Hayashi, M. (2002). Foxa (HNF3) Up-regulates Vitronectin 
Expression during Retinoic Acid-induced Differentiation in Mouse Neuroblastoma Neuro2a Cells. Cell 
Structure and Function 27, 181-188. 
Silvestroff, L., Bartucci, S., Soto, E., Gallo, V., Pasquini, J., and Franco, P. (2010). Cuprizone-induced 
demyelination in CNP::GFP transgenic mice. The Journal of comparative neurology 518, 2261-2283. 
Skripuletz, T., Hackstette, D., Bauer, K., Gudi, V., Pul, R., Voss, E., Berger, K., Kipp, M., Baumgärtner, 
W., and Stangel, M. (2013). Astrocytes regulate myelin clearance through recruitment of microglia 
during cuprizone-induced demyelination. Brain : a journal of neurology 136, 147-167. 
 References 131 
 
Sobel, R.A., Mitchell, M.E., and Fondren, G. (1990). Intercellular adhesion molecule-1 (ICAM-1) in 
cellular immune reactions in the human central nervous system. The American journal of pathology 
136, 1309-1316. 
Sofroniew, M.V. (2014). Astrogliosis. Cold Spring Harbor perspectives in biology 7. 
Sofroniew, M.V., and Vinters, H.V. (2010). Astrocytes: biology and pathology. Acta neuropathologica 
119, 7-35. 
Sousa, Vivian de Oliveira, Romão, L., Neto, V.M., and Gomes, Flávia Carvalho Alcantara (2004). Glial 
fibrillary acidic protein gene promoter is differently modulated by transforming growth factor-beta 1 
in astrocytes from distinct brain regions. The European journal of neuroscience 19, 1721-1730. 
Stadelmann, C., and Brück, W. (2008). Interplay between mechanisms of damage and repair in 
multiple sclerosis. Journal of neurology 255 Suppl 1, 12-18. 
Stangel, M., and Hartung, H.-P. (2002). Remyelinating strategies for the treatment of multiple 
sclerosis. Progress in Neurobiology 68, 361-376. 
Steimle, V., Durand, B., Barras, E., Zufferey, M., Hadam, M.R., Mach, B., and Reith, W. (1995). A novel 
DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte 
syndrome). Genes & development 9, 1021-1032. 
Sterba, G., and Wolf, G. (1969). Vorkommen und Funktion der Sialinsäure im Reissnerschen Faden. 
Histochemie 17, 57-63. 
Sunnemark, D., Eltayeb, S., Nilsson, M., Wallström, E., Lassmann, H., Olsson, T., Berg, A.-L., and 
Ericsson-Dahlstrand, A. (2005). CX3CL1 (fractalkine) and CX3CR1 expression in myelin 
oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and 
cellular origin. Journal of neuroinflammation 2, 17. 
Swoboda, P., Adler, H.T., and Thomas, J.H. (2000). The RFX-Type Transcription Factor DAF-19 
Regulates Sensory Neuron Cilium Formation in C. elegans. Molecular Cell 5, 411-421. 
Sztriha, L., Vos, Y.J., Verlind, E., Johansen, J., and Berg, B. (2002). X-linked hydrocephalus: a novel 
missense mutation in the L1CAM gene. Pediatric Neurology 27, 293-296. 
 References 132 
 
Takeuchi, I.K., Kimura, R., Matsuda, M., and Shoji, R. (1987). Absence of subcommissural organ in the 
cerebral aqueduct of congenital hydrocephalus spontaneously occurring in MT/HokIdr mice. Acta 
neuropathologica 73, 320-322. 
Takeuchi, I.K., and Takeuchi, Y.K. (1986). Congenital hydrocephalus following X-irradiation of 
pregnant rats on an early gestational day. Neurobehavioral toxicology and teratology 8, 143-150. 
Tanuma, N., Sakuma, H., Sasaki, A., and Matsumoto, Y. (2006). Chemokine expression by astrocytes 
plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary 
progressive multiple sclerosis. Acta neuropathologica 112, 195-204. 
Tarozzo, G., Bortolazzi, S., Crochemore, C., Chen, S.-C., Lira, A.S., Abrams, J.S., and Beltramo, M. 
(2003). Fractalkine protein localization and gene expression in mouse brain. Journal of neuroscience 
research 73, 81-88. 
Tchélingérian, J.-L., Monge, M., Le Saux, F., Zalc, B., and Jacque, C. (1995). Differential 
Oligodendroglial Expression of the Tumor Necrosis Factor Receptors In Vivo and In Vitro. Journal of 
neurochemistry 65, 2377-2380. 
Thomas, J., Morlé, L., Soulavie, F., Laurençon, A., Sagnol, S., and Durand, B. (2010). Transcriptional 
control of genes involved in ciliogenesis: a first step in making cilia. Biology of the cell / under the 
auspices of the European Cell Biology Organization 102, 499-513. 
Thompson, A. (2004). Overview of primary progressive multiple sclerosis (PPMS): similarities and 
differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. 
Multiple sclerosis (Houndmills, Basingstoke, England) 10 Suppl 1, S2-7. 
Toft-Hansen, H., Füchtbauer, L., and Owens, T. (2011). Inhibition of reactive astrocytosis in 
established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T 
cells and enhances severity of disease. Glia 59, 166-176. 
Torkildsen, O., Brunborg, L.A., Myhr, K.-M., and Bø, L. (2008). The cuprizone model for 
demyelination. Acta neurologica Scandinavica. Supplementum 188, 72-76. 
Valerio, A. (2002). Soluble Interleukin-6 (IL-6) Receptor/IL-6 Fusion Protein Enhances in Vitro 
Differentiation of Purified Rat Oligodendroglial Lineage Cells. Molecular and Cellular Neuroscience 
21, 602-615. 
 References 133 
 
Veto, S., Acs, P., Bauer, J., Lassmann, H., Berente, Z., Setalo, G., Borgulya, G., Sumegi, B., Komoly, S., 
and Gallyas, F., et al. (2010). Inhibiting poly(ADP-ribose) polymerase: a potential therapy against 
oligodendrocyte death. Brain : a journal of neurology 133, 822-834. 
Vio, K., Rodríguez, S., Navarrete, E.H., Pérez-Fígares, J.M., Jiménez, A.J., and Rodríguez, E.M. (2000). 
Hydrocephalus induced by immunological blockage of the subcommissural organ-Reissner's fiber (RF) 
complex by maternal transfer of anti-RF antibodies. Experimental Brain Research 135, 41-52. 
Voskuhl, R.R., Peterson, R.S., Song, B., Ao, Y., Morales, Laurie Beth J, Tiwari-Woodruff, S., and 
Sofroniew, M.V. (2009). Reactive astrocytes form scar-like perivascular barriers to leukocytes during 
adaptive immune inflammation of the CNS. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 29, 11511-11522. 
Voss, E.V., Škuljec, J., Gudi, V., Skripuletz, T., Pul, R., Trebst, C., and Stangel, M. (2012). 
Characterisation of microglia during de- and remyelination: can they create a repair promoting 
environment? Neurobiology of disease 45, 519-528. 
Webster, H. d. F (1997). Growth factors and myelin regeneration in multiple sclerosis. Multiple 
Sclerosis 3, 113-120. 
Williams, A., Piaton, G., and Lubetzki, C. (2007). Astrocytes--friends or foes in multiple sclerosis? Glia 
55, 1300-1312. 
Zeinstra, E., Wilczak, N., and Keyser, J. de (2003). Reactive astrocytes in chronic active lesions of 
multiple sclerosis express co-stimulatory molecules B7-1 and B7-2. Journal of Neuroimmunology 135, 
166-171. 
Zeinstra, E., Wilczak, N., Streefland, C., and Keyser, J. de (2000). Astrocytes in chronic active multiple 
sclerosis plaques express MHC class II molecules. Neuroreport 11, 89-91. 
Zhang, D., Harry, G.J., Blackshear, P.J., and Zeldin, D.C. (2008). G-protein pathway suppressor 2 
(GPS2) interacts with the regulatory factor X4 variant 3 (RFX4_v3) and functions as a transcriptional 
co-activator. The Journal of biological chemistry 283, 8580-8590. 
Zhang, D., Stumpo, D.J., Graves, J.P., DeGraff, L.M., Grissom, S.F., Collins, J.B., Li, L., Zeldin, D.C., and 
Blackshear, P.J. (2006a). Identification of potential target genes for RFX4_v3, a transcription factor 
critical for brain development. Journal of neurochemistry 98, 860-875. 
 References 134 
 
Zhang, D., Zeldin, D.C., and Blackshear, P.J. (2007). Regulatory factor X4 variant 3: a transcription 
factor involved in brain development and disease. Journal of neuroscience research 85, 3515-3522. 
Zhang, J., Williams, M.A., and Rigamonti, D. (2006b). Genetics of human hydrocephalus. Journal of 
neurology 253, 1255-1266. 
 
  
 
 
 
